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SUMMARY
The endothelins, recently discovered potent vasoconstrictor peptides, may be implicated in 
detrimental effects in cardiac ischaemia. Studies in the isolated rat heart show an increase in 
both their synthesis and binding following simulated ischaemia and reperflision. An increase 
in binding density does not necessarily correlate with an increase in numbers o f functional 
receptors. Hence studies were performed to confirm any selective potentiation o f 
endothelin effect, using a similar protocol of ischaemia and reperfusion to that producing an 
increase in binding.
An apparent increase in the coronary constrictor effect o f endothelins was shown to follow 
ischaemia and reperfusion, accompanied by loss o f their initial vasodilator action. This 
increase was, however, inconclusive as rising basal perfusion pressure in ischaemic / 
reperfused hearts made interpretation difficult. Desensitisation o f the coronary dilator 
component o f endothelin responses (using an ETB receptor agonist, sarafotoxin 6c) revealed 
that loss o f opposing vasodilatation alone is sufficient to enhance the vasoconstrictor action 
o f these peptides.
The relative potencies o f  the endothelin family o f peptides and use o f  a selective E T B 
receptor agonist and a selective ETA receptor antagonist showed that coronary dilatation 
was consistent with action via ETB receptors, whereas vasoconstriction was consistent with 
action through an ETA receptor.
An increase in intracellular calcium is an important signal transduction mechanism for 
endothelins, although reports o f the dynamics o f the increase include some inconsistencies 
which may depend on the model used. The effect o f endothelin-1 on calcium signalling in 
cultured porcine coronary smooth muscle cells was investigated by fluorimetric assay using 
fiira-2. Responses measured in cells in confluent monolayers, were compared with 
responses in single cells and in dispersed cell suspensions.
Cells from different hearts displayed variability in calcium responses in monolayers, but 
these usually included a peak and a plateau phase o f response as previously reported. 
Single cell responses were more inconsistent, with variability in the form o f responses in
cells from the saine heart. These included an initial peak followed by variable oscillations. 
Responses in suspensions of large cell numbers were less variable, including a peak and a 
plateau phase. However, different patterns of inhibition by BQ-123 were seen in 
monolayers and in suspensions.
In conclusion, selection o f the type o f cell preparation is important for comparison o f effect 
and a larger experimental number is required for investigations in primary cell cultures.
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INTRODUCTION
21.1 C oronary  heart disease
Epidemiological studies demonstrate that death from coronary heart disease is a major 
problem in the Western world, with England and Wales being among the worst affected 
countries, and Scotland and Northern Ireland having the highest death rates (Thom, 1989). 
This disease is usually a result o f  narrowing o f the coronary arteries, and may be manifested 
initially by angina pectoris (chest pain on exertion), where an increase in demand over 
myocardial blood supply leads to ischaemia o f the affected area o f myocardium. Myocardial 
infarction (death o f  cardiac tissue) is the result o f longer lasting coronary obstruction, and 
can be the result o f a coronary thrombosis, i.e. total interruption of supply to the area fed by 
the coronary artery concerned. However, the first indication o f disease may be the event of 
sudden cardiac death, where complete loss o f cardiac output may be the result o f an 
arrhythmia (Lorimer & Hills, 1985). The incidence and severity o f coronary heart disease 
have ensured considerable ongoing research activity.
1.1.1 Anatomy
The coronary vessels leave the aortic trunk as two main arteries from the left and right of 
the aorta, immediately above the aortic valve. These follow the epicardial surface and as 
they branch, smaller vessels enter the myocardium and endocardium and form the supply to 
the whole o f the left and right atria and ventricles o f  the heart. The size o f these arteries 
and arterioles gradually decreases from the larger conductance, to the small resistance 
vessels, the size o f which may be regulated by neural and humoral factors. The major 
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The human coronary circulation showing the anatomical position of the major branches ol 
the left and right coronary arteries.
41.1.2 Ischaemic changes
The oxygenated blood supplied to the myocardium by the coronary circulation allows 
energy for contraction o f the muscle to be provided by oxidative phosphorylation, where 
adenosine triphosphate (ATP) production is aerobic. Coronary insufficiency leads to 
anaerobic metabolism and the build up o f acidic metabolites. The symptom most commonly 
exhibited as a result o f this ischaemia is angina pectoris (chest pain).
Ischaemic damage to the cardiac muscle cells leads also to extracellular accumulation of 
potassium ions and thus local cell membrane depolarisation. Disruption o f the normal 
membrane potential, which in turn may reduce the ability o f the cells to conduct action 
potentials, may also result in the abnormal initiation o f action potentials. The end product is 
the loss o f  ordered conduction o f normal cardiac rhythm which is necessary for coordinated 
myocardial contraction, and this can result in a loss o f cardiac output which is life- 
threatening.
Coronary narrowing is usually caused by atheromatous plaques which may also disrupt the 
smooth endothelial layer, leaving a surface upon which platelets may aggregate, and leading 
to  thrombus formation obstructing the artery concerned. This results in myocardial 
infarction if untreated, reperfusion o f the affected area being an immediate aim o f therapy to 
prevent cellular necrosis. Narrowing may also be caused by, or exacerbated by coronary 
spasm, again leading to the possibility o f coagulation due to the disruption o f laminar flow 
o f blood. This variant angina may occur transiently with ischaemia usually followed by 
reperfusion o f the myocardial tissue on recovery.
1.1.3 Current treatments - medical and surgical
The current treatments for coronary artery narrowing are, in the first instance, reduction of 
cardiac oxygen demand using vasodilator agents and B-adrenergic antagonists, both of 
which reduce the oxygen demands o f the heart. This may be accompanied by use o f 
anticoagulant therapy to prevent thrombus formation. Where medical treatment fails to 
reduce angina pectoris or the risk o f  thrombosis is seen to be great, attempts are made to 
remove the stenoses. This can be achieved using the percutaneous transluminal coronary
5angioplasty technique, which employs inflation of a balloon to compress the atheromatous 
plaque into the vessel wall. This procedure may be accompanied by the use o f a stent to 
maintain the patency o f  the vessel. The surgical alternative to this procedure is coronary 
artery bypass, usually using a graft o f saphenous vein or internal mammary artery to restore 
blood supply to the ischaemic myocardium. The more invasive open heart surgery has been 
shown to be more effective in avoiding recurrence (King et a i , 1994), although the 
procedure carries greater immediate risk than angioplasty.
Treatment is available for recently occurring thrombosis, allowing salvage o f myocardium at 
risk o f  necrosis. This increasingly involves the use o f  thrombolytic agents which, if used in 
the early stages o f myocardial infarction, can restore perfusion and prevent or limit the 
progress o f cellular necrosis. However, this procedure has been shown to carry several 
risks, including that o f  reperfusion arrhythmias, and inadequate reperfusion o f the area at 
risk o f  infarction, the "no reflow" phenomenon (Kloner et al., 1974). The reperfused area 
may not recover its function, an occurrence known as myocardial stunning (e.g. Triana & 
Bolli, 1991).
1.1.4 Reperfusion
Ischaemia itself causes severe cellular damage and necrosis but the restoration o f blood flow 
is, paradoxically, an initiator o f more damaging processes. Much of the damage to 
cardiomyocytes leading to contractile dysfunction, is believed to be related to the 
intracellular accumulation o f calcium ions. The increased uptake o f these ions correlates 
with depressed recovery o f contractility after reperfusion o f the ischaemic heart (Tani, 
1990). This calcium overload is related to the development of ischaemic contracture in 
experimental hearts.
Coronary damage is also exacerbated by reperfusion. Lack o f reflow is a result o f changes 
in coronary vessels which include inappropriate vasospasm, loss of vasodilator function, and 
endothelial oedema and functional loss (Katz, 1992; Sobey & Woodman, 1993). The latter 
may involve accumulation, on reperfusion, o f  inflammatory cells such as neutrophils which 
can physically block vessels, and which also release factors (including superoxide anion)
6which exacerbate endothelial cell damage. This may be accompanied by platelet 
aggregation in the damaged vessels, a process exacerbated by loss o f the inhibitory presence 
of factors such as nitric oxide (NO) and prostacyclin (PGI2), production o f which may be 
compromised in post-ischaemic endothelium (Sobey & Woodman, 1993). The degree of 
damage and functional loss is related to the duration o f the ischaemic episode in 
experimental models (Kloner et al., 1974; Nevalainen et a l 1986; Viehman eta l, 1991). 
Among the local mediators which have been shown to contribute to coronary arterial spasm 
are a family o f  recently-discovered peptides, the endothelins (Kurihara et al., 1989).
71.2 Endothelins
1.2.1 Discovery of a novel vasoconstrictor peptide
It has become increasingly clear that the endothelium, once considered as simply a smooth 
physical barrier, plays an important role in the production of factors involved in the 
regulation o f vascular tone. For example, the cells o f the endothelial layer have been shown 
to produce vasodilator eicosanoids (PGI2, PGE2) and ATP (reviewed in Dale & Foreman, 
1989) and endothelium-derived relaxing factor (EDRF, Furchgott & Zawadski, 1980) which 
act on the underlying vascular smooth muscle cells to produce changes locally in the 
diameter o f the vessel. The discovery o f EDRF was followed by the finding that 
endothelium produces a peptide constricting factor (Hickey el al, 1985), and this novel 
factor was further identified and the gene cloned and sequenced by Yanagisawa et al., 
(1988). The peptide (relative molecular mass 2492) was isolated from supernatants o f 
porcine aortic endothelial cells and purified, before being identified as a 21 amino acid 
structure. This "endothelin*1 was noted to be the most potent naturally occurring 
vasoconstrictor yet discovered, having an EC50 of 0.4nM in various arterial preparations 
(Yanagisawa et al., 1988) and producing a long-lasting (>20minutes) vasoconstriction and 
pressor effect. A transient vasodilator effect was also seen prior to vasoconstriction in 
some preparations in these initial studies. The peptide discovered by Yanagisawa's group 
was later designated "endothelin-1", the only endothelin to be produced by endothelium. A 
preproendothelin o f approximately 200 amino acid residues and a 38 amino acid pro- 
endothelin, "big endothelin", were also determined and a synthetic pathway involving an 
endothelin converting enzyme (ECE) was proposed (Yanagisawa et al., 1988; see figure I- 
2). The production o f  endothelin-1 was found to be by de novo synthesis, its release being 
dependent on the microtubular system (Kitazumi el al., 1991).
Subsequent research demonstrated the existence of other endothelin species, designated 
endothelin-2 and endothelin-3 (Inoue et al., 1989), all products o f separate genes. The 
three peptides share the bicyclic structure produced by four cysteine residues (at positions 
1,3,11 and 15) which form disulphide bonds 1-15 and 3-11. These bonds suggest
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The synthetic pathway of endothelin-1, demonstrating the post-translational proteolytic 










Structures o f endothelins and the related snake venom-derived sarafotoxins. Homologous 
amino acid residues are shown as open circles, while those differing from endothelin-1 are 
shown as dark circles. (Figure shows structures described by Yanagisawa el al., 1988 (ET- 
1), Inoue el al., 1989 (ET-2, ET-3), Saida et a l, 1989 (VIC) and Kloog & Sokolovsky, 
1989 (sarafotoxins)).
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that the peptides form a helical structure (Sokolovsky, 1992). The main differences in their 
amino acid sequences occur between amino acid residues in the loop between the inner 
disulphide bonds (see figure 1-3). The endothelin peptides bear close sequence homology to 
murine vasoactive intestinal constricting substance (VIC, Nayler, 1990) and to the 
sarafotoxins, a family o f  snake venoms isolated from Actracfaspis engaddensis (Kloog & 
Sokolovsky, 1989).
The cleavage site for the formation o f  the three endothelin isopeptides from their 38-39 
amino acid precursor "big endothelins", is unusual, occurring between valine and tryptophan 
residues. Enzyme activity performing this function has been found in endothelial cells as 
well as in the membrane fraction o f  vascular smooth muscle cells (Hisaki et al, 1993; 
Tsukahara et al., 1993), suggesting a local function for the active peptide. Cleavage from 
big endothelin is important for hill vasoconstrictor function (Kimura et al, 1989), and is 
sensitive to metalloprotease inhibitors such as phosphoramidon.
1.2.2 Endothelin synthesis and release
The mRNA for all three endothelin isopeptides appears to be widespread, found in all 
mammals tested (Inoue et al., 1989) and in most organs in varying concentrations, although 
endothelin-2 is possibly less ubiquitous than the other isopeptides (Firth and Ratclifffe, 
1992). A variant o f endothelin-2, vasoactive intestinal peptide (see figure 1-3) is also found 
in mice. However, all three endothelins have been reported as present in human heart 
(Plumpton et al., 1993), and endothelin species have been detected in human coronary 
arteries and veins (Opgaard et a l , 1994).
Endothelin-1 is not stored in cells and is constitutively produced by endothelium at a basal 
level (Dickinson et a l , 1991). The expression o f its mRNA in cultured endothelial cells 
may be induced following stimulation by a variety o f  factors, including angiotensin II 
(Kohno et al, 1992), the calcium ionophore A23187 and thrombin, e.g. from aggregating 
platelets (Kurihara et al, 1989). The thrombin- and A 23187-stimulated production of 
endothelin-1 from endothelium of intact porcine aortae is inhibited by NO (Boulanger & 
Liischer, 1990) and by atrial and brain natriuretic peptides (Kohno et al, 1992), via a cyclic
11
guanosine 5'-monophosphate (cGMP)-sensitive mechanism. This may suggest that the local 
regulation o f  vessel size is influenced by the balance o f these mediators. Release of 
endothelins has been shown to occur mainly basolaterally, again supporting a role for the 
peptide as a local mediator (Wagner et a l , 1992).
Rat and rabbit aortic vascular smooth muscle cells in culture have also been shown to 
release endothelin-1, but at lower concentrations than endothelial cells (in the range 0.1-1 
compared with 10-80 fmol /105 cells/24 hours; Kanse et al., 1991). Suppression o f  this 
basal endothelin-1 release from smooth muscle (but not endothelial cells) has been shown to 
be cyclic AMP-sensitive.
It has also been demonstrated that low density lipoproteins in human and porcine tissues 
(Boulanger et al, 1992) and hypoxia in rat lung (Shirakami et al, 1991), can trigger the 
production o f  endothelins. These findings suggest that these peptides could be induced, and 
therefore may have a role to play in arterial pathology.
1.2.3 Degradation
Circulating endothelins are cleared rapidly from the blood. This may occur at or near the 
site o f  production, as the vasculature itself may possess a neutral endopeptidase which is 
phosphoramidon sensitive and actively metabolises endothelins (Dickinson et a l, 1991) . 
Extracts o f lung have also been shown to degrade the peptide efficiently. The renal 
contribution to  degradation may be o f  greatest importance under normal conditions 
(Rubanyi & Polokoff, 1994); a carboxypeptidase from soluble renal extracts has been shown 
to cleave the carboxyl terminal o f  the endothelin-1 molecule thus rendering it inactive (Jeng 
& Deng, 1993). In other organs enzymes could contribute to catabolism possibly with 
variations in optimal pH; for example, the degradation o f the peptide by myocardial extract 
was found to be more efficient at low pH (6.2), suggesting that removal mechanisms may be 
enhanced in ischaemic conditions (Gaijani et al, 1994).
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1.3 Endothelin Receptors
The vasodilator and vasoconstrictor components o f the vascular response to endothelins can 
be separated according to the order o f potency o f the isopeptides and sarafotoxins which 
provoke them. The vasoconstrictor component has been shown to respond with sensitivity 
as follows: ET-l>ET-2>ET-3>Sx6c, whereas the vasodilator response is equally sensitive 
to all three endothelins and sarafotoxin 6c. These results suggest activation o f two distinct 
receptors and this has been confirmed by further characterisation o f two receptors, one from 
bovine lung (designated ETA, Arai et al, 1990) and one from rat lung preparations 
(designated ETB, Sakurai et al, 1990), which show different pharmacological profiles. The 
ETa receptor corresponds to the potency response profile for vasoconstriction (ET-l=Sx6b 
>ET-2 »  ET-3), whereas the ETB receptor mediates vasodilatation with equal sensitivity 
to the endothelins and sarafotoxins (ET-1 = ET-2 = ET-3 = Sx6b).
The receptors cloned were both o f a structure comprising seven hydrophobic domains, 
likely to  be membrane spanning regions, and having a probable extracellular N-terminus and 
an intracellular C-terminus (figure 1-4). The seven membrane-spanning domains are a 
feature characteristic o f the rhodopsin-like receptor family which are linked to GTP-binding 
proteins (G-proteins - see section 1.6.1).
The endothelins bind to the ETA and ET B receptors with differing affinities which reflect the 
relative potencies described above with affinity constants as follows:
(From Sakamoto et al, 1993, and Williams et al, 1993).
Receptor Affinity: Kt (nM)
Endothelin-1 Endothelin-3 Sarafotoxin 6c 
ET a 3.5 1000 2800
ET b 0.95 2.0 0.29





From Sakamoto el al., 1993. Predicted structure o f  the endothelin receptors. The wavy 
line denotes a likely palmitoylation site, closed circles those amino acid residues 
homologous between ETA and ETB receptors.
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The dissociation o f the endothelins from their receptors has been shown to be extremely 
slow in vascular tissues, in common with other preparations (Hemsen et al, 1991) and this 
is complicated by the internalisation o f ligand-receptor complexes (Bax & Saxena, 1994). 
The binding o f  endothelins to either receptor is dependent on the presence o f the C-terminal 
Trp21 residue, and studies using chimaeric receptors have demonstrated that the tertiary 
structure o f  the molecule is important for the binding o f peptides to the ETA and ETB 
receptors: the highly conserved linear C-terminal "tail" has been shown to bind to either 
ETa or ETb receptors, whereas both the helically coiled "head" and the linear tail are 
necessary for the binding o f the peptides to the ETa receptor (Sakamoto et a l, 1993). The 
integrity o f the disulphide bonds, and hence the helical structure is also important for the 
vasoconstrictor activity o f the peptides (Cody et al, 1991). Much o f this information has 
been deduced using analogues o f the peptide, which have been shown to be selective for 
either ETA or E T B receptors. These include amino-terminally truncated linear endothelin 
analogues which bind selectively to the ETB receptor such as BQ-3020 and IRL 1620, 
where they act as agonists (see Haynes et al, 1993).
Several tools have been developed for the study o f  the receptor subtypes. ETA receptor 
antagonists have been produced including the cyclic pentapeptide BQ-123 (cyclo(-D-Trp-D- 
Asp-L-Pro-D-Val-L-Leu-), which was developed from products o f the culture o f 
Streptomyces misakiensis (Ihara et al, 1992). This has a pA2 value measured at 7.4 against 
endothelin-1-induced vasoconstriction in porcine coronary artery, and has been one o f  the 
most widely used ETA-selective antagonists, although non-peptide antagonists have now 
been produced. The development o f  ETB-selective antagonists has been more problematic 
and has taken longer to  achieve. ETB-selective agonists such as IRL 1620 (Takai el al, 
1992) mentioned above, and sarafotoxin 6c (Williams et a l , 1991), have instead been used 
for the study o f  receptor subtypes, as well as non-peptide, selective and non-selective 
endothelin antagonists such as PD 142893, PD 145065, FR 139317 (ETA), Ro 46-2005, SB 
209670, and BMS 1822874, and bosentan (e.g. Buchan et a l, 1994; Gardiner et a l, 1994). 
M ore recently a peptide, BQ-788, (N-c/s-2,6-dimethylpiperidinocarbonyl-L-y-methylleucyl- 
D-l-methoxycarbonyltryptophanyl-D-norleucine) has been described as a novel selective
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antagonist at the ETB receptor with a pA2 o f 8.4 (measured against pulmonary artery 
vasoconstriction to BQ-3020; Ishikawa et al, 1994).
There is evidence o f at least one further endothelin receptor, which is selective for 
endothelin-3. Stimulation o f this receptor results in the inhibition o f prolactin release from 
cultured anterior pituitary cells, and endothelin-3 was shown to be effective where 
endothelin-1 was not (Samson et al., 1990). A separate study has identified an endothelin- 
3-selective receptor in cultured bovine endothelial cells (Emori et al, 1990). An 
endothelin-3-specific receptor has since been cloned from amphibian dermal melanophores 
(Kame et al., 1993), although it is not clear whether this is the amphibian variant of, for 
example, the mammalian ETB receptor, or a distinct subtype o f  receptor. There is 
approximately 63% sequence homology between the ETA and ETB receptors and -50%  
homology with the proposed ETC receptor. In bovine cardiac sarcolemmal vesicles a 
protein binding endothelin-1 has been isolated but having a higher apparent molecular 
weight than that determined for ETA, ETB or ETC, suggesting yet another possible receptor 
may be present in this tissue (Shannon & Hale, 1994), although this has not yet been fully 
characterised. It has been suggested that the identification o f  receptor subtypes is 
complicated by the internalisation of the receptor, rapid down regulation and desensitisation 
o f  some subtypes o f receptor, and by the formation o f  ligand-receptor complexes o f 
different dissociative kinetics depending on the ligand used (Bax & Saxena, 1994). 
However, there is other evidence for the existence o f  receptors not conforming to the 
typical pattern o f  ETA or ETB. For example, Sumner et al (1992) described contraction of 
rat aorta to endothelin-3 which was more potently inhibited by the ETA-selective antagonist 
BQ-123 than that to endothelin-1. Eglezos et al (1993) again differentiated between 
receptors responsible for the endothelin-induced facilitation o f twitch response in vas 
deferens (guinea pig) by use o f  BQ-123. The ETA-selective antagonist had little effect on 
the endothelin-1 response, but inhibited the response to endothelin-3. Warner et al (1993) 
found contractions o f  smooth muscle to endothelins could be divided according to their 
inhibition by different antagonists (BQ-123 and PD 142893), and suggested a subdivision of 
the E T B receptor subtype (see section 1.3.1). Another study found the guinea pig gall
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bladder to contain a receptor mediating contraction, atypical o f the ETA and ETB subtypes 
(Battistini et al., 1994). From these and a growing number o f other examples, it is likely 
that more receptors will eventually be characterised.
The sequence o f  these receptors is unlikely to be homologous with those already discovered 
as no similar DNA has been found by low stringency probing o f a cDNA library. However, 
as the requirements for endothelin binding to its receptors include only a site for the helical 
"head" section (E T ^  and a site for the linear C-terminus "tail" to bind (see above), these 
would be fulfilled if only sections o f the extracellular domains were homologous.
1.3.1 Vascular and coronaiy receptors
Initial studies demonstrate that in vascular tissue, vasodilator ETB receptors are located on 
the endothelium (Sakurai et al, 1990). Stimulation o f  these may provoke release o f  local 
mediators (see section 1.4 below) producing vasodilatation which is not inhibited following 
administration o f ETA receptor antagonists (Fukuroda et al, 1992). With this and other 
evidence, it is accepted that the transient vasodilator or hypotensive effect produced 
following endothelin administration is mediated by the ETB receptor.
Vasoconstriction has been shown to be the result o f stimulation o f ETA receptors on smooth 
muscle. Indeed, in human coronary artery and vein, Opgaard et al (1994) found evidence 
o f ETA-mediated coronary constriction competitively inhibited by FR 139317. However 
this may not be the complete picture; in the anaesthetised rat, BQ-123 failed to inhibit 
completely the pressor response, suggesting that this is not the only vasoconstrictor 
receptor (McMurdo et al, 1993). There is further evidence o f vasoconstriction being 
mediated via ETB receptors, despite initial failure to demonstrate the mRNA for the ETB 
receptor in vascular smooth muscle (Sakurai et al, 1990). The case for the expression o f  
these receptors in vascular smooth muscle is complicated by the finding that in culture, the 
subtype expressed may change according to the culture conditions, ETB predominating at 
late passage numbers whereas ETA is predominant in cells at passages 10 to 15 (Eguchi et 
al, 1994). This suggests that smooth muscle cells at least contain the potential for the 
expression o f both ETA and ETB receptors. In functional studies, Clozel et a l (1992)
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describe the vasoconstrictor effect, in rat, o f the ETR-selective ligand sarafotoxin 6 c. In 
addition, Moreland et al, (1992) have demonstrated the presence o f vasoconstrictor ETR 
receptors in venous smooth muscle. ETR-mediated vasoconstriction has also been shown in 
human internal mammary artery and porcine coronary artery (Seo et al., 1994) where no 
endothelial vasodilator ETB receptors (linked to  either NO or PGI2), were found.
As well as the vasoconstriction mediated by ETB receptors, there is evidence for another 
vasoconstrictor "ETnon A" receptor; in endothelium-denuded porcine coronary artery, 
vasoconstriction to endothelin-1, sarafotoxin 6 b and endothelin-3 has been shown to be 
mediated by an ETA-like receptor whereas endothelin-3 and sarafotoxin 6 c activate a 
receptor which is not activated by endothelin - 1  or sarafotoxin 6 b, and hence has a profile 
unlike that o f  either ETA or ETB, (Harrison et al, 1992). In the dog, sarafotoxin 6 c caused 
reduced coronary flow despite the infusion o f the ETA antagonist BQ-123 (Teerlink et al, 
1994). In human vessels, Bax et al (1994), indicate that the contraction o f  coronary artery 
is mediated by a subtype o f ETA receptor based on the different effectiveness o f  the 
antagonists BQ-123 and FR 139317, against contractions induced by endothelin-1 and 
sarafotoxin 6 b.
From the evidence cited above, and further studies using different non-selective antagonists 
it is likely that the ETB receptor is divided into tw o pharmacologically distinct subtypes 
These can be distinguished according to the differential selectivity o f antagonists and 
according to the vascular site. The "classical" ETB receptor which mediates vasodilatation 
and which is situated on the endothelium is sensitive to the non-selective endothelin 
receptor antagonist PD 142893. This receptor has been provisionally termed ETB1. The 
ETB receptor which has been shown to mediate vasoconstriction in many preparations and 
is sited on vascular smooth muscle is PD 142893-insensitive and has been provisionally 
termed ET B 2  (Bax & Saxena, 1994; Douglas et al, 1994). These subtypes have yet to  be 
distinguished according to primary amino acid sequence.
It is likely that further work will reveal a wider range o f  endothelin/receptor interactions.
!
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1.4 Actions and proposed roles of endothelins
Following discovery o f the potent vasoconstrictor effect o f the endothelins, a considerable 
amount o f work was done to elucidate the role o f  these peptides in health and disease, but 
as yet, this has not been fully determined. Several studies performed measuring plasma 
levels o f endothelin - 1  by radioimmunoassay, in man gave ranges o f 0.26 to 2 . 6  pg .m l1. 
Measurements in disease states in man showed higher concentrations o f immunoreactive 
endothelin-1, in myocardial infarction (up to a 6.5x increase) and vasospastic angina 
pectoris (>2x increase). Other conditions where a rise was measured include uraemia and in 
patients undergoing haemodialysis (3.5x-6x increase), cerebral ischaemic conditions (4.4x- 
6 x increase), pulmonary hypertension (2.4x increase) and hypertension o f pregnancy (1.9x 
increase over a higher basal level in pregnant women); see Sokolovsky (1992) for review. 
The role o f  endothelins in regulation o f  vascular tone and in multiple other physiological 
processes has been highlighted following measurement o f  their activity by bioassay. Studies 
o f [ 1 2 5 I]-endothelin binding also show that the peptides may be active in a wide range o f 
species and in many different preparations, and the growing use o f antagonists, including 
those which are orally active, has led to further implication o f the endothelins in 
pathophysiological processes. For example, Clozel et al. (1993) used the orally active ETA 
and ETb non-selective compound Ro 46-2005 in a variety o f models and described its 
effectiveness against pathological vasospasm (renal and cerebral), as well as in a sodium- 
depletion model o f hypertension.
As well as the vasoconstrictor and vasodilator activity of the endothelins previously 
described, the peptides have been shown to stimulate the proliferation o f cells in culture 
(Battistini et al, 1993; MacNulty et al, 1990; Yamagishi et al., 1993) including that o f 
vascular smooth muscle cells. The mitogenic properties o f endothelins are complex and are 
synergistic with other mitogens such as platelet-derived growth factor (see Battistini et al. 
(1993) for review).
The effect o f these peptides also involves interactions with other vasoactive substances in 
several ways. Firstly the endothelins have been shown to  modulate the release o f  substances
such as noradrenaline from perivascular nerve endings (Wong-Dusting el al, 1989) 
probably via ETB receptor stimulation as these have been identified on both adrenergic and 
cholinergic neurons (Takimoto el al, 1993). The peptides have also been shown to release 
PGI2  and NO from endothelial cells (Warner et al., 1989; Emori et al., 1991; Namiki el 
al, 1992; White el al., 1993), endothelium-derived hyperpolarising factor from pulmonary 
vasculature (Lippton et al., 1991) and atrial natriuretic peptide from rat atria (Fukuda et al, 
1988). Secondly the endothelins have been shown to stimulate the enzymatic conversion of 
angiotensin I to angiotensin II in lung endothelium (Kawaguchi el al, 1990). Thirdly, the 
effect o f several vasoactive substances has been shown to be potentiated by the presence of 
sub-threshold concentrations o f endothelin-1; Yang et al. (1990) demonstrated that both 
noradrenaline and 5-hydroxytryptamine responses, as well as the sensitivity o f vessels to 
calcium chloride, were increased in the presence o f endothelin - 1 concentrations o f  up to 
InM, in human coronary and internal mammary vessels. A similar finding is reported in the 
contractile response to 5-hydroxytryptamine in porcine coronary artery (Nakayama et al, 
1991). In addition, the presence of monocytes or macrophages has been shown to increase 
the vasoconstrictor potency o f  endothelin-1 (Magazine et al, 1994), an effect which has 
implications for the role o f endothelins in inflammatory responses.
Some o f  the non-cardiovascular actions of the endothelin peptides are summarised in table
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Reduction in glomerular filtration rate 
Mesangial cell proliferation 
Reduction in renin release
Decrease in sodium reabsorption
Vasoconstriction (artery>vein); increased 
permeability
Increased mucus and chloride secretion; prostanoid 
release
Contraction (enhanced with epithelial loss)
Ulcerogenicity, vasoconstriction 
Contraction and relaxation 
Ion secretion
Glycogenolysis
Contraction o f bile cannaliculae
Vasoconstriction























ETa/ETh Prostanoid secretion stimulated
ETa./ETr Stimulation o f  contractions
? Mitogenesis
ETa Contraction
? Steroid synthesis stimulated
? Indirect inhibition o f  aggregation (via nitric
oxide/prostacyclin production).
? Stimulation o f  aggregation
? Chemotaxis
ETa/ETr Vasoconstriction, mitogenesis (pericytes and
endothelium)
ET r Modulation o f  pupil reaction and size
7  Inhibition o f aqueous humour production.
reduction in intra-ocular pressure 












? Inhibition o f thyroglobulin secretion
? Modulation of parathormone secretion
ET a/ETr Synergy with angiotensin II in stimulation o f
aldosterone secretion,
?ETC Stimulation of catecholamine secretion
Decrease in regional cerebral blood flow 
Inhibition of water intake 
Enhanced sympathetic efferent activity to kidney 
ETa/ETr Elevation o f plasma catecholamine, ACTH,
/ETC arginine vasopressin, and glucose level
Respiratory depression 
Increase / decrease in blood pressure 
Stimulation o f pyramidal neurones 




M otor and sensory nerves ? Redaction in motor and sensory neuronal blood
flow
Decreased conductance
Release o f Substance P to activate spinal cord
neurons
Parasympathetic system ? Stimulation o f  acetylcholine (ACh) release,
Sympathetic system
potentiation o f  ACh in intestine 
Inhibition o f noradrenaline release
Potentiation o f noradrenaline action
Suppression / augmentation of baroreceptor
reflexes
The cardiac effects and coronary effects of the endothelins are o f particular relevance to this 
study and are described below.
1.4.1 Coronary effects of endothelins
Vascular effects o f endothelins are o f interest in the light o f the vasospastic problems 
associated with coronary artery disease, and with reduced flow after reperfusion.
The endothelin-induced long-lasting vasoconstriction noted by Yanagisawa et al. (1988) is 
apparent in all vascular beds, but is often preceded by a transient vasodilator effect. This 
vasodilatation has been seen in several vascular beds but is not universally present. Its 
presence appears to be dependent on functional endothelium and is subject to tachyphylaxis 
(Le Monnier de Gouville & Cavero, 1991). In the coronary circulation also, the vasodilator 
/ vasoconstrictor effects have been demonstrated in isolated perfused rat hearts (Baydoun et 
al., 1990; Neubauer et al., 1990), with differential sensitivities among microvessels 
(Homma et al., 1992). The vasodilator component o f  the response in guinea pig hearts 
(Folta et al, 1989) and in porcine coronary strips (Ushio-Fukai et al, 1992) was shown to 
be endothelium dependent. The mechanism o f  this coronary vasodilatation has been shown
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to vary between species; a study in rat heart found no evidence o f PGI2  involvement 
(Baydoun et al., 1990) but in guinea pig heart (Karwatowska-Propopczuk & Wennmalm, 
1990) and dog heart (Okamura et al., 1992), PGI2  dependence has been demonstrated .
The stimulation o f endothelium to produce NO and PGI2  has been linked with the 
vasodilator action o f endothelins in several other preparations (Warner et al., 1989; Mehta 
et al., 1992; Namiki et al., 1992). In studies using either endothelin-1 or endothelin-3 in 
coronary vessels, dependence on endothelial function appears to be species or preparation 
related; e.g. in dog coronary, the removal o f endothelium does not result in reduction o f  the 
dilator phase o f  the response to endothelin-3 (Okamura et al, 1992), whereas in porcine 
coronary artery, endothelium dependence and release o f NO have been demonstrated 
(Pem ow & Modin, 1993; Ushio-Fukai et al., 1992). However, in cultured porcine 
coronary endothelial cells production of NO in response to endothelin - 1  was not o f major 
significance and PGI2  production was predominant (Suzuki et a l, 1991). In this latter 
study, the presence o f  the appropriate receptors in endothelial cells in culture was not
demonstrated and may be relevant to the effect seen (White et al., 1993).
Vasoconstriction to higher doses / concentrations o f  endothelins in coronary vessels is 
consistently reported. This may be seen in isolated coronary preparations or in isolated 
heart preparations in vitro, (e.g. in rat, Baydoun et a l , 1989; Neubauer et al., 1991) or 
following intracoronary injection of endothelins in vivo (e.g. in canine heart, Clozel & 
Clozel, 1989; Horn et al, 1992). This reduction in coronary flow in canine hearts in vivo 
was selective for sub-epicardial vessels (Clozel & Clozel, 1989), suggesting that endothelin 
may be involved in local flow regulation in the heart.
Another vascular effect of the endothelins is the hypertrophic and hyperplastic growth of 
smooth muscle cells in culture, which may be o f relevance to the development of
atheromatous plaques in which muscle cell growth is a factor (Bobik et al, 1990).
1.4.2 Other cardiac effects o f endothelins
In addition to their coronary effects, endothelins have been shown to increase rate of 
beating o f  isolated atrial preparations (Ishikawa et al, 1988). This was probably the result
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of a direct effect on the cells. However, in the intact rabbit heart, an overall negative 
chronotropic effect has been reported following bolus injection o f endothelins 
(Karwatowska-Propopczuk & Wennmalm, 1990). This could be an indirect result o f the 
response to reduced coronary flow provoked by the peptides.
Endothelin - 1  has been shown to be positively inotropic, increasing contractility of atrial or 
ventricular myocardium of rabbit, guinea pig and rat (Takanashi & Endoh, 1991; Horn et 
al, 1992) although results in canine hearts are less clear (Takanashi & Endoh, 1991). 
Baydoun et a l (1989) reported an early positive inotropic followed by an irreversible 
negative inotropic effect in rat hearts after repeated bolus injection o f endothelin in rat 
hearts; this could be a secondary effect o f coronary vasoconstriction.
Another effect described for endothelin-1 is a hypertrophic action on rat myocardial cells. 
Evidence suggests that this is as a result o f increasing transcription o f  specific genes such as 
those encoding a -  and 6 -myosin heavy chain (Wang et al., 1992).
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1.5 Intracellular calcium as a second messenger
1.5.1 Calcium and vascular tone
Changes in coronary vascular resistance are dependent on the tone o f smooth muscle cells 
which surround the lumen of the vessel. Changes in this tone are important in maintenance 
o f adequate coronary flow where the blood pressure may be unstable (Hoffman & Spaan, 
1990). Ionised calcium is important in maintenance o f tone and for contraction o f  the 
vascular smooth muscle cells, the interaction o f calcium with contractile proteins being a 
major part o f the development o f  tone. The calcium for contraction is therefore increased in 
local concentration in response to extracellular stimuli. It is, however, possible for 
contraction to occur without any discernible increase in intracellular calcium, and this could 
be due to a local change not being detectable within the overall cell calcium concentration, 
to increased sensitivity o f contractile proteins to the calcium present (which may be 
modulated by DAG (diacylglycerol)), or to a direct phosphorylation o f the contractile 
proteins themselves which may have a modulating effect (Morgan & Suematsu 1990). The 
contractile proteins actin and myosin overlap in the cells by an active process involving ATP 
and calcium in the manner outlined in figure 1-5.
Briefly, three or four calcium ions are required to bind with a single molecule o f  calmodulin, 
an acidic protein within the smooth muscle cell, before this calcium-calmodulin complex will 
activate a molecule o f myosin light chain kinase. This activated enzyme phosphorylates two 
light chains o f myosin, by transference o f a phosphate group from ATP. The 
phosphorylated myosin may then interact with the contractile protein actin by the formation 
and cycling o f cross bridges, allowing sliding of one protein over another (see Bolton 
(1986) for review). Other structural proteins are involved in smooth muscle contraction, 
notably caldesmon which binds to filamentous actin in the absence o f calcium (see M organ 
& Suematsu, 1990) and may help to stabilise the actin-myosin complex and maintain a 
degree o f smooth muscle contractile tone. Other kinases may also be involved in the 
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Figure 1-5
Scheme for the biological regulation of myosin phosphorylation in smooth muscle cells 
CM=calmodulin, MLCK=myosin light chain kinase; myosin-P = phosphorylated myosin. 
From Kamm & Stull (1985).
1.5.2 Calcium homeostasis
In order for this calcium-mediated effect to be controlled adequately, there must be constant 
regulation of the intracellular concentration o f calcium ions, and mechanisms for an increase 
in calcium concentration when signalled by extracellular stimuli such as receptor activation 
Under resting conditions, [Ca2"], in smooth muscle remains at nanomolar levels, 50-150nM 
concentrations o f free calcium being regularly quoted. However, on stimulation this value 
has been shown to reach micromolar levels for a brief period Following stimulation, the 
excess calcium is lowered following uptake into sarcoplasmic reticulum stores via a calcium 
calcium/magnesium ATPase or sequestered into organelles, or removed from the cell via 
extrusion mechanisms such as the calcium/magnesium ATPase and the sodium/calcium 
exchanger in the cell membrane (see Bolton, 1986)
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1 .5 .3  I n c r e a s e s  in i n t r a c e l l u l a r  c a l c i u m
The rise in intracellular calcium following interaction between a ligand and its receptor may 
be brought about via several linked mechanisms. The release of stored calcium is most 
commonly triggered by inositol (1,4,5) triphosphate (IP3) acting on its receptor in the 
sarcoplasmic reticulum, this release from stores being responsible for the immediate 
transient [Ca2+]s increase seen on stimulation. Another trigger is the activation of the so- 
called ryanodine receptor for which an endogenous sensitising ligand has been proposed 
(cyclic AJDP ribose - Galione, 1992), and this is linked to a positive feedback o f calcium- 
induced calcium release, via an action on the ryanodine receptor. This latter sarcoplasmic 
reticulum channel may also be opened by caffeine (Berridge, 1993).
1.5.4 Signal transduction for intracellular calcium increase
The intracellular events leading to release o f DP3  are usually evoked by a ligand acting on a 
GTP-dependent protein (G-protein)-linked receptor. The subsequent activation of 
phospholipase C ( 6 ,) results in the hydrolysis o f  PEP2  (phosphatidylinositol 4,5- 
bisphosphate) giving the products IP 3  and DAG (see above). DAG may also activate 
protein kinase C (PKC) which is involved in the process o f mitogenesis. PKC may also be 
involved in the amplification o f the calcium signal through its phosphorylation o f the L-type 
calcium channel. The activation of phospholipase C (yt) and subsequent IP 3  production, 
may also be brought about via activation o f a tyrosine kinase-linked receptor, using ATP 
rather than GTP as a source o f high energy phosphate. Following activation o f a tyrosine 
kinase-linked receptor, other intracellular second messengers may be activated including 
phosphatidylinositol (PI) 3 kinase and mitogen activating protein (MAP) kinase which may 
both have a role in gene transcription and mitogenesis.
When intracellular stores in some cells are depleted, this has been shown to trigger the 
release o f a small molecular weight messenger molecule (calcium influx factor; 
Randriamampita & Tsien, 1993), which provokes calcium influx through the cell membrane, 
allowing the calcium message to be prolonged.
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As well as release of calcium from intracellular stores, the increase in [Ca2']; may arise 
following increased entry of calcium into the cell. This is secondary to activation o f either 
receptor-operated calcium channels (ROCC) linked to specific receptors, or the activation 
o f voltage-operated calcium channels (VOCC - predominantly L-type on smooth muscle) 
which respond to depolarisation of the cell membrane. These channels interact as described 
above, raising intracellular levels of calcium which may then be amplified by calcium- 
induced calcium release from sarcoplasmic reticulum. A further way in which these 
channels may interact with the other signalling apparatus is in the effect o f  PKC on the 
channel opening again potentiating the calcium signal.
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1.6 Endothelin-stim ulated signal transduction
There has been little distinction made between the second messenger systems employed by 
all three endothelins whether acting via ETA or ETn receptors, and so the intracellular 
effects o f  endothelins as a peptide group will be discussed together, unless it is indicated 
that a particular receptor subtype has been implicated in the response seen. The second 
messenger systems activated by the endothelins and which are described below, interact in a 
complex manner, and are still under investigation.
1.6.1 G-Proteins involved in transmembrane signalling by endothelins
Both the ETa and ETB receptors are o f the conformation associated with G-protein 
interaction as stated above (section 1.3). In several studies, the effects o f endothelins have 
been shown to be pertussis toxin sensitive, suggesting that the effect o f the peptide is 
mediated via Gi or Go. In porcine coronary smooth muscle, for example, there is evidence 
that following receptor-ligand interaction the signal is transduced via such a G-protein, 
leading to opening o f VOCC either directly or indirectly (Kasuya et al, 1992). In rabbit 
rectosigmoid smooth muscle cells, endothelin receptors were found to be coupled to  two 
subtypes o f the Gi protein, each with a different signalling outcome (Bitar et al, 1992). In 
porcine endothelial cells in situ, a pertussis toxin-sensitive mechanism for the elevation of 
intracellular calcium via calcium influx, has been described (Aoki et al, 1994), and in guinea 
pig atrial myocytes a pertussis toxin sensitive G-protein (probably Gi) has been implicated in 
cardiac inhibition by endothelin acting on ETA receptors, reducing cyclic AMP formation 
(Ono et al, 1994).
However, some transduction events in response to  endothelins are pertussis toxin- 
insensitive (Bobik et al, 1990), hence it is possible that some events are either mediated 
through different G-proteins or not G-protein-linked at all. In another tissue (rat liver, 
Jouneaux et al, 1994), ETB receptors have been shown to be coupled to Gs and Gq, 
suggesting tissue specificity o f the transmembrane coupling.
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1.6.2 Calcium signalling
Endothelin was initially postulated as an endogenous ligand for L-type voltage operated 
calcium channels, as antagonists to these channels reduced the effect o f endothelin 
(Yanagisawa et al, 1988). However, though chelation o f extracellular calcium removed 
contractile responses in rat aortic strips, the response was not totally abolished using a 
dihydropyridine ((+)PN200-110). The effect on the ion channel was shown to be indirect, 
as no displacement o f  binding o f L-type calcium channel ligands by endothelin was seen 
(van Renterghem et al, 1988). One later report suggests that the binding o f tritiated 
nicardipine to calcium channels in the renal artery may be displaced by endothelin - 1  
(Amenta et al, 1993) but the significance of this, and its relevance to other calcium channel 
ligands, need further clarification. Many further studies have shown that endothelins do 
indeed produce an increase in intracellular calcium and this has been demonstrated by 
functional studies and calcium imaging techniques as well as by voltage-clamping studies 
(van Renterghem et al, 1988).
The increase in [Ca2+]i in response to endothelins is initiated via several different pathways. 
Tritiated rP 3  metabolism has been shown to increase as a result o f endothelin stimulation of 
smooth muscle (van Renterghem et al, 1988) leading to a transient increase in [Ca2+]i; and 
this response has since been demonstrated in many different cell types and preparations. 
For example, in human atrial myocytes (Vogelsang et al, 1993), fibroblasts (MacNulty et 
al, 1990) and in endothelial cells (Emori et al, 1991), a rise in IP 3  has been shown to 
follow endothelin-1 stimulation. Other receptors on the sarcoplasmic reticulum may also be 
activated following endothelin stimulation, including the ryanodine receptor (W agner Mann 
et al, 1992; W agner Mann & Sturek 1992), again resulting in the release o f calcium from 
stores. M ore detail on the actions of endothelin in increasing [Ca2_]j in smooth muscle cells 
is included below (section 1.7), as this may be o f particular relevance to the development of 
vasospasm in coronary heart disease.
32
1.6.3 Activation of other ion channels
1.6.3.1 Cation channels
Van Renterghem el al., (1988) also describe effects o f endothelin on membrane potential in 
a rat smooth muscle cell line, comprising a transient hyperpolarisation followed by 
depolarisation with calcium spiking. These phases corresponded with an outward K" 
current, followed by influx of cations probably via a non-selective cation channel which is 
permeable to Ca2+. This early study suggested that the depolarisation allowed membrane 
potential to reach the threshold for L-type channels to  be activated. Kasuya et al, (1992) 
argue that depolarisation alone, however, is insufficient to explain the degree o f calcium 
channel activation by endothelin-1 , hence a receptor operated mechanism may also be 
involved. A link has been demonstrated between increases in [Ca2+]j and [Na"]; in rat 
vascular smooth muscle cells (Okada et al, 1991), the uptake o f both o f these ions being 
stimulated by endothelin-1 .
1.6.3.2 Chloride channels
Opening o f the chloride channels in smooth muscle leads to depolarisation as the chloride 
reversal potential is less polarised than the resting potential in this tissue. Mesangial cells 
are closely related to smooth muscle cells, and retain many o f their features. In experiments 
in mesangial cells, there is evidence that the ETB receptor is linked to depolarisation via the 
opening of chloride channels and the closure o f  a potassium channel (Hu et al, 1993). It 
has been reported that endothelin also induces depolarisation in smooth muscle cells by the 
opening o f a chloride channel which is calcium activated (Iijima et al, 1991). 
Depolarisation also would potentiate the existing calcium signal by allowing further calcium 
entry through voltage operated channels. The overall importance of this mechanism is not 
clear, but is another mechanism o f potentiation o f the endothelin effect which adds to its 
overall potency. In cardiomyocytes, however, the chloride conductance has been shown to 
be inhibited by endothelin-1, the mechanism being E T A mediated, and pertussis toxin- 
sensitive (James et al, 1993).
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1.6.3.3 Potassium channels
It has been reported that endothelins block the ATP-sensitive potassium channels in porcine 
coronary smooth muscle and initiate depolarisation in this way (Miyoshi et al, 1992). 
These events lead to an increase in vascular tone. This increase in tone may, though, be 
alleviated in turn by the production o f endothelium-derived hyperpoiarising factor which 
opens potassium channels in smooth muscle as described in rat coronary vascular beds by 
Sakum ae/a/. (1993).
In the heart, the potassium channel effects are complex. Ono et al, (1994) describe 
hyperpolarisation o f cardiac cell membranes by ETA receptor-mediated stimulation o f an 
outward potassium current, and subsequent effects included inhibition o f inward calcium 
current. In contrast, PKC-mediated potassium channel inhibition has been reported to result 
in the potentiation o f calcium currents by endothelins in rat cardiac myocytes (Damron et 
al, 1993).
1.6.4 PKC activation
PKC effector mechanisms are complex involving feedback on calcium entry (see above), 
and the enzyme is also involved in the activation o f the NaVH+ exchanger which is reported 
to result in intracellular alkalinisation. PKC activation has been demonstrated as a result of 
endothelin-receptor interaction in vascular smooth muscle cells, the effects o f endothelin on 
intracellular pH being blocked by staurosporine, a PKC inhibitor (Danthuluri & Brock 
1990). This pH rise may be responsible for sensitisation o f the contractile proteins to 
calcium, allowing contraction without a discernible rise in [Ca2~];. The sensitisation o f the 
contractile apparatus following endothelin receptor activation has been shown also in strips 
o f rat aorta, where sarafotoxin 6 b initiated a contraction apparently independent o f release 
o f  calcium from stores in calcium-free buffer. This effect was sensitive to the PKC inhibitor 
H-7 (Watanabe et al, 1993). Endothelin-1-induced activation o f the Na+/H+ exchange has 
also been reported in rat mesangial cells and rat ventricular myocytes. The mechanism 
identified again includes an increase in intracellular alkalinisation (Simonson et al., 1989;
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Kramer et al, 1991), resulting in increased sensitivity to calcium of the contractile proteins 
in myocytes. In mesangial cell experiments, the increase in PKC activity on endothelin 
stimulation was accompanied by stimulated mitogenesis (Simonson et al, 1989). The 
adverse effects o f endothelins on contraction and intracellular metabolism after ischaemia / 
reperfusion may be partly attributed to the activation of NaVH+ exchange as these have 
been shown to be reversed by methylisobutyl amiloride, which inhibits this mechanism 
(Khandoudi eta l, 1994).
The activation o f the Na+/H+ exchange mechanism by endothelins may be independent of 
PKC activation, in response to the peptide binding to some subtypes o f the endothelin 
receptors, a possible means o f differentiation between the subtypes o f receptor on functional 
grounds (Frelin et al., 1991).
The measurement o f  pH generally incurs use o f fluorescent markers such as BCECF, which 
are usually used in a HEPES-buffered medium. The effects o f endothelins in physiologically 
buffered systems are not so clearly documented. In human umbilical artery smooth muscle 
cells, however, no effect from endothelin on intracellular pH was seen, using BCECF in a 
HEPES-buffered medium (Gardner et al, 1992). This may suggest that the effect of 
endothelin on the Na+/H+ exchanger is cell or species dependent, in addition to other 
considerations.
1.6.5 Phospholipase activation
As well as the activation of phospholipase C, which results in IP3  production, as discussed 
above (section 1.5.4), the interaction o f endothelins with their receptors initiates enzyme 
activity in other phospholipases. These include phospholipase D (PLD) (Plevin et al.. 
1994), which, through its hydrolysis o f phosphatidyl choline, releases phosphatidic acid, 
which in turn may have second messenger roles in the contraction o f smooth muscle. The 
further hydrolysis o f phosphatidic acid (by phosphatidic hydrolase) to diacylglycerol may 
indicate that the activation o f PKC by this route may also be a method by which endothelins 
are involved in the calcium message and cell growth. It has been shown that the endothelin- 
stimulated effect o f PLD may be itself regulated by PKC in hypoxic smooth muscle cells
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(Plevin el ai, 1994). The interaction between PKC and PLD in other cells has been 
demonstrated, where PLD activation by endothelins has been shown to be by both PKC- 
dependent and -independent pathways (rat fibroblast and glioma cell lines - Ambar & 
Sokolovsky 1993; rat mesangial cells - Kester el al., 1992). It has also been shown that 
PLD activation is dependent on the action o f tyrosine kinase (see below), in a rat aortic 
smooth muscle cell line (Wilkes & Boarder, 1992).
The activation o f phospholipase A2  (PLA^) by endothelins has been reported, probably by 
direct coupling o f the receptor to the enzyme in renal interstitial cells, and resulting in an 
increase in prostaglandin E 2  production (Barnett el ai, 1994). This activation may also be 
independent o f  PKC.
1.6.6 Tyrosine kinase activation
Endothelins have been shown to stimulate the phosphorylation on tyrosine in several 
proteins. MAP kinase p42 phosphorylation on both tyrosine and threonine has been shown 
in mesangial cells to follow endothelin - 1  stimulation, and involvement o f both tyrosine 
kinase and PKC has been implicated (Wang et al, 1993). In osteoblast-like cells, DNA 
synthesis stimulated by endothelin - 1  has been associated with an increase of tyrosine 
phosphorylation, in a manner synergistic with platelet-derived growth factor (PDGF) 
(Schvartz et al., 1992). This parallels the synergy o f endothelins with PDGF and other 
mitogens described by Battistini el ai, (1993). In (rat aortic) vascular smooth muscle cells, 
tyrosine kinase activation in response to endothelin-1 has also been demonstrated (Koide et 
ai, 1992a,b). However, it was not considered that this was sufficient to account for 
stimulation o f  muscle cell proliferation, as increased DNA synthesis and increase in cell 
number did not accompany the phosphorylation seen (Koide et ai, 1992a). In view o f the 
finding that the same set o f proteins was also phosphorylated on tyrosine by PDGF, this 
indicates that synergistic interaction of endothelin with other growth factors may be 
necessary in vascular smooth muscle cell proliferation. It is possible also that tyrosine 
kinase activation in vascular smooth muscle may not be associated with cell proliferation, 
but with other responses such as contraction. It has been demonstrated, however, that
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DNA synthesis may be stimulated in similarly cultured vascular smooth muscle cells in 
response to endothelin, the effect being mediated via ETA receptors (Eguchi et a i,  1992).
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1.7 Models of measurement of intracellular calcium in smooth muscle cells
1.7.1 Calcium indicators
Intracellular calcium may be measured using a generation o f fluorescent calcium indicators 
which were developed for their ability to bind to calcium with high affinity, and for their 
fluorescent qualities. Many are analogues o f the calcium chelating agent BAPTA (1,2-bis- 
(2-aminophenoxy)ethane-A(Ar,Ar' A^-tetra-acetic acid, a double aromatic analogue o f EGTA) 
which are highly selective for calcium (Grynkiewicz el al., 1985). Compounds such as 
quin2 are not fluorescent unless calcium is bound. Fura-2 is a compound fluorescent at a 
380nm excitation wavelength, which fluoresces in response to a different excitation 
wavelength (340nm) when calcium binding occurs, allowing calculation o f the ratio of 
bound to unbound fura-2. The advantage o f this is that differences in total fluorescence 
related to the local concentration o f the indicator are accounted for. Indo - 1  also has the 
advantage o f allowing the bound:unbound ratio to be calculated but, in this case, the 
excitation wavelength remains the same whereas the emission from the two forms o f the 
indicator occurs at different wavelengths (Cobbold & Rink, 1987).
1.7.2 Fluorimetric assay of calcium responses to endothelins in vascular smooth 
muscle cells
Many studies on vascular smooth muscle cells have been performed using endothelins, 
giving a variety o f different results, some showing a plateau phase o f calcium elevation after 
an initial spike, and others with only the transient which has been attributed to IP3-induced 
mobilisation o f calcium from intracellular stores. The variability has been attributed to 
differing effects o f high and low doses o f endothelins as well as to the multiplicity o f  models 
used in measurement o f [Ca2+]i (Wagner Mann & Sturek, 1992). Species differences as 
well as differences in the manner of cell preparation and observation are possible reasons for 
the variation o f responses described. Some o f the models which have been used are 
outlined below, together with examples o f the experimental findings from their use.
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/. 7.2.1 Single cell studies
Responses in fresh enzymatically-dispersed porcine coronary smooth muscle cells were 
described by Wagner Mann & Sturek (1991). These authors suggest that a freshly 
dispersed single smooth muscle cell more closely approaches physiological reality than, for 
example cultured cell preparations. From using a combination of endothelin treatment with 
caffeine-depletion o f  intracellular stores and potassium-induced depolarisation they 
conclude that the stores from which calcium is released are different in porcine preparations 
than in bovine smooth muscle cells. The stores in porcine cells are described as less 
ryanodine sensitive than those in their bovine equivalent (Wagner Mann eta l, 1991). Both 
peak and plateau phases of the response are described as inclusive o f calcium influx. In 
porcine cells, however, no plateau phase o f  sustained calcium rise was evident when 
exposure o f the single cells to the peptide was prolonged (Wagner Mann & Sturek, 1991), 
superfusion o f  the cells being included in the protocol in experiments where the plateau was 
demonstrated. This is attributed to depletion o f  intracellular stores with time, and the net 
calcium influx being balanced by efflux.
In single cells from rat aortic smooth muscle cell cultures also, a biphasic calcium increase 
has been demonstrated (Iijima et al, 1991). The sustained phase was virtually abolished in 
the absence o f  extracellular calcium. The efflux o f chloride ions, through chloride channel 
activation, and subsequent depolarisation was cited in this study as responsible for the 
plateau phase o f the increase in [Ca24];.
It can be argued that the detail o f the calcium response in a single cell can more clearly be 
described than in a larger population.
1.7.2.2 Cell populations in suspension
Calcium measurements from cells in suspension give the mean response of a larger number 
o f cells, allowing for responses in small numbers o f atypical cells to be ignored. 
Disadvantages include the excessive numbers required in a single experiment, and the loss 
o f responses in individual cells such as the spiking o f calcium transients. The disruption of a 
growing monolayer for dispersal may also result in some damage to cells.
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Van Renterghem el a!., (1988) measured intracellular calcium rise in a rat vascular smooth 
muscle cell line (suspensions of A7r5 cells) by flow cytometry. The increase in [Ca2*]; 
could be explained mainly by a mechanism of IP3-mediated release, rather than entry 
through calcium channels. A sustained phase o f calcium elevation was not evident in these 
experiments.
Wallnofer el al, (1989) also performed some o f the earlier fluorimetric assays to determine 
whether endothelin acted as an endogenous VOCC activator. They concluded that this is 
not the case but that their results were compatible with endothelin activation o f a receptor- 
operated calcium channel (ROCC). In a suspension o f cells from a rat aortic cell line (A 1 0 ), 
a peak and plateau response to endothelin were seen, the peak and plateau both being 
susceptible to removal o f extracellular calcium, although the initial component o f  the 
response was not completely lost in calcium-free conditions. Parallel experiments revealed 
that the sustained intracellular calcium increase was greater than could be explained by entry 
alone, as measured by .45Ca influx.
Ihara et al., (1991) describe the calcium responses in porcine coronary artery smooth 
muscle cells in culture to endothelin-1 and endothelin-3. Endothelin-1 initiated an increase 
in [Ca2+]i whereas endothelin-3 had little effect compared to endothelin-1. Parallel binding 
studies revealed no ETB-like receptors (with potency o f ET-l=ET-3) on the cultured cells, 
although on cell membranes from the original endothelium-denuded porcine coronary 
arteries two binding sites were found, one endothelin-1-selective (ETA) and the other 
resembling ETB in its potency profile. The contraction o f coronary arteries to both 
endothelins was demonstrated leaving the receptor subtype involved in question. It is 
possible that cells containing ETB receptors are not present after cell culture, or that this 
subtype is downregulated under some culture conditions.
1.7.2.3 Cell populations in confluent monolayers
Cells grown in this manner have the capability o f intercellular communication, and could be 
argued to be more likely to act as a physiological unity in response. Smooth muscle cells
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which grow in culture in this manner do not require dispersion. However, some o f  the 
detail o f an individual cell's response will be lost.
The requirement o f calcium for both phases of the calcium response was demonstrated by 
Gardner et al, (1992) in human umbilical artery smooth muscle cells grown to confluence 
on coverslips. Low extracellular calcium, as well as nicardipine, attenuated both the 
immediate spike and sustained phases. The presence and involvement o f VOCCs in the 
endothelin - 1  response, was demonstrated using the fluorescence-quenching properties of 
Mn2+ which enters via these channels in depolarised cells.
Okishio et al., (1992) demonstrated a peak and plateau phase o f the response to endothelin- 
1 in rat aortic smooth muscle cells grown in monolayers on coverslips. The peak and 
plateau phases were sensitive to addition of S-nitrosothiols, NO-donating compounds, with 
the plateau most severely attenuated. The authors suggest that the calcium influx 
component o f the rise in [Ca2+]i is thus affected by these compounds, but not release from 
stores.
Using rat aortic smooth muscle cells grown in monolayers, Little et al, (1992) compared 
responses in [Ca2+]i following addition o f  endothelin - 1  and endothelin-3. A sustained rise in 
[Ca2+]i is not clearly indicated and is not discussed. The endothelin-1 - and endothelin-3- 
stimulated calcium transient was reduced in the absence o f extracellular calcium. The 
transient was described as being due to mobilisation o f  intracellular stores as well as to entry 
through calcium channels. IP 3  production was also determined by chromatographic 
measurement o f  the tritiated compound. The results indicate that mechanisms o f calcium 
increase differ between the two endothelins, although mobilisation o f intracellular stores of 
calcium was a feature o f  the response to both. IP 3  was not increased by addition of 
endothelin-3 to a level which would mobilise calcium, whereas endothelin-1 was responsible 
for a greater increase in production above basal levels. The authors postulate that cADP 
ribose could release the intracellular calcium stores. There is no evidence to suggest which 
receptor subtype is involved in the response to either peptide.
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/. 7.2.4 l<ran! surface fhiorimeiry
This technique involves more specialised equipment, but measures [Ca2+]; in cells in situ. 
Thus the findings from these studies should more closely resemble the physiological state 
and in some studies, the calcium measurement can be performed simultaneously with 
measurement o f  developed force. Yoshida et ai, (1994) performed such studies in 
endothelium-denuded rabbit mesenteric artery. In these smooth muscle cells, the contractile 
responses were shown to be mediated by ETA receptors as BQ-123 was completely 
inhibitory and the ETB receptor agonist IRL 1620 was ineffective. The calcium responses 
were shown to  be due to influx at low endothelin concentrations, as there was no increase in 
[Ca2+]j to these concentration in calcium-free extracellular solution. Higher concentrations 
did result in mobilisation of calcium from stores. The increase in force in the strips was out 
o f proportion to the rise of [Ca2 + ] i 5 when compared with the contractions produced by 
noradrenaline and by high potassium. In permeabilised muscle strips, increasing 
extracellular calcium concentrations caused a simultaneous increase in [Ca2+]; and in force 
development. Endothelin - 1  had little effect on [Ca2+]j but very markedly increased force, 
suggesting that the peptide increased the sensitivity o f  the contractile proteins. BQ-123 
inhibited the endothelin-1 -induced enhancement o f  this calcium-induced contraction 
suggesting that the protein sensitisation is mediated via ETA receptors.
The question remains o f the contribution o f the choice o f model to the results gained. 
Whether the same cell type grown under identical culture conditions will respond to 
endothelin in the same way if measurements are made in a cell suspension, in monolayers of 
confluent cells or in single cells, is not clear.
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1.8 Role of endothelins in ischacmia and rcpcrfusion
There are several indications o f a potential role for the endothelins in the cardiac damage 
which follows ischaemia and/or reperfusion (see section 1 . 1  above), most o f which mirror 
the evidence o f the involvement of these peptides in ischaemic damage o f other organs, such 
as the kidney and brain (see Simonson, 1993). Direct injection of endothelin-1 into dog 
coronary arteries results in coronary vasospasm and prolonged myocardial ischaemia (e.g. 
Kurihara et al, 1989). The initial evidence for the endothelins' involvement in ischaemic 
heart disease was for an increase in cardiac and plasma concentrations o f immunoreactive 
endothelin after myocardial infarction (Watanabe et al., 1990) and possibly following 
coronary vasospasm and percutaneous transluminal coronary angioplasty, although there is 
conflicting evidence in the latter case (see Tonessen et al, 1993). These increased levels 
probably result from an increase in de novo synthesis o f  the peptides, as there is no evidence 
o f vesicular storage o f  endothelins. Indeed there are reports in several models o f  an 
increase in gene expression and subsequent release o f endothelin - 1  from the heart after 
ischaemia / reperfusion. In one study in porcine hearts, reperfusion after 10 minutes of 
coronary arterial occlusion resulted in an increase o f released endothelin-1 (Tonessen et al, 
1993). A separate study in a porcine model suggested the endothelium as source o f  the 
increased endothelin levels released on reperfiision (Franco-Cereceda et al, 1994). The 
endothelial cells may not be the source o f the increase in endothelin synthesis, however. In 
another report, porcine cardiomyocytes biopsied from animals undergoing coronary ligation 
were found to contain increased endothelin-1 mRNA on Northern blotting, compared with 
controls, although there was no increase in coronary vascular mRNA (endothelial or smooth 
muscle; Tonessen et al, 1995). In the isolated rat heart model also, an increase in 
endothelin release was seen in early reperfusion following low-flow hypoxic ischaemia, 
which could adversely affect the coronary vasculature although it is suggested (Brunner et 
al, 1992) that the concentrations reached are too low to have an effect on myocardial 
contractile function (stunning).
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In line with the increase in local accumulation of endothelins after ischaemia / rcperfusion. 
there are several reports relating to the involvement o f endothelins in subsequent cardiac 
damage. The coronary vasospasm which follows experimental balloon-induced arterial 
injury in pigs can be significantly reduced after intracoronary injection o f the E T A antagonist 
BQ-123 (Fukai et al, 1993), suggesting potential involvement of the peptides in vasospasm 
after percutaneous transluminal coronary angioplasty. Involvement in the development of 
myocardial infarction is also suggested; a study by Watanabe et al, (1991) showed that 
anti-endothelin antibodies could reduce the size o f myocardial infarction in the rat. This 
potential involvement o f the peptides in myocardial pathology is further supported by a 
study in which BQ-123 reduced infarct size in the dog heart by up to 40% (Grover el al, 
1993). However, this projected (ETA receptor-mediated) involvement o f endothelins in 
exacerbating the size o f myocardial infarction may not be common to all species, as 
M cM urdo et a l, (1994) found no reduction in infarct size in the rabbit after infusion o f  the 
ETA receptor antagonist FR 139317. Conversely, another report suggests that pathological 
concentrations o f  endothelins following coronary occlusion may have positive effects on 
collateral flow; in a study in dogs (Donckier et al, 1994) injection o f  endothelin-1 appears 
to have caused a selective increase in collateral blood flow to the ischaemic region without 
resulting in changes in flow to the non-ischaemic region. The increased flow, however, did 
not ameliorate recovery o f function which was indeed exacerbated in endothelin-treated 
hearts. The mechanism o f this loss o f cardiomyocyte function may be related to increased 
calcium toxicity; endothelin - 1  has been shown to cause increased cellular damage in 
simulated ischaemia in myocytes, through an effect blockable by use o f nifedipine (Stawski 
el al, 1991).
The damage resulting from endothelin administration may not be completely due to a direct 
action o f the peptides. For example, a role for blood cells in the damage in which 
endothelin is implicated has been postulated. Lopez Farre et al (1993) describe endothelin- 
stimulated neutrophil adhesion in the rabbit heart in vivo and in vitro, via increased 
expression o f  integrin adhesion molecules (CD 18 and CD l ib  complex). Increased 
accumulation o f  neutrophils and their release o f  superoxide and other reactive species could
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contribute to the vascular damage leading to increased development of infarct size and other 
postulated detrimental effect o f endothelins. It is also likely that the ST segment elevation 
o f the electrocardiogram (an indicator o f myocardial injury) and capillary leakage resulting 
from endothelin - 1 administration may be aggravated by its release o f other local mediators 
(Filep et al, 1994) such as thromboxane and platelet activating factor, via activation of 
ETa receptors. Another study in isolated canine blood vessels provides evidence against 
hypoxic vasoconstriction being mediated by endothelin-1, however, as BQ-123 was 
ineffective against its development (Douglas et al., 1993).
In order to investigate further the background for the involvement o f endothelins in 
myocardial infarction, Liu et al, (1990) explored the circumstances in which [ l2 5 I]- 
endothelin - 1  binding to rat cardiac membranes was increased, selecting cardiac acidosis, 
hypoxia, reoxygenation and ischaemia / reperfusion or recurrent ischaemic episodes. These 
experiments were performed in isolated perfused rat hearts under conditions o f constant 
flow using modified Krebs perfusate. It was found that 30 minutes global ischaemia alone, 
30 minutes o f ischaemia with reperfusion, and reoxygenation after 30 minutes o f hypoxia 
(but not hypoxia alone) resulted in a significant increase in for endothelin-1 . The 
mechanism o f this increase in binding site density was also investigated by separation of 
membrane fractions and evidence was found o f increased extemalisation of receptors (Liu et 
al, 1989), and it was suggested that these were probably o f the ETA receptor subtype. An 
increase in cardiac membrane binding (Bmax) o f endothelin-1 was also seen in isolated 
perfused rabbit hearts (Fushimi et al, 1992) under a similar protocol. The time-dependent 
increase in Bmax o f endothelin-1 binding can be attenuated by pretreatment with amlodipine 
in rat hearts in a dose-dependent manner (Nayler et al, 1992) or by L-nitro-arginine in 
rabbit hearts (Saito et al, 1993).
With the above evidence o f increased binding site density, the question needs to  be 
addressed of whether this represents an increase in functional receptors for endothelin-1 , 
accompanied by an increase in coronary or myocardial endothelin reactivity to the peptides. 
In dog coronary arteries, a report by Fushimi et al, (1992) describes increased reactivity,
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selective to endothelin-1 , following 60 minutes of ischaemia and 1 2 0  minutes o f reperfusion. 
It was suggested that the increased reactivity could be mediated by polymorphonuclear 
leucocytes (PMNs) as when ex vivo preparations o f dog coronary were subjected to 
simulated ischaemia and reperfusion, it was necessary for activated PMNs to be present for 
the enhancement o f reactivity to be seen. This potentiation would not necessitate the 
presence o f an increased number of functional contractile receptors, but in a later study in 
rabbit heart, upregulation of binding sites does appear itself to be potentiated by the 
presence o f  PMNs (Saito et al, 1993). McMurdo et al, (1991) describe an increase in the 
duration o f  coronary constriction to a single (lOOpmol) dose o f endothelin-1 in the isolated 
perfused rat heart, although the magnitude of the response was not affected. In the isolated 
rat hearts in this study, the conditions under which the increase in endothelin - 1  binding 
density were found to be increased are reproduced. Similar experiments in rat hearts were 
performed by Neubauer et al., (1991) measuring changes in coronary flow rate to 
successive bolus doses o f endothelin-1 at constant perfusion pressure. The contractile 
responses to endothelin-1 after 30 minutes o f ischaemia with subsequent reperfusion, were 
found to  be significantly enhanced but the enhancement was accompanied by loss o f  the 
initial vasodilator component o f the response described by Baydoun et al, (1990). The 
same authors also attempted to investigate the effects o f hypoxia and reoxygenation on 
responses to endothelin-1. However, it was impossible to reproduce the severity o f  the 
hypoxic conditions used in Liu's study, with the result o f increased endothelin binding, 
without loss o f  steady state; hence these conditions were modified to allow measurements 
to be made. The lack of enhancement of the vasoconstrictor endothelin-1 response after 
reoxygenation must be considered in the light o f these modifications, as no binding studies 
were performed under the new conditions.
The above evidence is certainly suggestive o f an increase in coronary reactivity following 
ischaemia and reperfusion, which correlates with the increase in binding site density and 
putative receptor number. However, the contribution made by loss o f a physiologically 
opposing vasodilatation after reperfiision is not clear.
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1 .8 . 1  Models of ischaemia and repcrfnsion
The model o f ischaemia / reperfiision used by Liu el al., (1990) and later by others to 
determine whether the upregulation o f binding sites resulted in an increased functional effect 
for the endothelins, is the Langendorff heart preparation. In this model, the coronary 
arteries in the isolated heart are perfused by retrograde perfusion of the aorta. Perfusion is 
achieved using an oxygenated, physiologically balanced and pH-buffered solution o f salts, 
commonly Kreb's Henseleit solution. The heart may be perfused either at constant pressure, 
measuring the changes in flow rate as utilised by Neubauer et al., (1991), or at a constant 
flow rate, measuring changes in perfusion pressure, as utilised by McMurdo et al., (1991). 
These parameters may both represent changes in coronary radius, as demonstrated by use of 
derivations o f the Hagen-Poiseuille equation: -
Pressure 1 / . rj . 8
  ---- —  x ------------------
Flow r4  7 u
Where r is radius o f the vessel, /  is the length o f  the tube system, and rj is the fluid viscosity.
The viscosity o f  the perfusate and length o f the system remain constant under experimental
protocol, so the equation may be simplified as follows
Pressure 1
Flow j4
As either pressure or flow is constant this will allow further simplification, allowing 
measurement o f  the variable parameter to reflect changes in vessel radius.
The isolated perfused heart model cannot replicate exactly the conditions o f physiological 
perfusion, as no perfusion system exactly mimics the fluctuations of perfusion pressure 
provoked by systole and diastole o f the normal heart in vivo. Moreover, myocardial 
contraction compresses the coronary arteries cyclically, and a mean value o f the pressure or 
flow must be taken (Hoffman & Spaan, 1990), which also may overlook differences in 
vascular resistance across different areas o f the myocardium.
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Ischaemia is the insufficiency of blood flow to meet the demands of the affected area, hence 
the reduction or removal of How of a perfusate should not strictly be termed ischaemia. 
However, for simplicity, the term ischaemia will be used below to describe both situations. 
Simulation o f ischaemia may be achieved by stopping flow to the heart completely, (global 
zero-flow ischaemia), or by occlusion of a vessel supplying part of the myocardium. A low- 
flow ischaemia may also be used to mimic more closely the pathological processes which 
are sequelae o f  coronary narrowing. In the binding experiments performed by Liu et al., 
(1991), a global model of zero-flow simulated ischaemia was used to produce an 




1.9.1 I s c h a e m i a  /  r e p e r f i i s i o n  e x p e r i m e n t s
In view o f the changes in binding density o f endothelin-1 after 30 minutes o f global zero 
flow ischaemia in rat hearts (Liu et al., 1990) and the reported increase o f effect of 
endothelin-1 (Neubauer etai, 1991; McMurdo etai, 1991):
To investigate whether the coronary responsiveness to all three endothelin peptides 
and to an ETB-selective agonist (sarafotoxin 6 c) is similarly increased after a similar 
period o f  ischaemia with reperfiision.
To determine whether vasodilator loss is a feature of this protocol by using a range of 
vasodilator agents with different mechanisms o f action.
To evaluate the contribution o f vasodilator loss to the increase in contractile response. 
To determine the selectivity o f the vasoconstrictor enhancement by use o f  other 
vasoconstrictors.
To evaluate which receptor subtypes are responsible for the components o f the 
coronary response to endothelins in this model, by investigation o f the effect o f  BQ- 
123.
1.9.2 Calcium  experim ents
In view o f the atypical endothelin receptor subtypes found by Harrison et al., (1992) to be 
involved in contraction o f  porcine coronary arteries:
To investigate the receptor subtype involved in the intracellular increase in free 
calcium in porcine coronary artery smooth muscle cells in response to endothelin by 
use o f the antagonist BQ-123.
With regard to the differences in the form o f the [Ca2+]j response in smooth muscle cell 
preparations as described by Wagner Mann & Sturek (1991):
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To evaluate the manner in which the intracellular calcium responses to endothelins are 
dependent upon the preparation of vascular smooth muscle cells and the model used.
With regard to the tyrosine phosphorylation seen in response to endothelins in smooth 
muscle described by Koide et a l 1992) and the complex interactions o f the endothelin- 
induced signal transduction mechanisms:
To determine whether there is a contribution from tyrosine kinase activation to the 




2.0 C oronary reactivity in rat hearts
2.1 Modified Langendorff perfusion technique
Materials and solutions (see section 2.7)
Perfusate: Modified Krebs Henseleit Solution 
Composition (mM):
NaCl 118
k h 2 p o 4 1 . 2
CaCl2 1.23
N aH C 0 3 25
D-Glucose 1 1 . 6
M gS 0 4 1 . 2
KC1 4.7 (
The perfusate was gassed using 95% 0 2: 5% C 0 2  and warmed to 37°C using a heating coil 
in the perfusion circuit. Following gassing, pH was within physiological limits (7.35 - 7.45).
Methods
Male Wistar rats weighing 250-350g were anaesthetised using sodium pentobarbitone 
(Sagatal 75mg.Kg-1) injected intraperitoneally (i.p ). Following sacrifice by cervical 
dislocation, hearts were rapidly excised and immersed in ice-cold Krebs Henseleit solution, 
before being perfused via the aorta, at a constant flow rate of lOml.mim1 with warmed, 
oxygenated perfusate. The heart was maintained at 37°C using a heating jacket. Thebesian 
vein effluent was removed via a 25G needle inserted into the left ventricle.
Coronary perfusion pressure was measured via a pressure transducer attached to the aortic 
cannula and developed tension measured under 2 g resting tension by an isometric 
transducer attached to the apex o f  the left ventricle. This apical deflection was used to
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trigger a heart rale meter. All parameters were recorded using a Devices chart recorder or 
a Grass Polygraph.
Each preparation was allowed to equilibrate for a minimum of 20 minutes prior to 
commencement o f the experimental protocol. Experiments were performed with 
appropriate time-matched controls and in parallel where possible.
2.2 Ischaemia /  reperfusion experiments
Following equilibration, 30 minutes o f global zero-flow "ischaemia" was achieved by- 
cessation o f perfusion. Superfusion was commenced (at lOml.mim1) to avoid cooling, using 
deoxygenated (95% N 2: 5% C 0 2 -gassed) Krebs Henseleit solution at 37°C for the duration 
o f  the ischaemic period. This maintained temperature within the left ventricle at 36-37°C, 
as measured using a thermistor inserted via the left atrium. Following reperfiision with 
oxygenated perfusate, hearts were allowed to re-equilibrate for 1 0  minutes before injection 
o f  cumulative bolus doses o f endothelins (10-70pl). A single dose response curve was 
produced in each preparation as endothelin responses were affected by previous exposure to 
the peptide. This protocol was repeated for comparison o f all vasoactive agents used. 
Vehicle boluses were included in all experiments in the volume o f the largest agonist 
injection and no injection artefact was noted.
A control group o f hearts underwent perfusion alone for the total experimental time ( 1 1 0  
minutes) and was compared with a group o f  hearts which underwent the ischaemia / 
reperfiision protocol, again without addition o f agonists.
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2.3 Effect of perfused indom ethacin and L-NMJV1A on responses to endothelin-3
Following initial equilibration, a combination o f indomethacin (IOjiM) and the L-arginine 
derivative NG monomethyl L-arginine (L-NMMA, lOOfiM) was perfused, in order to inhibit 
both cyclooxygenase and nitric oxide synthase. Responses to a sub-maximal SOpmol dose 
o f endothelin-3, and to lOnmol sodium nitroprusside, lnmol bradykinin and 0.5u thrombin 
were compared following 15 minutes' equilibration with the inhibitors. Initial attempts to 
perform paired comparisons o f responses before and after perfusion of the inhibitors were 
not continued as perfusion pressures were significantly higher at the time o f the second 
agonist doses in both control and treated preparations. Hence separate preparations were 
used for treated and control (vehicle only) responses.
2.4 Studies using glibenciamide
After initial equilibration, hearts were perfused with either glibenciamide lOpM or vehicle 
(dimethyl sulphoxide). Following 15 minutes' equilibration with glibenciamide or vehicle, 
the response to a single bolus injection o f the potassium channel opener lemakalim (lOnmol) 
was assessed in order to demonstrate the effectiveness o f the concentration o f glibenciamide 
used. A single dose-response curve to endothelin-3 was then performed in each heart.
2.5 Studies using the perfused ETA receptor antagonist BQ-123
Following equilibration, hearts were perfused with IpM  BQ-123 for 20 minutes before 
injection o f bolus doses o f endothelin-1 or endothelin-3 to produce cumulative dose- 
response curves. Preliminary studies were carried out similarly to test the selectivity of 
sarafotoxin 6 c for ETB receptors, but using a single sub-maximal dose o f sarafotoxin 6 c, 
(lOpmol) following perfusion o f 2pM  BQ-123 for 10 minutes. The effect o f  this
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concentration o f BQ-123 at ETA receptors was tested by subsequent injection of endolheim- 
1 (50pmol).
2.6 Desensitisation of ETH receptors using sarafotoxin 6c
The rapid desensitisation of the ETB] receptor-mediated vasodilator response (Le Monnier 
de Gouville & Cavero, 1991) was exploited by repeated administration o f a maximal 
lOOpmol dose o f the selective ETB receptor agonist sarafotoxin 6 c.
2.6.1 Selection of interval between doses
The Krebs Henseleit perfusate used contained the lower potassium concentration indicated 
in section 2.1 (3.2mM) in order to raise coronary tone and thus reveal the full extent of 
sarafotoxin 6 c-induced vasodilatation. Following equilibration, four lOOpmol doses of 
sarafotoxin 6 c were administered to each preparation with inter-dose intervals o f 1 0 , 2 0  and 
30 minutes. The order o f the dose intervals was randomised (using a Latin square) for each 
heart, to eliminate the possibility of influence from the number o f previous doses. Results 
o f this are seen in figure M -l, the 10 minute interval giving the greatest degree of 
desensitisation.
2.6.2 Selection of number of doses used
The lower potassium concentration indicated in section 2.1 was perfused as in the previous 
section. A sarafotoxin 6 c dose was repeated at 10 minute intervals until desensitisation was 
apparent. After 3 doses, the dilatation to sarafotoxin 6 c was reduced by over 90% as 





































C o n t ro 10 20 3 0 m m
n te r v a  1 b e tw e e n  d o s e s
Figure M -l
The effect on the vasodilator response to a lOOpmol dose o f sarafotoxin 6c in the isolated 
rat heart preparation, of repeating the dose at a 10, 20 or 30 minute interval after the initial 
dose. Results are shown as mean ± SEM reduction from basal perfusion pressure (of 83 ± 3 
mmHg) for n=4 preparations.
** denotes P<0.01 when compared with control vasodilatation (initial response) using two- 




2 n d  3 rd
Dose of Sxdc
Figure M-2
The influence o f the number of repetitions at 10 minute intervals of a bolus dose of 
sarafotoxin 6c, on the magnitude of the vasodilator effect in the isolated rat heart 
preparation. Effects of first, second and third successive doses shown as mean (± SEM, 
n=10) reduction from basal perfusion pressure (of 83 ± 3 mmHg).
** denotes P<0.01 when compared with the first dose by two-way ANOVA and post hoc 
Tukey's test.
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2 . 6 . 3  D e s e n s i t i s a t i o n  o f  the  v a s o d i l a t o r  c o m p o n e n t  o f  t h e  e n d o t h e l i n - 1  r e s p o n s e
As a result o f the information derived from experiments in sections 2 .6 . 1  and 2 .6 . 2  above, a 
protocol o f three lOOpmol doses of sarafotoxin 6 c given at 10 minute intervals, was used. 
Hearts were perfused using modified Krebs Henseleit solution (see section 2.1) with the 
potassium concentration returned to the 5.9mM used in the ischaemia / reperfusion 
experiments. Sarafotoxin 6 c desensitisation preceded the injection o f a single sub-maximal 
(30pmol) dose o f endothelin-1. In separate preparations, sub-maximal doses o f  the 
vasodilators bradykinin (lOpmol) and sodium nitroprusside (lOnmol) and the 
vasoconstrictors Bay K 8644 and phenylephrine were given following the same 
desensitisation protocol. Controls consisted o f vehicle (saline) bolus injections in the same 
volume and at the same time points as the sarafotoxin 6 c, prior to administration of 
vasoactive substances.
2.7 Materials used in perfusion experiments
Endothelins were obtained from Novabiochem U.K., Ltd. and sarafotoxin 6 c from Peninsula 
Laboratories. These were dissolved in physiological saline solution to make a 10 or lOOpM 
stock solution and further diluted in saline for bolus injection.
BQ-123 was a gift from Dr M. Sumner at Glaxo pic and a number o f different stock 
concentrations were prepared in distilled water and stored at -20°C until required. 
Bradykinin, sodium nitroprusside, adenosine, phenylephrine, thrombin, and papaverine were 
obtained from Sigma (Poole, Dorset); lemakalim was obtained from Beechams. All were 
prepared daily. Verapamil (Abbott Laboratories) was similarly prepared as required from 
the manufacturers' stock solution.
Bay K 8644 (Bayer AG) was dissolved in methanol to a stock concentration o f IOitlM, 
which was stored in an airtight container at -20°C until further dilution in physiological 
saline solution was required for use.
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Nf; monomcthyl L-arginine, (Sigma) was initially dissolved in distilled water and sonicated 
prior to final dilution in Krebs Henseleit perfusate.
Indomethacin (Sigma, Poole, Dorset) was initially dissolved in a minimum volume of 1M 
N a ^ O j prior to final dilution in Krebs Henseleit solution.
Glibenciamide was dissolved in dimethylsulphoxide (Sigma, DMSO) to give a stock 
solution of lOmM prior to dilution in Krebs Henseleit perfusate. Vehicle control perfusate 
for glibenciamide consisted o f a 1 : 1 0 0 0  dilution o f DMSO alone.
NaCl, KH 2 P 0 4, CaCl2, N aH C 03, D-Glucose, M gS 04, KC1, N aC 0 3  and other salts were 
obtained from BDH chemicals, Poole, Dorset.
Sagatal (sodium pentobarbitone) was obtained from RMB Animal Health Ltd, Dagenham.
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3.0 Cell signalling
3.1. Culture methods for porcine coronary smooth muscle cells
3.1.1 Cell explantation
Materials and solutions (see section 3.3).
Buffer for collection o f porcine hearts:
Sterile Hanks buffered salt solution (HBSS) with additions:
Gentamicin 200pg.m l1 (recommended dose where contamination known to 
exist or is likely)
Streptomycin / penicillin mixture lOOu.mk1 each 
Amphotericin B (Fungizone) O.Spg.mh1
Growth medium:
Sterile Dulbecco's Modified Eagle's Medium (DMEM), with additions:
Streptomycin / penicillin mixture lOOu.mk1 each. Amphotericin B (Fungizone) 
O.Spg.ml' 1
10% heat-inactivated foetal calf serum (FCS)
Methods
Hearts from adult pigs were collected from a local abattoir within 30 minutes o f slaughter 
and the coronary arteries flushed via the aorta, using ice-cold HBSS. The hearts were 
transported and kept on ice until coronary excision.
A wedge o f myocardium containing the right coronary artery was excised from each heart 
under aseptic conditions. This was done by making a first incision from the aortic root 
through the right ventricle to the posterior septum l- 2 cm below the line o f the right 
coronary artery. This was located by following the visible streak o f periarterial fat. A 
second incision was then made in the right atrium 1 cm above the line o f the coronary artery.
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The wedge was freed and kepi in ice-cold HBSS in a sterile container until the following 
stages could be carried out.
The remainder o f the explant procedure was performed in a laminar flow cabinet using a 
sterile technique and instruments. The coronary arteries were removed from the wedges 
and placed into growth medium until required. Each artery was then trimmed o f excess fat 
and pinned out on a dissection board before being cut longitudinally, leaving the endothelial 
surface upward. The artery was kept moist at all times with DMEM. Endothelium was 
removed using a scalpel blade drawn over the inner surface and this procedure was 
repeated. The artery was then cut into small (2-5mm) squares which were then placed, 
tunica media side down, onto the growing surface o f an upright T75 culture flask. A 
spatula was used to position the patches at 1 cm intervals and leaving 2 cm at the bottom of 
the flask for growth medium to be added. The patches were each moistened by addition of 
a minimum amount o f DMEM by capillary attraction, and the bottom o f the flask was 
covered with medium before placing in the incubator under an atmosphere o f 5% C 0 2: 95% 
air, at 37°C for 3 hours to allow adherence. After this time, the flasks were carefully laid 
down flat, allowing the DMEM to cover the tissue and were left undisturbed for 3-5 days to 
allow cells to explant. Cells could be seen growing out from the arterial patches at 5-10 
days following dissection. Feeding was performed every 5 days by removal o f old DMEM 
and any loosened arterial patches, and replacing it with fresh solution.
3.1.2 Cell passaging
When cells grew to a confluent monolayer, each T75 was passaged into 2xTl50 flasks. 
This rapid expansion to a larger surface area for cell growth allowed rapid production o f the 
cell populations necessary for experimental use whilst using cells at as low a passage 
number as possible (below passage 1 0 ), as some cell characteristics have been shown to 
change following repeated passaging (see discussion).
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Materials and solutions (see section 3.3)
Trypsin / EDTA solution (1:250 ratio) at 37°C: (T/E, Trypsin 0.5gT ' with 
ethylenediaminetetraacetic acid, 0 .2 gT ', in saline).
Phosphate-buffered saline without calcium and magnesium (PBS) at 37°C.
Method
Cells were washed twice using 10ml PBS at 37°C, and sufficient T/E mixture was added to 
cover the monolayer. Cells were incubated with the enzyme mixture for 2-5 minutes under 
frequent observation to minimise cell damage while ensuring maximum cell numbers were 
harvested from flasks.
When cells were fully suspended the T/E was diluted in excess DMEM containing 10% FCS 
which contains anti-trypsin.
The remaining enzyme mixture was removed by centrifugation at lOOOrpm for 7 minutes 
and cells were resuspended in DMEM o f the required volume for the size o f flask used (e.g. 
30ml for each T150 flask). Cells adhered to the growth surfaces o f flasks after 2-4 hours 
and regained their typical flattened, elongated shape overnight.
3.1.3 Storage o f cells in liquid nitrogen
To preserve excess cells at low passage number (see section 3.1.2) for future use, cells at 
2nd or 3rd passage were frozen for storage in liquid nitrogen.
Materials and solutions (see section 3.3)
DMSO
FCS
DMEM, with added antibiotics as above (section 3.1.1)
Method
Washed, passaged cells from a confluent T150 flask resuspended to 1 ml were divided into 4 
aliquots o f 0.25ml (approximately 8x l0 5  cells each) before addition o f the freezing mixture
of 0.2ml FCS and 0.05ml DMSO to give final concentrations as follows: cells 50%, FCS 
40% and DMSO 1 0 %. The cells were then frozen down in cryotubes by slowly lowering 
them into liquid nitrogen, immersing cells gradually over 6  hours using a commercial;} 
available cryotube holder with winding mechanism, and thus decreasing their temperature 
slowly. For use, cells were thawed rapidly at 37°C, rapidly mixed in 10ml o f  DMEM and 
washed in DMEM twice before final resuspension in medium and plating into flasks.
3.1.4 Identification of smooth muscle cell phenotype
Cells were observed under the light microscope and when confluent, the "hill and valley" 
appearance typical o f vascular smooth muscle cells (VSMC) was as described by Chamley- 
Campbell et al., (1979). See figure M-3.
For further confirmation, it was necessary to exclude the possibility o f contamination by 
other cell types such as fibroblasts and endothelial cells. The immunocytochemistry staining 
method used was selective for a smooth muscle cell-specific actin as described by Skalli et 
al, (1986) and this is outlined below. Antibody concentrations were optimised in 
preliminary experiments.
Materials and solutions (see section 3.3)
Dulbecco's phosphate-buffered saline (DPBS) containing both magnesium and 
calcium (each at 1  mM)
Primary antibody: Monoclonal Anti-a, smooth muscle actin antibody (mouse 
IgG2a). 1:500 dilution in DPBS.
Secondary antibody: Rabbit anti-mouse IgG (Fab fragment), conjugated to
Fluorescein (FITC): 1:200 dilution in DPBS.
Blocking serum : Normal rabbit serum. 1 :200 dilution in DPBS.
Ice-cold methanol.
1:1 glycerol:DPBS mixture for fixing slides.
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M ethods
Cells grown to sub-confluence on glass coverslips were washed twice in DPBS to remove 
any remaining serum before being immersed in 1 0 0 % methanol at -20°C for 1 0  minutes. It 
was found in preliminary experiments that if cells were fixed in this way, further 
permeabilisation was unnecessary. Following this, cells were again washed twice in DPBS 
and incubated in blocking serum for 1  hour at room temperature to block non-specific 
binding o f the secondary antibody. Following repeated washes as previously, coverslips 
were incubated at room temperature in anti-cq smooth muscle actin primary antibody for 1  
hour. Washes were repeated as described. Coverslips were again incubated at room 
temperature in the secondary rabbit anti-mouse antibody for 1 hour. Two final washes in 
DPBS were performed and coverslips were mounted on glass slides with a 1 : 1  
glycerokDPBS mounting solution. Slides were kept refrigerated in the dark until viewed 
under fluorescence microscopy using an excitation wavelength of 495nm (and emission at 
525nm).
A known fibroblast cell preparation (human synovial fibroblast primary cell culture) was 
also grown on coverslips as a negative control, and specificity of the secondary antibody 
was demonstrated by omission o f  the primary antibody on some coverslips.
Positive staining was identified by eye under fluorescent light, and negative staining by 
microscopic comparison o f cell numbers visible under tungsten light with numbers o f cells 
having fluorescent filaments.
Photography was performed using a Nikon Optiphot-2 microscope with an Olympus OM 2  
camera. Optimum exposure times were determined in preliminary' studies to be around 30 
seconds using Kodak ektachrome ELITE 400/27° film.
Cell purity
Following application o f the above staining technique, > 99% of all cells cultured from 
coronary arteries stained positive for a-sm ooth muscle actin. No synovial fibroblasts were 
identified which stained positively for a-sm ooth muscle actin, and where the primary
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antibody was omitted, no fluorescence was detectable. The positively stained cells can be 
seen in figure M-4.
Figure M-3
Photomicrograph of a monolayer o f porcine coronary smooth muscle cells grown to 
confluence and displaying typical "hills and valleys" characteristics. Taken under xlOO 
magnification using Kodak ISO 64 tungsten film.
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Figure M-4
Photomicrographs o f examples o f porcine coronary artery smooth muscle cells, following 
staining with anti a-sm ooth muscle actin primary antibody,and FITC-conjugated secondary 
antibody (see section 3.1.4) according to the method o f Skalli et a/., (1986).
66
3 . 2  Calcium m e a s u r e m e n t s
3.2.1 Cell culture techniques for calcium measurements in single cells, monolayers 
and cell suspensions
Cells at early passage numbers ( 2  to 6 ) were used as smooth muscle cells in culture may 
change phenotype following multiple passage (e.g. Eguchi et al, 1994; Yamamoto et al, 
1983). Cells were grown in 96 well tissue culture plates (NUNC) and on glass coverslips 
(Chance-Propper # 1 ) for measurement of calcium in single cells and groups o f cells in 
monolayers. Cells were grown in T 150 tissue culture flasks where large cell numbers were 
required for use in suspensions at a density o f 1 0 6  cells, m l 1 (for total cell volume in each 
cuvette o f  1.5ml). From preliminary assessments, it was determined that each T150 flask 
contained approximately 3-4xl0 6  cells when grown to confluence, hence the number of 
flasks required for each experiment could be estimated. For experimental use, serum 
deprivation was required. This was firstly in order to promote cell differentiation, as cells in 
culture become "modulated" and undergo phenotypic change (Chamley-Campbell et al, 
1979). Secondly, it was noted in preliminary experiments, that addition o f  1 0 % FCS to 
cells during fluorimetry resulted in a large increase in intracellular calcium, hence exposure 
to  high levels o f  growth factors and other constituents o f serum was reduced prior to cell 
use. Serum deprivation was performed by leaving cells in 0.1% FCS in DMEM for a 
minimum o f 24 hours, following the method of Little et al. (1992). After serum starvation, 
there was no apparent increase in cell numbers when counted under light microscopy.
3.2.1.1 Culture of cells in 96 well plates
Cells were passaged into the central 60 wells o f a plate at an initial density o f 1 0 5  cells per 
well, a seeding density which rapidly allowed near-confluent cell growth. Outer wells were 
filled with medium alone to increase humidity. Cells were cultured for up to 4 days in the 
plates before use and deprived o f serum for 24-48 hours.
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3.2.1.2 Culture o f celts on glass coverslips
In initial experiments, cells were passaged into 6  well plates containing one 22mm diameter 
glass coverslip per well. The cells were left to attach in DMEM containing 10% FCS. 
However, cells were detaching from the glass after 24-48 hours, despite attempts to prolong 
this period using a variety of proteins (gelatin, collagen, laminin, and fibronectin) to coat the 
glass.
A marked loss o f cells away from edges o f multi-well plates was noted and to avoid this 
effect, sterile coverslips were inserted into T150 culture flasks via the flask neck. Using this 
technique, cells were adherent for at least 7-10 days. Hence this method was used to grow 
cells to  confluence whilst allowing a consistent period o f serum deprivation. This technique 
permitted the assessment o f calcium responses in single cells grown as part o f a monolayer 
or in groups o f  cells within the monolayer.
3.2.1.3 Culture o f cells in T150 flasks
Ceils were passaged into T150 flasks (Falcon) as described previously, and allowed to grow 
to full confluence prior to use for calcium measurements in cell suspensions. Where 
incubation with an antagonist was required for a longer period, this was added to the flask 
during serum deprivation.
3.2.2 Loading of cells with the calcium indicator fura-2
Materials and solutions (see section 3.3)
Assay buffer:
HEPES-buffered Tyrode (HBT) at room temperature. (HEPES buffering to prevent 
increase in pH associated with loss of dissolved C 0 2  with bicarbonate buffering).
Composition (mM unless stated):
NaCl 145
HEPES 10






Bovine serum albumin 0.25%
Fura-2/acetoxymethylester (AM) mixed with equal volume o f 25% Pluronic 
F-127 prior to final dilution in HBT to 5pM
3.2.2.1 Loading o f cells on 96 well plates
Cells were washed twice with HBT to remove any trace o f remaining serum, which would 
contain esterases. Cells were then covered using the fiira-2/AM / Pluronic F-127 mixture 
which was added to each well, and incubated for 30 minutes in the dark at 37°C. The fiira- 
2/AM was pre-mixed with the non-ionic surfactant Pluronic F-127, a dispersing agent which 
prevents formation o f precipitate of fura-2 and improves loading. Precipitation was visible 
as bright localisations o f fluorescence under microscopy in preliminary experiments where 
Pluronic F-127 was not used. Following loading, the cells were washed twice to remove 
any extracellular fura-2/AM which is fluorescent but calcium insensitive and would interfere 
with recording o f  calcium responses. VSMC were then left to equilibrate in HBT 
containing ImM  calcium for 30 minutes, prior to use. This allowed intracellular de- 
esterification o f  fura-2/AM to produce the calcium-sensitive fiira-2.
3.2.2.2 Coverslips
Coverslips were transferred to 6  well plates and washed twice in HBT before loading using 
a similar technique to that used for 96 well plates (section 3 .2.1.1)
3.2.2.3 Cell suspensions 
Harvest from flasks:
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Dissociation o f VSMC from flasks required a technique different from that used for 
passaging, as trypsin digestion would cleave extracellular domains o f membrane proteins, 
including receptors. Hence calcium was chelated using EDTA to aid dissociation.
Additional materials and solutions (see section 3 .3)
PBS (calcium and magnesium-free), at 37°C 
EDTA dissociation buffer: in milli-Q de-ionised water and at 37°C 
Composition (mM unless stated):
NaCl 130
KC1 6
NaH 2 P 0 4  1 . 2




pH to 7.4 using 2M NaOH solution
HEPES-buffered DMEM.
DMEM to which was added 26mM HEPES
pH checked and adjusted to 7.4 if necessary using 2M NaOH or HCI
Methods
Cells were washed twice using calcium / magnesium-free PBS to remove DMEM (which 
contains calcium and magnesium). ETDA buffer (5ml to cover the cells) was added to each 
flask, tapping to assist recovery until cells were dispersed (approximately 2 0  minutes). 
After the VSMC were dissociated, 10ml o f HBT containing ImM calcium was added to 
each flask to replace chelated calcium, and this was repeated to wash the maximum number 
o f  cells from each flask. Cells were then centrifuged at lOOOrpm for 7 minutes. Cells were
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resuspended thoroughly by trituration and diluted to a volume o f 20ml HBT to wash off any 
remaining EDTA before being re-centrifuged.
Loading
Ail steps using fura-2/AM were performed with light excluded to reduce photo-bleaching of 
the dye.
The cell pellet was resuspended in 5ml HEPES-buffered DMEM to which had been added 
the fiira-2/AM / Pluronic F-127 mixture. The cells were stirred gently during loading to 
prevent aggregation and to allow even distribution of the fura-2/AM. This was performed 
using a magnetic stirrer on low setting, for 45 minutes at room temperature. Cells were 
then washed tw ice by centrifugation and resuspension in 30ml volumes o f HEPES-buffered 
DMEM to  remove any remaining extracellular fura-2/AM. Finally, cells were resuspended 
to  a concentration o f IxlO 6  cells per ml in DMEM and divided into 1.5ml aliquots. The 
cells w ere equilibrated at room temperature for 30 minutes to allow maximal intracellular 
de-esterification o f  the fiira-2/AM as described above. Immediately prior to use, VSMC 
were briefly spun using an Eppendorff centrifuge, and resuspended in 1.5ml warmed HBT 
assay buffer before addition to the cuvette.
3.2.3 The fluorimetry set-up
The calcium signal was measured using a Photon Technology International (PTI) Deltascan 
fluorimeter with a fibre optic light-guide. This could be used to illuminate a microscope 
stage or a cuvette system as required. Excitation wavelengths for fura-2 were set at 340 
and 380nm using monochromators, and these wavelengths were alternated at a rate o f 60Hz 
via a rotating mirror (chopper). Emitted light at 510nm was detected using a 
photomultiplier tube and the image differentiated using PTI software into 340/380 ratio. 
The microscopy setup required a dichroic mirror to allow passage to the stage o f the 
excitation signal as well as to filter the 510nm emission wavelength in the opposite 
direction. Other refinements for the microscopy setup included a shutter which could be 
used to select an area under the microscope stage for fluorescence measurement.
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3.2.3.1 96 well plates
A Nikon Diaphot inverted microscope was used to view 20-30 loaded cells and VSMC 
were viewed using a 2 0 x fluorescence objective at room temperature.(the greatest 
magnification available with the focal distance required for the plate). The shutter was used 
to select an area containing ~ 2 0  VSMC in which calcium was to be measured.
3.2.3.2 The Intracell chamber for coverslips
Coverslips were secured in an Intracell coverslip holder and sealed using silicone rubber. 
The holder was then placed in a heating chamber (Intracell, Cambridge) and allowed to 
equilibrate to 37°C. After this period, single cells or groups o f 5-10 cells were selected for 
measurement using the diaphragm. It was also possible to view single cells as the cells were 
viewed using a 40x 1.3F oil immersion quartz fluorescence objective. Use of this objective 
was possible due to the single layer of thin glass separating the cells from the lens.
3.2.3.3 The cuvette system
The cell suspensions were added to a cuvette and placed in a heated chamber warmed to 
37°C. The fibre optic light guide was diverted from the microscope system to illuminate the 
cells and the detector wavelength was selected using the PTI software. A dichroic mirror 
was unnecessary as the excitation and emission wavelengths followed separate pathways.
3.2.4 Protocols for measurement of intracellular calcium in single cells and 
monolayers
3.2.4.1 Cells in 96 well plates
VSMC were left bathed in a known (250gl) volume o f HBT to equilibrate and a field of 
view was chosen as described in section 3.2.3.1.
Basal calcium was measured, endothelin-1 added to the well (as a 1:10 dilution following 
removal o f  an equal 25pi volume) and subsequent change in intracellular calcium ([Ca2+];) 
monitored. A single concentration of any one agonist was added to each group o f cells as 
the initial added concentration remained in contact with the cells throughout and
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desensitisation was possible Second agonist additions were performed in the presence of 
the initial agonist but maintaining the same bathing volume by removal o f 25pi before 
addition. For example where sarafotoxin 6 c was used, the response to endothelin-1 was 
assessed afterwards, and a standard 1 pM bradykinin concentration was added to wells after 
the addition o f  endothelin - 1  in order to confirm cell viability where responses to the first 
agonist were lost or reduced.
In experiments where concentrations o f BQ-123 were used, the antagonist was added to the 
cells at least 3 minutes prior to the addition o f  endothelin-1, again isovolumetrically. In a 
separate series o f experiments, BQ-123 was added as above prior to the addition of 
bradykinin.
Where 5mM NiCl2  was used to determine the effect o f extracellular calcium on the 
endothelin - 1  response, this was added immediately prior to the addition o f endothelin-1 , 
again keeping the bathing volume constant.
3.2.4.2 Cells on glass coverslips
VSMC were left bathed in 500pl final volume o f  HBT and allowed to equilibrate to 37°C 
for 60 seconds. Agonist addition (50pl volume) was performed as described in 3.2.4.1 and 
responses monitored for up to 6  minutes. The addition o f BQ-123 was performed in a 
similar manner to  that used in monolayers.
3.2.4.3 Cell suspensions
VSMC suspensions were added to the cuvette, maintained in suspension with a magnetic 
stirrer and allowed to equilibrate at 37°C for 1 minute. Recording of 340 and 380 signals 
was performed for a further minute prior to addition o f a concentration of endothelin - 1 in a 
1 : 1 0 0  dilution. Separate cell suspensions were used for each endothelin concentration in 
the range o f 1 to 300nM, again to avoid desensitisation (see section 3.2.4.1). Dose 
response curves were produced in the presence or absence o f  concentrations o f  the ET A 
receptor antagonist BQ-123. The antagonist was added at either 3 minutes prior to the 
addition o f  endothelin-1 or simultaneously with the agonist. Where the tyrosine kinase
73
inhibitor herbimycin-A was used, it was added to culture flasks 20-24 hours prior to the 
experiment and these cultures were prepared separately from the controls.
3.2.5 Calibration of intracellular calcium concentrations from fluorescence ratios
3.2.5.1 Single cells and monolayers
The method o f Grynkiewicz et al. (1985) was not suitable for cells under microscopy, as the 
maximum calcium signal could not be determined by cell lysis, the loss o f fura - 2  from the 
focused field o f view being the result (Roe et al., 1990). Measurement o f the maximum 
calcium value using the non-fluorescent calcium ionophore, ionomycin was also 
unsuccessful as calcium did not equilibrate across the cell membrane, again a well 
recognised problem (ibid). "Maxima" thus obtained were consistently smaller than changes 
in [Ca2+]j obtained using the agonist endothelin-1. Minima also were problematic as 
alkalinisation could result in cell lysis and again there were equilibration difficulties with 
EDTA. This method was abandoned, in favour o f a series o f  calcium standard solutions 
which were added to successive wells or coverslips and resulting calcium readings in 1 pM 
fura-2 free acid were fed into a look-up table on the PTI software.
3.2.5.2 Cell suspensions
As some flasks were prepared separately and cells were likely to form aggregates in 
suspension, calibration o f the calcium signal was performed in each cuvette. This was done 
according to the method o f Grynkiewicz et al. (1985). In brief, the maximum fluorescence 
signal was obtained by lysis o f the cells in ImM calcium using digitonin (4mg.mh1) 120pl 
per cuvette, and the minimum value found by chelation o f  calcium using lOpl o f 1 M ED TA  
all performed following alkalinisation with lOpl o f  2M NaOH solution. The equation used 
by Grynkiewicz et al. is as follows:
R  - Rmin X Sf2
[Ca2+] =  K d  __________________________
Rmax - R  X Sb2
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where Kc/ is the dissociation constant tor the Ca2: / fura-2 complex at 37°C (taken as 
224nM and assuming constant intracellular ionic concentrations), Rmin and Rmax are the 
340/380 ratios obtained in calcium-free and calcium-saturated conditions respectively, Sk 
and Sb2  are the fluorescence measurements at 380-nm in calcium-free and calcium-saturated 
conditions respectively and R is the 340/380 ratio from which the calcium concentration is 
to be derived.
3.3 Additional materials for cell culture and fluorimetrv
Cell culture media and antibiotics were obtained from GIB CO, concentrated solutions being 
reconstituted and pH balanced where necessary, according to the manufacturers' 
recommendations.
Phosphate-buffered saline (PBS: Composition (mM) KFljPO,* 1.5; NaCl 154; Na 2  H P 0 4  
2.35) and Dulbecco’s phosphate-buffered saline (DPBS: Composition (mM) CaCl2, 1; KC1, 
2.7; MgCl2, 0.5; NaCl, 137; Na2  H P 0 4, 8 . pH balanced using 5N NaOH solution) were 
both obtained as lOx stock solutions from GIBCO and also prepared using deionised sterile 
water.
Other sterile plastics and tissue culture materials were all obtained from GIBCO except for 
T150 tissue culture flasks which were bought from Falcon.
Antibodies were obtained from Sigma Immunochemicals, and aliquoted before being stored 
at -20°C. Solutions in current use were stored at 4°C.
Fura-2/AM and fiira-2 free acid (Molecular Probes Inc, USA), were dissolved in dry DMSO 
(Sigma) and stored at -20°C. Pluronic F-127 (Molecular Probes) was also prepared in dry 
DMSO but stored at room temperature for up to one week, being prepared freshly if any 
precipitate was seen. Ionomycin (Molecular Probes) was also dissolved in dry DMSO and 
kept refrigerated until required.
The standard calcium solutions were purchased as a kit from Molecular Probes. These 
were prepared by addition o f  fiira- 2  free acid in the minimum dilution volume to produce a 
final fura-2 concentration o f  1 pM.
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Herbimycin-A was bought from GIBCO and dissolved in DMSO prior to storage at -20CC. 
Digitonin (BDH chemicals, Poole Dorset) was prepared as a dmg.ml.'1 stock solution as 
required.
Other chemicals used in preparation for and during the fluorimetry experiments were 
obtained from Sigma.
All agonists for fluorimetry were dissolved in calcium-free physiological saline solution
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4.0  S ta tis tic a l analyses
The statistical tests outlined below were applied to experimental data either by hand, or by 
application o f the University of Bath INSTAT computer programme.
4.1 Acceptance o f the null hypothesis
In the comparison o f samples, the null hypothesis, i.e. the probability o f the difference 
between them being obtained by chance alone (denoted "P"), was accepted at values o f 
greater than P>0.05. The null hypothesis was rejected where P<0.05. Two-tailed tests 
were used in all cases.
4.2 Tests o f the null hypotheses
4.2.1 Parametric tests
4.2.1.1 Student's t-test
This test was used to compare means of data from samples o f control versus treated groups 
where only two means were to be compared. This test is more powerful that the equivalent 
non-parametric test (Mann-Whitney U-test), and is less likely to result in a type II error 
where the null hypothesis is erroneously accepted; hence small but significant differences 
between data groups are more likely to be revealed. Where appropriate, the paired t-test 
was used, comparing mean difference between pre- and post-test data in the same tissue 
preparation or sample. The criteria for selection o f Student's t-test also included 
determination o f  equality o f  variances o f the samples by use o f Fishers F-test.
4.2.1.2 Analysis o f variance
Where more than tw o means were to be compared, the above test was selected. Where a 
difference was identified between the means tested, the data groups were identified using an 
appropriate post hoc test as indicated.
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4 . 2 .2  N o n - p a r a m e t r i c  t es t s
These tests were used where the variances o f the samples used were unequal or otherwise 
did not fulfil the criteria for use o f a parametric test. In a series of experiments where one 
group o f the data required a non-parametric test the others in the set were also tested using 
a non-parametric test for continuity. The increased likelihood of a Type II error was 
considered preferable to the possibility o f a Type I error where the null hypothesis would be 
erroneously rejected.
4.2.2.1 Mann Whitney U-test
This test is based on the summed ranks assigned to the data from both control and test 
preparations. Where means could not be compared using Student's t-test, this was the test 
o f  choice.
4.2.2.2 Wilcoxon's signed rank test
This test was used for data not fulfilling the criteria for parametric testing where control and 
experimental recordings were obtained from the same preparation, and is the equivalent o f 
the paired t-test.
The statistical test used is indicated as appropriate in the results section.
RESULTS
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5 . 0  C o r o n a r y  r e a c t i v i t y
5.1 Effects of ischaemia and reperfusion alone
5.1.1 Effect of ischaemia followed by reperfusion on coronary perfusion pressure
Hearts which were simply perfused for a total 2  hour period (30 minutes' equilibration, and 
90 minutes' perfusion) were compared with hearts which were subjected to 30 minutes o f  
ischaemia after 30 minutes' equilibration and reperfused for 60 minutes. The last 50 minutes 
corresponded with the period o f agonist administration in control and ischaemic / reperfused 
hearts.
In control hearts, during the last 50 minutes o f perfusion, there was a steady rise in 
perfusion pressure, from a mean level of 96 ± 17 mmHg rising to a final mean recording o f  
111 ± 2 1  mmHg (mean ± sem, n=5). The corresponding period in ischaemic / reperfiised 
hearts showed a starting mean perfusion pressure o f  8 8  ± 7 mmHg rising to a final 116 ± 18 
mmHg (n=4; figure R -l). There was no statistically significant difference between the 
control and the ischaemic / reperfiised hearts when compared using Student's t-test, 
although there is a trend for a greater rate o f rise in the ischaemic /  reperfiised hearts.
5.1.2 Effects of ischaemia and reperfusion on developed tension and heart rate.
The mean heart rate following equilibration was 318 ± 26 beats per minute (n=5) and this 
did not change significantly after 110 minutes' perfusion (P>0.05, n=5). Developed tension 
in control hearts was initially stable after equilibration at a mean level o f 7.6 ± l.Og (n=5) 
after adjustment to 2g resting tension. This showed a tendency to decrease with time, 
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Figure R -l
The effect o f time alone on coronary perfusion pressure in control (o-o) and ischaemic / 
reperfiised hearts (•-• ) . Perfusion pressure is given as mean ± SEM for n=4 hearts. The 
period shown corresponds with that used for agonist administration in subsequent 
experiments. There are no significant differences between mean perfusion pressures at any 
o f the individual time points (Student's t-test).
Ischaemia resulted in a loss of developed tension, and in the development o f an ischaemic 
contracture, manifest as an increase in resting tension. The maximum increase in resting 
tension o f 4.9 ± 0.6g (n=4) was recorded after a mean o f 22 ± 1 minutes (n=4) of stopped 
flow. Following reperfusion, resting tension returned to near pre-ischaemia levels although 
recovery o f developed tension was minimal (< 2 g) and was therefore not measurable with 
accuracy. The heart rate, triggered by the tension transducer was not therefore recordable 
after reperfusion.
Examples o f  traces showing the protocol, and responses to endothelin - 1  in control and in 
ischaemic / reperfiised hearts are seen in figure R-2a
5.2 Effect of ischaemia and reperfusion on coronary responses to endothelins 
and sarafotoxin 6c
5.2.1 M orphology o f endothelin and sarafotoxin 6c responses in controls hearts
Endothelin-1 and endothelin-2 had dilator and constrictor actions in the coronary circulation 
(figure R-2). In the dose range producing coronary dilatation, a transient vasodilator phase 
was followed by a sustained vasoconstriction (plateau phase). At doses lower than the 
threshold for vasodilatation (e.g. l - 1 0 pmol), the vasoconstrictor phase was slower in onset, 
and sustained. At doses of 200pmol and above, the vasodilator phase was absent, probably 
due to desensitisation (see section 5.7) and the onset o f  vasoconstriction was sharper. 
Endothelin-3 was less potent as a vasoconstrictor than endothelin - 1  and endothelin-2 , the 
threshold for this phase of the response being ~200pmol. A vasodilator response was 
produced in a similar dose range to that o f endothelins -1 and -2 (lO-lOOpmol). The 
morphology o f  the vasoconstrictor responses was therefore different, vasodilatation 
occurring alone at the lower doses (up to lOOpmol), and at higher doses (200pmol and 
above) the vasoconstrictor phase consisted o f an initial peak preceding a return to near basal 
values, the plateau phase being comparatively small (figure R-3).
Sarafotoxin 6 c produced a marked coronary dilator response at doses o f l- 2 0 0 pmol, but no 






0  1 
DT
3 20 200pm ol
F i g u r e  R - 2
Representative responses to three bolus doses o f endothelin-1 (3, 20 and 200pmol) in normally perfused rat hearts. Upper traces show changes in 
perfusion pressure (PP) and lower traces developed tension (DT). Endothelin-2 responses were similar in morphology in a similar dose range to 
those to endothelin - 1
Figure R-2a
Two original traces representing the ischaemia reperfusion protocol followed in experiments described on page 52. The upper trace shows heart 
rate (HR), perfusion pressure (PP) and developed tension (DT) in a control preparation perfused for a period corresponding to the 30 minute 
period in the lower trace during which the heart was subjected to global zero flow ischaemia and superfused. Differences in the morphology o f the 
responses are apparent after the ischaemic period in the lower trace when compared with the control.
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The responses to two bolus doses o f endothelin-3 (ET-3; 100 & 400pmol, upper traces) and 
sarafotoxin 6 c (Sx6 c; 50pmol & lnmol, lower traces) in isolated perfused rat hearts, 
showing perfusion pressure changes (PP) and developed tension (DT). The ET-3 responses 
are from the same preparation, and were part o f a series of increasing doses. Sx6 c 
responses are shown to a 50pmol dose from one heart, and a lnmol dose which was the 
sole dose administered in a separate preparation.
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hearts produced vasodilatation but no accompanying vasoconstrictor effect, suggesting that 
the lack o f vasoconstriction was not due to a desensitisation o f the receptor involved (figure 
R-3). The vasodilator effect o f a single higher dose o f sarafotoxin 6 c indicates that the 
diminishing effect after repeated bolus doses in one preparation (figure R-6 ) may be due to 
a desensitisation o f this component o f the response.
None o f  the endothelins nor sarafotoxin 6 c had any significant effect on heart rate in control 
hearts (P>0.05). Developed tension was not significantly altered by endothelin - 3  and 
sarafotoxin 6 c, there being no significant difference between pre- and post-dose tension 
measurements over the full range o f doses tested for each peptide. Higher doses o f 
endothelins - 1  and - 2  suppressed developed tension as compared with pre-dose levels, this 
achieving statistical significance (P<0.05, Student’s t-test) at the 200pmol dose where also 
the vasoconstriction was maximal.
5.2.2 Morphology o f endothelin and sarafotoxin 6c responses in ischaemic /  
reperfused hearts
Following ischaemia and reperfusion, the vasodilator phases o f the responses to endothelins 
and sarafotoxin 6 c were severely compromised. This was accompanied by changes in the 
morphology o f the vasoconstrictor phases o f the responses which were sharper in onset for 
endothelins -1 and -2 (see figure R-4). This was less marked in the response to endothelin- 
3 where the onset o f vasoconstriction was already more acute than in the response to 
endothelins -1 and -2. These changes in morphology are consistent with the loss o f  the 
vasodilator phase. Even with vasodilatation attenuated, sarafotoxin 6 c did not produce any 






















T he changes in perfusion pressure (PP, upper traces) in response to endothelins -1 (E T -1) and -3 (E T -3) and sarafotoxin  6c (Sx6c) in ischaem ic / 
reperfused hearts, showing differences in m orphology o f  the responses when com pared w ith similar doses in figures R-2 and R-3. L ow er traces 
show developed tension (D T), which is severely attenuated  after ischaemia and reperfusion.
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5.2.3 Effects of ischaemia / reperfusion on the m agnitude of responses to endothelins 
and sarafotoxin 6 c
5.2.3.1 Vasodilatation
As stated in the previous section, responses to endothelins and sarafotoxin 6 c were altered 
by an attenuation o f  the vasodilator phase following ischaemia and reperfusion, and the 
difference from control responses achieved statistical significance (P<0.05) where the 
vasodilatation was marked, i.e. for endothelin-3 and sarafotoxin 6 c. This is summarised in 
figures R-5 & R-6 .
5.2.3.2 Vasoconstriction
The vasoconstrictor effect o f all three endothelins was enhanced following ischaemia and 
reperfusion (figures R-7 & R- 8 a). although the difference between control and ischaemic / 
reperfused hearts was not statistically significant for all doses. It should be noted that the 
cumulative increases in perfusion pressure include any change in underlying perfusion 
pressure which might occur as a result o f ischaemia alone (see figure R -l)  The minimal 
vasoconstrictor responses to sarafotoxin 6 c showed no enhancement following ischaemia 










































The initial coronary dilator component o f the responses to endothelin-1 and endothelin-2 
(pmol) in control (o-o) and ischaemic / reperfiised ( • - • )  hearts. Values are mean 
vasodilatation ± SEM (n=5-6). There are no statistically significant differences between the 













































Figure R - 6
The initial coronary dilator component o f the response to endothelin-3 and sarafotoxin 6c 
(pmol) is shown as reduction from basal perfusion pressure. Mean vasodilatation (± SEM, 
n=4-5) in time-matched control hearts (o-o) is compared with that following ischaemia / 
reperfusion (•-•). The attenuation o f vasodilatation in ischaemic / reperfused preparations 
achieves significance when analysed by Mann Whitney U-test, as denoted by * (P<0.05) and 





















































The cumulative responses elicited by endothelin- 1 and endothelin - 2  (pmol) in control 
perfused (o-o) and ischaemic / reperfused preparations (•-•). Responses are from the same 
hearts as seen in figure R-5 (mean ± SEM, n=5-6). The enhancement at some doses 



















































Figure R - 8
Vasoconstriction elicited by injection o f endothelin-3 and sarafotoxin 6 c (pmol) is shown as 
mean ± SEM (n=4-5, same preparations as for figure R-6 ) increases above initial perfusion 
pressure (NB. Different y  axis scale for sarafotoxin 6 c). The responses in time-matched 
control preparations (o-o) are compared with those in ischaemic / reperfused hearts ( • - • )  by 
Mann Whitney U-test. Statistical significance is donated as asterisks above the relevant 
dose as * (P<0.05).
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5.3 Com parison of the effects of ischaemia and reperfusion on the responses to 
the endothelin pentides and sarafotoxin 6 c, with effects on responses to o ther 
vasoactive substances
5.3.1 C oronary vasodilator agents
As the vasodilator component o f the endothelin response was affected by this ischaemia / 
reperfusion protocol, other vasodilator agents were similarly examined. This was done to 
verify whether the vasodilator loss was selective for endothelins.
Figures R-9 to  R - l l  show the effect of ischaemia / reperfusion on responses to non- 
endothelin coronary dilator agents. The responses to adenosine, bradykinin, papaverine and 
sodium nitroprusside are attenuated following ischaemia / reperfusion when compared with 
time-matched controls. The reduction in the verapamil response (figure R - l l )  is smaller in 
contrast to the effect on other agents.
5.3.2 Coronary vasoconstrictor agents
The selectivity o f  the vasoconstrictor enhancement seen with the endothelins was 
investigated by use o f two different vasoconstrictors, phenylephrine and Bay K 8644. 
Responses to these agents in this preparation are shown in figure R-12. There is a slight 
inhibition o f the vasoconstriction evoked by these agents after ischaemia and reperfusion 
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Figure R-9
The mean (± SEM) coronary dilator responses to adenosine (n=4) and bradykinin (n=6 - 1 2 ) 
are shown above as reduction from basal perfusion pressure. Responses in time-matched 
controls (o-o) are compared with those in ischaemic / reperfused preparations by Mann 
Whitney U-test. Statistical significance is denoted as asterisks above the relevant dose as * 
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Figure R - 1 0
The mean (± SEM) coronary dilator responses to papaverine and sodium nitroprusside (n = 4  
for both graphs) are shown as reduction from basal perfusion pressure. Responses in time- 
matched control hearts (o-o) are compared with those in ischaemic / reperfused 
preparations (• - • )  by Mann Whitney U-test. Statistical significance is denoted as an 
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Figure R - l l
The coronary dilator responses to verapamil are shown above. Mean (± SEM, n=4) 
responses are shown as reduction from basal perfusion pressure in control hearts (o-o) and 
ischaemic / reperfused preparations (•-•), and compared using Mann Whitney U-test. 
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Figure R-12
The vasoconstrictor responses elicited by phenylephrine and Bay K 8644 in isolated 
perfused rat hearts are shown in the above figure. Mean (± SEM, n=4) responses are 
shown in control perfused (o-o) and ischaemic / reperfused (• - • )  preparations. Where the 
attenuation o f the responses achieves statistical significance by Mann Whitney U-test, this is 
denoted by * (P<0.05).
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5.4 Effect of indonietharin  and L-NM MA on vasodilator responses to 
endothelin-3, com pared with the effect on o ther coronary vasodilators
The enhancement o f the vasoconstrictor response to the endothelins following ischaemia / 
reperfusion could simply be due to a loss of the vasodilator component o f the response. In 
order to investigate the effects o f  vasodilator loss, cyclooxygenase and nitric oxide synthase 
inhibitors were used to attenuate the vasodilator component o f  the response to endothelin- 
3, in the absence o f ischaemia / reperfusion. Combinations o f other NO synthase inhibitors 
(NG-nitro L-arginine methyl ester and N G-nitro L-arginine, both lOOpM) with indomethacin 
(lOpM ) in preliminary experiments were ineffective in eliciting any inhibition o f either the 
thrombin- or the bradykinin-induced vasodilatation. Hence L-NMMA was used in 
combination with a similar concentration o f indomethacin. A dose o f endothelin-3 was 
selected which had a sub-maximal vasodilator effect but which caused minimal 
vasoconstriction (see figures R - 6  and R - 8 ). The effects o f these inhibitors on coronary 
vasodilatation to bradykinin and thrombin were compared with those on endothelin-3. The 
combined inhibitory agents L-NMMA (IOOjiM) and indomethacin (lOgM ) had no 
significant effect on basal perfusion pressure (P>0.05) measured at the time o f addition of 
coronary dilators.
The mean coronary vasodilator responses to bradykinin and thrombin were reduced by 74% 
and 72% respectively from control values (figure R-13), suggesting that the concentrations 
used were sufficient to attenuate the effect o f  nitric oxide synthase or cyclooxygenase 
products (without distinguishing which was the effector).
In control hearts, the mean vasodilator effect o f a sub-maximal (50pmol) dose of 
endothelin-3 was 22 ± 2 mmHg. There was, however, a wide degree o f variability in the 
post-inhibitor response to endothelin-3 (from 0 to 27 mmHg vasodilatation). Hence, 
although a trend toward an inhibitory effect from these combined agents was seen this was 
not statistically significant. Therefore, the inhibition o f neither NO synthase or 
cyclooxygenase could be considered responsible for the abolition of the vasodilator phase o f 
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Figure R-13
Mean (± SEM, n=4-6) coronary dilator responses to sodium nitroprusside and bradykinin and the vasodilator phase o f the response to thrombin 
are compared with the coronary dilator phase of the response to 50pmol endothelin-3. Open bars denote means from control preparations, and 
hatched bars give data from preparations perfused using a combination of indomethacin (INDO, 10gM) and N monomethyl-L-arginine (L- 
NMMA, lOOpM). The response to sodium nitroprusside is unchanged following combined INDO / L-NMMA perfusion, whereas responses to 
bradykinin and thrombin are significantly attenuated (denoted by ** (P<0.01) and *** (P<0.001). Coronary dilatation to endothelin-3 appears to 
be attenuated but this does not achieve significance.
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significant enhancement of vasoconstriction to the endothelin-3 dose selected, when 
compared using Mann Whitney U-test.
5.5 Effect of glibenclamide on responses to endothelin-3
Another mechanism o f vasodilatation investigated, was the ATP-dependent potassium 
current (Lippton et al., 1991). Perfusion o f lOpM glibenclamide to block this current had 
the effect o f  increasing basal perfusion pressure by a mean value of 20 ± 8  mmHg (mean ± 
SEM, n=4) whereas vehicle alone had no effect on coronary perfusion pressure (P>.0.05). 
This makes the interpretation o f changes in the vasodilatation response difficult.
Following glibenclamide infusion, the vasodilator responses to a range o f doses of 
endothelin-3 were enhanced, presumably as a result o f  the increased basal perfusion 
pressure (figure R-14a). However, despite the difference in perfusion pressure, the 
vasodilator response to the potassium channel opener lemakalim was almost completely 
abolished (figure R-14b) suggesting that the concentration o f glibenclamide used was 
sufficient to overcome any vasodilatation due to opening o f the ATP-dependent potassium 
channel, and that other mechanisms were responsible for the vasodilatation to endothelin-3. 
However, it is not possible to eliminate a partial contribution to the vasodilatation from an 
ATP-dependent potassium current as a reduction would have been masked by the 
enhancement in vasodilatation resulting from increased basal perfusion pressure.
In contrast, the vasoconstrictor phase o f the endothelin-3 response was attenuated after 
glibenclamide perfusion, this being a significant effect at the 2 0 , 1 0 0  and 2 0 0 pmol doses 
(P<0.05 by Mann Whitney U-test; see figure R-14c).
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Figure R-14 a& b
The vasodilator phase of the endothelin-3 response in isolated perfused rat hearts (a) is compared here in DMSO vehicle control (o-o) and in 
(lOpM) glibenclamide-perfused hearts (•-•). Figure R-14b shows the effect of the glibenclamide perfusate on a response to a submaximal dose of 
lemakalim. Mean (± SEM) responses are shown as reduction from basal perfusion pressure which was 79 ± 4mmHg in control hearts and 110 ± 
11 mmHg in glibenclamide-perfused hearts (n=4). Statistical significance (Mann Whitney U-test) is denoted as * (P<0.05).
Figure R-14c
The effect o f glibenclamide perfusion on the vasoconstrictor response to endothelin-3 in the 
same hearts as shown in R-14a. Responses are shown as mean (± SEM, n=4) cumulative 
increase from basal perfusion pressure and controls (o-o) are compared with glibenclamide 
perfused preparations ( • -• )  using Mann Whitney U-test. Statistical significance is denoted 
by * (P<0.05) and ** (P<0.01).
5.6 Effect of perfusion of BO-123 on responses to endothelin-1 and endothelin-3
The receptor subtype involved in the vasoconstrictor and vasodilator phases o f the 
endothelin peptide responses was investigated, initially using an ETA receptor antagonist, 
BQ-123 (Ihara et ai, 1991). This agent has been shown to be highly selective for ETA 
receptors but to have no effect on coronary vasoconstriction to potassium chloride, 
noradrenaline, prostaglandin F20t, acetylcholine or histamine (Ihara et al.\ ibid).
Perfusion o f lpM  BQ-123 had no significant effect on basal perfusion pressure ( 7 5  ± 5  
mmHg) after 20 minutes' perfusion, when compared with time-matched control (82 ± 4 
mmHg, P>0.05 by Student’s t-test, n=9-10). This concentration o f BQ-123 was sufficient 
to cause a significant antagonism of the vasoconstrictor responses to both endothelin - 1  and 
endothelin-3, (figure R-15) when compared with controls using Mann-Whitney U-test. 
However, the magnitude of the vasodilator response to  both endothelins was unaffected in 
the same experiments (figure R-16). Following BQ-123 perfusion, the morphology o f  the 
endothelin - 1  responses at doses where vasoconstriction was abolished ( 1 0 - 1 0 0 pmol 
endothelin-1) more closely resembled that o f sarafotoxin 6 c, the ETB-selective agonist (see 
figure R-17). The duration o f the vasodilatation to endothelin-1 was increased by BQ-123 
perfusion when compared with controls and this difference gained statistical significance at 
one point on the dose-response curve (P<0.01, n=5-6; figure R-18a). The duration o f  the 
vasodilator effect o f endothelin-3 was not significantly changed by BQ-123, (P>0.05 at all 
doses, n=4; figure R-18b), and this may reflect the less potent vasoconstrictor effect o f  this 
isopeptide in the range o f its vasodilator effect.
In addition to this evidence for different receptors mediating the two phases o f endothelin 
responses, a preliminary study testing the selectivity o f  sarafotoxin 6 c for ET B receptors 
showed that 2pM  BQ-123 did not affect the response to a lOpmol dose o f  the peptide 
compared with a parallel control. This concentration o f BQ-123 resulted in complete 
inhibition o f  the vasoconstrictor response to a subsequent injection o f  endothelin - 1  
(50pmol) in the same experiment, this dose subsequently eliciting a prolonged vasodilatation
102
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Figure R-15
Coronary constrictor responses elicited by endothelins -1 and -3 in perfused rat hearts. 
Control responses (o-o, n=6) are compared with responses following 20 minutes' perfusion 
with lpM  BQ-123 (*-•, n=5). Statistical significance in the attenuation o f vasoconstriction 
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Figure R-16
Coronary dilator responses elicited by endothelins -1 and -3 in perfused rat hearts in the 
same preparations as figure R-15. The control responses (o-o, n=6) are compared with 
responses after 20 minutes' perfusion with lpM  BQ-123 (•-• , n=5). There are no 
significant differences in the magnitude of the dilator responses to either peptide following 
















Examples o f the changes in perfusion pressure (PP) in response to endothelin-1 (ET-1, left) 
and endothelin-3 (ET-3, right), comparing controls (upper traces) with responses following 
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Figure R-18
The above figure shows the duration of the coronary dilator response (minutes from onset 
o f vasodilatation to recovery o f the initial perfusion pressure) in response to bolus injection 
o f endothelins -1 and -3 in the same preparations shown in figures R-15 and R-16. The 
mean (± SEM, n=5-6) duration of response in control hearts (o-o) is compared to that 
following perfusion o f  BQ-123 (pM, •-•). The significant increase in duration o f  the 
response to lOOpmol endothelin-1 in BQ-123 perfused hearts is denoted by ** (P<0.01, 
Mann Whitney U-test).
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of 16mmHg. In the control heart however, the endothelin-1 response was purely 
vasoconstrictor (20mmHg magnitude).
5.7 Effect of ETP receptor desensitisation with sarafotoxin 6c, on vasodilator 
responses to endothelin-1 and comparison with other coronary vasodilator and 
vasoconstrictor agents
Following three lOOpmol doses o f sarafotoxin 6c repeated at 10 minute intervals, the 
vasodilator phase o f the endothelin-1 response was completely inhibited (P O .O l, n=6, 
figure R-19a). The inhibitory effect was selective for endothelin-1 as the responses to  other 
coronary vasodilator agents tested (sodium nitroprusside and bradykinin) were unchanged 
after desensitisation (P>0.05, n=4). However, the vasoconstrictor phase o f the endothelin-1 
was enhanced following desensitisation o f the ETB receptor with sarafotoxin 6c, the 
enhancement being o f a magnitude similar to the degree o f  vasodilator loss (figure R-19b). 
This enhancement was again confined to the endothelin responses as the phenylephrine and 
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Effects of ETb receptor desensitisatioo, using SxlOOpmol doses of sarafotoxin 6c, on 
coronary dilator responses to endothelin-1, sodium nitroprusside and bradykinin (a). 
Effects of desensitisation on coronary constrictor responses to endothelin-1, phenylephrine 
and Bay K 8644 are shown in the lower figure (b). Controls (open bars) are compared with 
desensitised preparations (hatched bars) using Mann Whitney U-test, and significance is 
denoted by ** (P<0.01). n=6 for endothelin-1 responses and n=4 for all other agonists.
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6 . 0  C e l l  s i g n a l l i n g
6.1 Calcium responses to endothelin-1 using monolayers of cells in 96-well 
plates
Initial experiments used groups of fura-2-loaded cells observed under low power (20x 
quartz fluorescence objective) in 96 well plates. This provided the intracellular calcium 
concentration ([Ca2+];) for an area o f about 20 confluent cells per view in a monolayer. 
[Ca2+]j thus recorded had a mean basal value o f 73 ± 6 nM (n=4) calculated using a 
standard curve (see section 3.2.5.1).
Under these conditions the effects o f endothelin-1 on [Ca2"j; were established.
6.1.1 Effects of endothelin-1 on intracellular calcium concentration in coronary 
smooth muscle cell monolayers
Endothelin-1 (O.lnM to lOpM) produced a rise in [Ca2+]j which was variable between cell 
cultures from different hearts. Despite standardisation o f cell culture conditions, the peak 
calcium response to the lOpM concentration o f endothelin-1 ranged from 160nM to 
570nM, suggesting that the sensitivity of different cell cultures (from different hearts) was 
greatly variable (see section 6.1.2 below). Following the initial peak in [Ca2+]i5 a more 
prolonged "plateau phase" o f calcium increase was evident in most preparations and can be 
seen in response to a 10pM concentration o f endothelin-1 in figure R-20. A concentration- 
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Figure R-20
A representative trace from a monolayer of porcine coronary smooth muscle cells, showing 
the increase in [Ca2+]j to a lOpM concentration of endothelin-1 (added at arrow) which 
demonstrates the peak and subsequent plateau phases o f the response
1 1 0
6.1.2 Effect of BQ-123 on calcium responses to endothelin-1 in coronary smooth 
muscle cell monolayers
Figure R-21 shows the increase in [Ca2'], to endothelin-1 (InM -ljiM ) in a monolayer of 
coronary smooth muscle cells. The effect appears to be concentration-related and the initial 
response is inhibited almost completely when cells were preincubated for 3 minutes with 
lp M  BQ-123 (R-21b). The effect o f the ETA receptor antagonist BQ-123 (0.1-10nM) on 
the peak calcium response in these cells is summarised in figure R-22 which reveals 
inhibition at only the highest (lOnM) BQ-123 concentration used, this appearing to be non­
competitive. As the responses in cells from different primary cultures showed such 
variability, the individual experiments from which this summary is derived are illustrated in 
figure R-23. The trend for inhibition of the response by BQ-123 is seen in each o f  the cell 
preparations included, and the wide range of responsiveness is also apparent. However, 
these figures combined demonstrate that the endothelin-1 response is concentration 
dependent, and that the response is clearly inhibited by lOnM BQ-123. This inhibition is 
statistically significant (P<0.05) at higher endothelin concentrations.
The inhibition o f  endothelin-1 responses by BQ-123 was selective, as demonstrated by the 
lack o f  effect o f  this compound (1-lOOnM) on responses to a sub-maximal (InM ) 
concentration o f  bradykinin (figure R-24). There was no significant difference between 
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Figure R-21
The increases in [Ca2'] ( in porcine coronary smooth muscle cell monolayers, in response to 
InM (a), lOnM (b), lOOnM (c),and lgM  endothelin-1 (added as indicated by the arrow) 
Each trace represents a separate group of cells from the same preparation. The upper panel 
shows responses in control hearts whereas the lower panel shows responses following 3 
minutes' incubation with B Q -123 (1 pM).
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Figure R-22
Effects of endothelin-1 on [Ca2J J; in monolayers of cultured porcine coronary artery smooth 
muscle cells grown in 96 well plates. Responses are shown as mean (± SEM, n=4) 
increases in [Ca2+]i in control cells (o-o), and in cells preincubated for 3 minutes with 0. InM 
(•-• ) , InM (v - v ) and lOnM ,( ) BQ-123. Inhibition is achieved at the lOnM
concentration of antagonist only, significance being indicated as * (P<0.05), using ANOVA 
with post hoc Dunnetf s test for comparison with controls.
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Figure R-23
Effects o f BQ-123 on endothelin-1-induced increases in [Ca2 ], in four separate experiments 
(a, b, c, and d). Controls (o-o) are compared with BQ-123 O.lnM (•-•) , InM (v V), and 
lOnM (▼ V/ respectively.
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Figure R-24
Effects of BQ-123 (l-100nM) on [Ca2+]; responses to bradykinin (InM ) in porcine coronary 
smooth muscle cell monolayers. Cells were preincubated for 3 minutes with BQ-123. 
Responses shown as mean ± SEM, n=4. No significant differences between means are seen 
on comparison using ANOVA.
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6 . 1 . 3  R o l e  o f  e x t r a c e l l u l a r  ca l c i u m  in t h e  e n d o t h e l i n - 1  r e s p o n s e
At the higher concentrations used, endothelin-1 elicited an initial peak response followed by 
a plateau phase o f calcium elevation in most cell groups. The larger divalent ion, Ni2' 
(NiCl2, 5mM) was used to inhibit the influx of extracellular calcium by blocking calcium 
channels (e.g. Tsien et al., 1988; James el al., 1993), and its effects on both peak and 
plateau phases o f the endothelin-1 response are seen in figure R-25. The differences 
between the responses are not statistically significant, but demonstrate an inhibitory trend in 
both the peak and plateau phases of the response.
6.1.4 Effect of sarafotoxin 6c on intracellular calcium
As with endothelins, the effect o f sarafotoxin 6c on monolayers o f smooth muscle cells was 
also variable. In two experiments, sarafotoxin 6c in concentrations o f up to lOpM elicited 
no change in [Ca2+]j when added to monolayers o f smooth muscle cells (data not shown). 
However, a 5pM  concentration elicited a ~180nM [Ca2+]j increase in a separate preparation 
(R-26), subsequent addition o f endothelin-1 (lpM ) eliciting a further and larger calcium rise 




































d V .( I cl 1\
n
-n
1 I ' l l  l i l t  1 T T T m T f  1---- 1 I I I T m  1 ' rTTTTTJ r  t-IT T T T T
0 10 100 1 0 0 0 1 0 0 0 0






T T T T T T T j  1 T rTTTTT]--------- 1— I I T T T n ------- ~T— ’ T T
0 1 10 100 1000 10000 
CT—1 c o n c e n t r a l i o n  (n.M)
Figure R-25
The results o f experiments investigating the role o f extracellular calcium in the rise in [Ca2‘], 
in response to endothelin-1 in porcine coronary smooth muscle cell monolayers. Mean (± 
SEM, n=4) increase in [Ca2+]j in ImM extracellular calcium (o-o) is compared with the 
responses elicited in the presence o f 5mM extracellular NiCl2 («-•) in both the peak and the 
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Figure R-26
The effect of sarafotoxin 6c and endothelin-1 added successively to a monolayer of porcine 
coronary smooth muscle cells. The initial increase in [Ca2']: to sarafotoxin 6c (5gM) 
returned to basal levels before addition of endothelin-1 (in the continuing presence ol 
sarafotoxin 6c) initiated a further increase in [Ca2+]r
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6 . 2  C a l c i u m  r e s p o n s e s  in cells g r o w n  o n  co v e rs l i p s
The measurement o f calcium responses in single cells was not practicable with the 
magnification (20x objective) used for multi-well cell culture plates, hence the culture of 
cells on thin glass coverslips which allowed viewing o f lower cell numbers and single cells 
using a 40x objective. These experiments were carried out at 37°C which was not possible 
in the multi-well plates. The basal [Ca2+j; (73 ± 13nM, mean ± sem, n=4) in single cells 
measured under these conditions was similar (despite any temperature difference) to that in 
larger areas o f cells in the 96 well plates when using ANOVA for comparison with 
monolayers and suspensions. However, it became apparent that agonist responses 
measured using small cell numbers, were highly variable, both in initial peak o f  the response 
to endothelin-1 and in the latency to response. For this reason, the remainder o f section 6.2 
concentrates on responses in single cells. None o f the cells tested gave a response to 
vehicle alone (n=4).
6.2.1 Responses to endothelin-1 in single cells
It can be seen from figure R-27 that the addition o f endothelin-1 to the chamber resulted in 
an initial peak increase in [Ca2+]j with some variation in latency. This was followed by slow 
oscillations in [Ca2+]j rather than by a plateau phase. The frequency o f the oscillations was 
variable and not related to the endothelin concentration. This can be seen more clearly in 
figure R-28a, where the amplitude o f the peak response as well as the oscillation frequency 
is different for two cells given the same endothelin concentration. The inconsistency in peak 
response between cells from the same preparation is highlighted in figure R-28b, where the 
initial component o f the response to lOOnM endothelin-1 is seen in four separate cells.
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Figure R-27
The above traces show [Ca2 ], in two single porcine coronary smooth muscle cells grown 
on glass coverslips. The time course and amplitude of responses to different concentrations 
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Figure R-28
Responses in [Ca2"]i to a single concentration of endothelin-1 (lOOnM added as indicated) 
in single porcine coronary smooth muscle cells grown on coverslips The time course of 
responses in two separate cells can be seen in th^ upper panel, highlighting the difference in 
frequency of the oscillatory' response possible between cells. In the lower panel, the 
differences in the amplitude and latency of the initial peak [Ca2*], can be seen in four 
separate cells.
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The variability o f the [Ca: ], change was not confined to endothelin-1; oscillatory responses 
were also seen with IpM  bradykinin, with as much inconsistency in peak response as with 
endothelin-1 (not shown). In addition, o f cells from four separate preparations, some 
individual cells (4 o f 24) were unresponsive to lOOnM or lpM  endothelin-1 whereas 
subsequent addition o f lpM  bradykinin continued to elicit a clear response (not shown). In 
other cells responding to endothelin-1 (7 o f 24), further response to bradykinin (IpM ) was 
absent or reduced. 6 o f  24 cells did not respond to either bradykinin or endothelin.
Owing to the marked variability o f the initial calcium response and the number of 
preparations not responding to endothelin-1, the effect o f  BQ-123 was not determined.
6.2.2 Responses to sarafotoxin 6c in single cells
The responses o f individual cells in different preparations to sarafotoxin 6c were also 
inconsistent. In three preparations, the maximum response to Sx6c was a 30nM increase in 
intracellular calcium above the basal level, which was not dose-related and could be 
described as "all or none". For comparison, a lOOnM dose o f  sarafotoxin 6c produced no 
response in 2 preparations, a 29nM increase in a third cell and a 255nM increase above 
basal [Ca2+]j with subsequent oscillations in another cell. This could indicate a sub­
population o f cells which are responsive to this ETB receptor agonist. The cells not 
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Figure R-29
The trace above illustrates the increase in [Ca2+], in response to endothelin-1 in a single cell, 
where no response was elicited following prior addition of sarafotoxin 6c (added as 
indicated by arrows)
6.3 Calcium responses to endothelin-1 in cell suspensions
123
To gain an overall view of the effect o f endothelin-1 on large numbers o f cells and hence the 
meaned effect on a population, the cells were grown in larger populations and dispersed. 
The mean basal intracellular calcium levels recorded in these preparations (calibrated using 
the method o f Grinkiewicz et al., 1985) were 226 ± lOnM (n=4), a level significantly higher 
than that measured in single cells (73 ± 13nM, n=4) or monolayers (73 ± 6nM, n=4; 
P<0.001 using ANOVA, and Tukey’s test post hoc).
6.3.1 Intracellular calcium responses to endothelin-1 in populations of dispersed 
coronary smooth muscle cells
Endothelin-1 application resulted in a peak and a more consistent plateau phase o f  the 
[Ca2+Ji response in cell suspensions when compared with the fewer cell numbers in 
monolayers. The peak response to concentrations 3-300nM endothelin-1 is illustrated in 
figure R-30a, which shows a clear concentration relationship in the experiment illustrated. 
The endothelin-1-induced plateau phase was not concentration-related in its magnitude nor 
affected by any o f  the antagonist concentrations used in ceil population experiments. The 
level o f  the plateau phase o f calcium increase measured at 200s after agonist addition, was 
40-85nM above the initial [Ca2+];. There was no significant difference in the level o f  the 
plateau phase between the concentrations o f endothelin-1 used (data not shown).
6.3.2 Effect o f BQ-123 on responses to endothelin-1 in populations of dispersed 
coronary smooth muscle cells
As the inhibitory effect of lOnM BQ-123 in cell monolayers appeared to be non­
competitive, the effect o f this antagonist added simultaneously and with three minutes' 
incubation was compared as the non-competitive action o f this antagonist has been linked to 
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Figure R-30a & R-30b
The representative experiments above show the effect on [Ca2 ], of concentrations of 
endothelin-1 added as indicated, to a suspension o f porcine coronary smooth muscle cells 
The upper panel (a) shows responses in control preparations, and the lower panel (b) the 
effects o f 3 minutes' preincubation with lOnM BQ-123. Peak increase in [Ca2"], appears to 
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Figure R-30c
Responses in the same experiment where addition of BQ-123 (lOnM) was simultaneous 
with the endothelin-1 The apparent inhibitory effect on responses, compared with R-30a, 
remains despite lack of equilibration time in this example.
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The responses to endothelin-1 in the presence of BQ-123 remain concentration related, as 
seen in the traces in figure R-30b and R-30c. These demonstrate the effects of 
preincubation o f cells with (R-30b) or simultaneous addition (R-30c) of BQ-123 (lOnM). 
Both preincubation with the antagonist and its simultaneous addition appear to result in 
inhibition of the peak responses when compared with controls (R-30a).
The results o f  4 experiments with control responses and where BQ-123 (3nM and lOnM) 
was preincubated with the cells for 3 minutes, are summarised in figure R -31. There are no 
significant differences from control values at any o f the data points when compared by 
ANOVA.
The effect o f simultaneous addition o f BQ-123 (lOnM) with the endothelin-1 is shown in 
figure R-32. Again, there is no significant difference from controls or from the data from 
preincubated cells.
From the data obtained, it is not possible to determine if the interaction with the lOnM BQ- 
123 is competitive or non-competitive.
Sarafotoxin 6c (lOOnM) was added in two experiments only but with no effect on [Ca2+]j, 
although cells subsequently responded to endothelin-1 (lOOnM).
6.3.3 Effect o f herbimicin-A
Incubation o f  the cultured cells for 24 hours with herbimycin-A (875nM) caused no 
significant inhibition o f the initial peak increase in [Ca2Qj provoked by endothelin-1 in the 
cell suspensions. The combined results can be seen in figure R-33 (upper figure). There 
does, however, appear to be a trend toward inhibition o f the peak response. There was no 
significant difference in the plateau phase of the response to endothelin-1 in herbimycin-A 
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Figure R-31
The increase in [Ca2+]i in response to endothelin-1 using large numbers of porcine coronary 
artery smooth muscle cells in suspension is shown as mean ± SEM (n=4) Responses in 
controls (o-o) are compared with those in cells from the same preparations preincubated 
with BQ-123 3nM (■ ■) and lOnM (▼ ▼) for 3 minutes There are no significant differences 
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Figure R-32
The increase in [Ca2+]; in response to concentrations of endothelin-1 in the same 
experiments as described in figure R-3 1 are shown as mean ± SEM (n=4). Controls (o-o) 
are compared with preparations where BQ-123 (lOnM, ) was added simultaneously with the 
endothelin (▼ v) There are no significant differences between means (ANOVA)
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Figure R-33
The mean (± SEM, n=4) increases in [Ca2+]j in porcine coronary smooth muscle cell 
suspensions in response to 30 and lOOnM endothelin-1 are compared in control 
preparations (taken from the experiments shown in R-31 & R-32; open bars), and in 
preparations treated with herbimycin-A (875nM; filled bars) . The upper figure shows 
changes in peak initial response, while the lower figure gives data from the plateau phase o f 
the responses. There are no significant differences when compared using ANOVA
DISCUSSION
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7.0  Effects o f  ischaem ia and reperfusion
The effect o f ischaemia / reperfusion alone on coronary perfusion pressure, during the time 
course o f  the experimental protocol (figure R -l), was a steady rise. Although there is no 
significant difference when each point is compared with the control perfusion pressure, the 
rate o f  rise may be important in the interpretation o f results measured cumulatively over the 
same period. The difference between mean perfusion pressure at the start o f  measurements 
and mean perfusion pressure at the end o f  the experimental period in controls was 15mmHg 
whereas the difference in ischaemic / reperfused hearts was 28mmHg. This is a large 
enough difference between means over the measurement time, to be considered when 
comparing a cumulative increase in perfusion pressure in ischaemic / reperfused hearts with 
control values.
The initial perfusion pressure is lower in post-ischaemic hearts which contributes to the 
difference in means at the start and end o f  the dose-response curve period. The mechanisms 
underlying this and the subsequent increase in perfusion pressure have not been explored 
here. However, the phenomenon o f post-reperfusion vasoconstriction has been described in 
dog heart in vivo (Sobey et al., 1990). The loss o f release o f  endothelially produced 
mediators o f  vasodilatation has been cited as a contributory cause (Sobey & Woodman,
1993), damage to, or stunning o f the endothelium o f  microvessels being a sequel o f 
ischaemia (Nevalainen et al, 1986; Kim et al., 1992). It is possible also that the increased 
release o f  vasoconstrictor substances during ischaemia or after reperfusion may contribute 
to this phenomenon. These may include endothelin-1 itself which has been shown to be 
released from rat hearts after reperfusion (Brunner et al, 1992), and endothelium-derived 
lipoxygenase products as well as noradrenaline and 5-hydroxytryptamine (Kwan et al, 
1990). The presence o f  increased concentrations o f  endothelin-1 could be important in 
potentiation o f  the effects o f both 5-hydroxytryptamine and noradrenaline (Yang et al, 
1990; Nakayama et al, 1991) and this would exacerbate the rise in perfusion pressure seen. 
Whatever the underlying mechanism, the increase in basal perfusion pressure makes 
interpretation o f  cumulative vasoconstriction problematic.
1 3 2
7.1 Effects of ischaemia and reperfusion on endothelin and sarafotoxin 6c 
responses:
Binding sites for a  t-adrenoceptor agonists have been shown to increase after a 30 minute 
period o f  ischaemia (Allely & Brown, 1988) in rat hearts in vivo but these changes were not 
confirmed by a later study in vitro (Dillon et al, 1988) and do not necessarily represent an 
increase in functional receptors. The experiments on the effects o f  endothelins after 
ischaemia / reperfusion were performed in an attempt to discover whether the increase in 
endothelin binding sites described by Liu et al., (1990) represented an increase in functional 
receptors, following a similar protocol in vitro to  that which revealed the increased binding 
sites.
The change which was seen in the current study in the responses to endothelins after 
ischaemia / reperfusion can be separated into the morphological change in the responses and 
the apparent increase in the magnitude o f  the responses.
7.1.1 Morphological changes
The morphology o f the endothelin-1 and -2 responses after ischaemia / reperfusion appeared 
to change at doses o f each isopeptide where a vasodilator component was present in control 
hearts (see figure R-4). The ischaemic / reperfused preparations showed a loss o f the 
vasodilator component accompanied by a change in the morphology o f the upstroke o f  the 
vasoconstriction which appeared more acute. The responses to endothelin-3 where 
vasoconstriction occurred in control hearts were not in a range at which vasodilatation was 
a feature and so the morphological change is less apparent. The changes identified in this 
study show similarities to changes in the responses to  endothelin-1 described after injection 
o f air through the coronary vasculature to remove endothelium (Baydoun et al., 1989). 
Following air injection, the response to a single dose o f  endothelin-1 lacks any vasodilator 
component and appears to be more acute in onset than that seen in the control preparations 
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Figure D-l
The effect o f injection of air through the coronary circulation o f the rat isolated heart on the 
perfusion pressure response to a bolus dose of endothelin-1 (3pmol). (Baydoun et al, 
1989).
7.1.2 Changes in m agnitude
Changes in the magnitude o f the responses to all three endothelins are more difficult to 
differentiate. At first approximation, the results suggest that responses to all three 
endothelins are enhanced after ischaemia / reperfusion (figures R-7 & R-8) However, it is 
probable that at least part o f this enhancement is due to the inclusion of a rising basal 
perfusion pressure in the cumulative measurement, and separation of this component is not 
possible. It is likely that part of any real increase would be contributed by loss of a 
functionally opposing vasodilatation, but to what extent this is important is not clear.
The experiments o f Neubauer et al., (1991) describe an enhancement o f endothelin-1 - 
induced reduction o f coronary flow after 30 minutes o f ischaemia followed by reperfusion. 
Determination of coronary resistance by measurement o f flow (see introduction section
1.8.1) would lead to a similar inclusion of any increase in basal coronary resistance similar 
to that seen in the current study. The effects o f ischaemia and reperfusion alone on
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coronary flow were not described by Neubauer et al, (1991), and it is conceivable that a 
reactionary vasoconstriction would be manifest over the same period in their experiments as 
was demonstrated here by an increase in perfusion pressure.
M cMurdo el al., (1991) show an enhancement after ischaemia / reperfusion, not of 
magnitude o f the response to a single lOOpmol dose o f endothelin-1, but o f  its duration. 
Use o f  a single bolus dose removes much o f the problem arising from cumulative 
measurement o f vasoconstrictor effect on perfusion pressure. The authors o f  this study 
suggest that the prolongation may be due to impairment o f  prostacyclin production which 
would otherwise oppose the vasoconstriction, as indomethacin further potentiated the 
duration o f  response. However, this study demonstrated no vasodilator component to  the 
endothelin-1 response in control hearts, despite use o f  a model similar to that in the current 
study.
The only conclusion that can be drawn from these results, in the light o f  the rise in basal 
perfusion pressure, is that the attenuation o f  the dilator phase o f  the response after 
ischaemia /  reperfusion is common to all three endothelins and to sarafotoxin 6c, and this 
loss could contribute to vasoconstrictor enhancement as described by Neubauer et al, 
(1991).
7.2 Selectivity o f the changes in the endothelin response: vasoconstrictors and
vasodilators
The selectivity o f  the changes in the responses o f the endothelins and sarafotoxin 6c was 
tested by use o f  the same protocol for other coronary constrictor and dilator substances. 
The coronary vasodilatation produced by all the agents used except verapamil was 
significantly attenuated after 30 minutes o f ischaemia followed by reperfusion. This 
suggests that attenuation o f vasodilatation is common to  agents acting by different 
mechanisms, both endothelium-dependent and independent. Impairment o f  coronary 
relaxation after ischaemia / reperfusion is a well documented event, having been
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demonstrated in different preparations after varying durations o f ischaemia and reperfusion. 
M ost o f  the data produced to date has been indicative o f an impairment o f endothelial 
function; for example the responses to bradykinin and acetylcholine, but not sodium 
nitroprusside, have been shown to be reduced after ischaemia / reperfusion in dogs (Mehta 
1989; Kim et al., 1991) and in porcine vessels (Dignan et al., 1992). Responses to 
thrombin (Ku, 1982) have also been attenuated after an ischaemia / reperfusion protocol in 
dogs. The phenomenon o f "endothelial stunning” has been cited as a result o f  brief 
ischaemia, the temporary effect inducing loss o f vasodilatation (Kim et al., 1992). 
However, using the current protocol, responses to some agents acting directly on vascular 
smooth muscle (adenosine, sodium nitroprusside and papaverine) have also been attenuated. 
In the case o f vasodilator agents which may not be dependent on the endothelium for their 
action, there are also previous examples o f loss o f responsiveness in different preparations. 
Attenuation o f the adenosine response in the dog has been ascribed to the effects o f 
ischaemia /  reperfusion (60 minutes o f  each) on a specific (A j) receptor (Cox et al., 1994) 
and the reduction o f  adenosine and papaverine responses to "microvascular stunning" 
(Triana & Bolli, 1991), after a brief period o f ischaemia (15 minutes) and persisting for 4 
hours after reperfusion. "Microvascular stunning", whatever the mechanism(s), is clearly 
not confined to  endothelium-dependent responses and appears also to  be a feature o f  the 
protocol used in the current study. Vasodilatation in response to verapamil is as a result of 
an effect on L-type calcium channels, a response which does not require an intracellular 
signal transduction component or the utilisation o f  high energy phosphates. It could 
therefore be argued that vasodilator responses to agents requiring receptor activation or 
intracellular transduction processes will be more greatly attenuated than responses to these 
vasodilators. Further work would be required to elicit the reasons why signal transduction 
o f vasoconstriction responses does not appear to be similarly affected if this is the case. 
There was no enhancement o f  the vasoconstriction produced by either phenylephrine or Bay 
K 8644, the response to neither o f which has a vasodilator component. As these responses 
returned to baseline values rapidly they were not measured cumulatively, so there can be no 
contribution to the vasoconstriction from a baseline rise in perfusion pressure, which is a
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problem with the endothelins. This lack of significant effect o f a period o f ischaemia with 
subsequent reperfusion on responses to phenylephrine concurs with the results o f a study by 
M cM urdo et al (1991), where the ischaemia / reperfusion protocol is similar. The 
enhancement o f the duration o f vasoconstriction to a single bolus dose o f endothelin-1 was 
not found with either phenylephrine or U46619 (a thromboxane analogue).
It was necessary to test the effects o f this particular protocol, including a period o f  30 
minutes o f  ischaemia and 10 minutes o f  reperfusion, on responses to other vasoconstrictors 
as previous studies have shown contradictory results. For example, following 15 minutes o f 
ischaemia in dogs, vasoconstrictor responses to U46619 and potassium were enhanced 
(Kim et al, 1992). This concurs with the results o f  an earlier study in dogs in which both 
potassium and ergonovine responses were enhanced after 60 minutes each o f  coronary 
occlusion and reperfusion (Van Benthuysen et al, 1987). A  separate study describes the 
progressive attenuation, rather than enhancement, o f  a vasoconstrictor response to 
potassium in isolated porcine coronary vessels which were removed following increasing 
periods o f  ischaemia in vivo (Dignan et al., 1992). Hence the effects o f  ischaemia and 
reperfusion on responses to vasoconstrictor substances are variable and may be dependent 
on the period o f  ischaemia involved and possibly on the species or preparation used.
7.3 Mechanism of the vasodilator component of the endothelin-3 response
No information on the mechanism o f the vasodilatation induced by the endothelins in this 
preparation could be gleaned from the results o f the ischaemia / reperfusion experiments as 
the "microvascular stunning” phenomenon appears to be non-selective. Hence the 
isopeptide with the clearest vasodilator effect, endothelin-3, was selected for further study. 
The inhibition o f  the vasodilator component by use o f  an antagonist would create a situation 
where the effects o f loss o f the vasodilator component on the vasoconstriction phase could 
be assessed in the absence o f ischaemia / reperfiision.
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This was initially attempted by perfusing a combination o f indomethacin and L-NMMA. 
However, the effect o f this perfusate on the response to a submaximal vasodilator dose o f 
endothelin-3 was not significant, despite a marked inhibition o f  thrombin- and bradykinin- 
induced vasodilatation. Therefore the inhibition was insufficient for an assessment o f  the 
effect o f  vasodilator attenuation to be made. No significant enhancement o f 
vasoconstriction was apparent under these experimental conditions.
In the rat coronary circulation the evidence for the mechanism o f  vasodilatation by 
endothelin-3 is incomplete. There are reports o f a role for prostacyclin in the vasodilator 
component o f the endothelin response in hearts o f other species, such as the guinea pig 
(Karwatowska-Propopczuk and Wennmalm, 1990) and dog (Okamura et a l, 1992). In 
porcine coronary artery, a mediator o f vasodilatation has been identified as endothelially 
produced nitric oxide (NO), (Pemow & Modin, 1993; Ushio-Fukai et al, 1992). However, 
there is little evidence for the release o f NO in rat coronary artery, although other rat tissues 
have been shown to produce this substance in response to  endothelins (Lawrence & Brain, 
1992, in rat skin; Warner et al, 1989, in rat mesentery). In the present study, there was no 
increase in basal perfusion pressure in response to perfusion o f combined indomethacin 
(lOpM ) and L-NMMA (lOOpM). This suggests that the role o f constitutively produced 
endothelial NO in the modulation o f basal coronary artery tone in this preparation is not an 
important one. However, one report o f basal coronary release o f NO in the rat uses a 
higher L-NMMA concentration (500pM ) than that used in the current study (Amrani et al, 
1992). A higher concentration o f the NO synthase inhibitor might therefore have been used 
with better effect.
An inhibitor o f ATP-sensitive potassium currents (Ikatp), glibenclamide, was also used in 
order to attempt inhibition o f the vasodilator component o f the endothelin-3 response. The 
vasodilator effects o f endothelins in the vasculature have been attributed to  a 
hyperpolarising effect which may be a result o f direct action upon endothelin receptors in 
smooth muscle, or via release o f endothelium-derived hyperpolarising factor (EDHF) both 
o f which may result in opening o f potassium channels. This potassium channel activation 
has been demonstrated in endothelin-induced vasodilatation o f  the cat pulmonary circulation
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and this has been shown to be sensitive to the Ikatp channel inhibitor glibenclamide (Lippton 
et al, 1991). The involvement of an outward potassium current in the rat heart has also 
been demonstrated (Sakuma et al., 1993), where an increase in the potassium concentration 
o f  the perfusate abolished the coronary dilator component o f  the endothelin-3 response.
In the current study, the perfused glibenclamide concentration was sufficient to inhibit the 
vasodilator response to  an opener o f Ikatp channels, lemakalim, although the vasodilatation 
produced by endothelin-3 was significantly enhanced after glibenclamide perfusion, rather 
than inhibited (figure R-14a). This enhancement is likely to be an effect o f the significantly 
higher basal perfusion pressure which was present in glibenclamide-perfiised hearts. Hence 
no confirmation o f the involvement o f the Ikatp channel in the vasodilator effect o f 
endothelin-3 can be made from this study. This is supported by the results o f  another study 
in rat hearts where glibenclamide was ineffective in modifying the vasodilator component of 
the endothelin-3 response (Sakuma et al, 1992).
However, vasoconstriction to endothelin-3 was attenuated after glibenclamide perfusion, 
this being a significant effect at 20, 100 and 200pmol doses (P<0.05; see figure R-14c). 
This is interesting in terms o f  the depolarising effect o f  endothelin acting via blockade of 
Ik atp in porcine coronary smooth muscle reported by Miyoshi et al, (1992). If  this 
blockade were important in the vasoconstrictor response to endothelin-3 in rat coronary 
smooth muscle, then prior treatment with the antagonist glibenclamide, might be expected 
to limit the endothelin's depolarising effect, and hence vasoconstriction. This has in fact 
occurred, suggesting that one mechanism of the vasoconstrictor component o f the response 
may be the inhibition o f IKATP, although this cannot be the only mechanism as a substantial 
vasoconstrictor response remains. There may also be a contribution to the reduced 
vasoconstrictor activity from the increased basal perfusion pressure, where increased 
vasodilator activity obscures part o f the vasoconstriction.
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7.4 Effects of BO-123 on vasoconstriction: receptor involvement in phases of 
the endothelin responses
The role o f different receptors for endothelins in the different phases o f the response was 
investigated using the ETA-selective competitive antagonist BQ-123. Coronary constrictor 
responses to both endothelin-1 and endothelin-3 were significantly attenuated following 
perfusion with BQ-123 (figure R-15). This compound has been shown to be highly 
selective for the ETA receptor; the IC50 value o f BQ-123 against [125I]endothelin-l binding 
to  vascular smooth muscle has been measured at 7.3nM, compared with 18000nM at 
cerebellar ETB receptors (Ihara et al, 1991), and similar figures have been obtained in 
separate studies (e.g. Sakamoto et al, 1993). The reduction o f  the vasoconstrictor 
response to endothelins by BQ-123 therefore suggests that at least part o f this constriction 
is mediated via ETA receptors. This is also in keeping with the relative potencies o f the 
endothelins in causing coronary constriction, the doses o f  endothelins -1 and -2 required to 
produce -lOOmmHg increases in perfusion pressure being similar whereas (>10x) higher 
doses o f  endothelin-3 were necessary to produce a comparable level o f effect (see figures 
R-7 & R-8). The ETB-selective agonist sarafotoxin 6c was ineffective in producing 
vasoconstriction (figure R-8), which is consistent with there being no role for ETB2 
receptors in endothelin-induced vasoconstriction.
The receptor subtype involved in the coronary constrictor response in various species has 
been the subject o f investigation. An early study by Ihara et al, (1991) investigated the 
binding o f radiolabelled endothelin-1 and endothelin-3 to porcine coronary arteries and 
suggested that only ETA receptors are found on the vascular smooth muscle. However in 
the same preparation the coronary constrictor phase o f  the response appears to  be mediated 
by a receptor subtype which does not conform to the profile o f  either "known'' receptor 
(Harrison et al, 1992). In this species also, the ETB (ETB2) receptor has been implicated in 
this contraction, but this required the removal o f the endothelial barrier (Shetty et al, 1993) 
suggesting a site on the underlying smooth muscle. A further study (Schoeffter & 
Randriantsoa 1993) describes contraction mediated by both ETA and ETB2 receptors on
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porcine coronary smooth muscle, as well as a further component to the contractile response, 
which supports the results described by Harrison et al, (1992). In man, Bax et al, (1993) 
suggest a subtype o f the ETA receptor is present on coronary artery, as well as ETB2 which 
could be responsible for contractile responses, and Seo et al, (1994) describe constriction 
mediated by both ETA and ETB2 receptors in human coronary.
There is little data referring to an ETB2 mediated vasoconstriction in rat heart, but a study 
by Balwierczak (1993) suggests that both ETA and ETB2 receptors are involved in 
vasoconstriction in this preparation, as an ETB selective agonist (IRL 1620) induced this 
effect. The differences in the findings between this and the current study are difficult to 
reconcile, as the results here show no coronary constriction to the ETB selective agonist 
sarafotoxin 6c (Williams et al, 1991). However, the role o f the endothelium in protection 
against ETB mediated vasoconstrictor action in this preparation has not been clarified. The 
study performed by Balwierczak (1993) showed no vasodilator phase to the endothelin 
response and involved a higher (20ml.min'1) flow rate. Though endothelial denudation was 
not performed, the higher flow rate involved might have been responsible for some 
increased drug access to  underlying smooth muscle. However, confirmation o f  this would 
require investigation o f  the integrity o f the endothelium under the experimental conditions in 
each study.
There was no attenuation o f the coronary dilator component o f the response to either 
endothelin-1 or endothelin-3 with BQ-123, suggesting that this phase is not ETA receptor- 
mediated. In fact the duration o f vasodilatation to endothelin-1 is prolonged (figure R-18), 
possibly because the later part o f  dilatation in controls is partly masked by the constrictor 
phase. The response to endothelin-3 was not prolonged, however, possibly because 
vasoconstriction is less marked in the dose range where the vasodilatation is present (10- 
lOOpmol). The vasodilatation response has been associated with ETB] receptors found on 
endothelium (Sakurai et al, 1990). This receptor is not selective for the different 
endothelin isopeptides and this is also consistent with the vasodilatation seen in these 
experiments in the isolated perfused rat heart, where all three endothelins and sarafotoxin 6c 
act as coronary dilators in the 10-100pmol dose range.(see figures R-5 & R-6).
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The information gained in the current study is limited in terms o f the nature o f the 
endothelin receptors involved in both phases o f  the response. The subtype o f receptor 
involved could be further investigated using a wider range o f antagonists, including the 
ETB-selective BQ-788 (Ishikaw ae/a/., 1994).
7.5 Desensitisation of the coronary dilator effect o f endothelin-l
The experiments performed exploited the cross tachyphylaxis seen between the endothelin 
isopeptides which is extended to the ETB selective agonist sarafotoxin 6c. The response to 
a single submaximal dose o f endothelin was completely inhibited following a protocol o f 
desensitisation using three lOOpmol boluses o f sarafotoxin 6c at 10 minute intervals. The 
lack o f  effect o f  this protocol on the responses to  other coronary dilator and constrictor 
agents shows the selectivity of the desensitisation. This sarafotoxin 6c-induced 
tachyphylaxis is strongly indicative that the coronary dilatation produced by endothelins in 
the rat is mediated by the ETB1 receptor subtype.
Cross desensitisation has previously been demonstrated by Le Monnier de Gouville & 
Cavero (1991) in endothelin-induced hypotension in the rat, and is normally associated with 
the vasodilator phase o f  the endothelin response mediated by ETB1 receptors. In one report, 
however, a sarafotoxin 6c constrictor response has been the subject o f tachyphylaxis 
(Sudjarwo et al., 1993). The mechanism o f desensitisation has been investigated by 
Hollenberg et al., (1993) and has been shown to depend on the internalisation o f endothelin- 
receptor complexes, as when this process was antagonised using dansylcadaverine, the 
desensitising effect was inhibited. In another study, the action o f a C-terminal portion o f 
endothelin-l on the guinea pig ileum did not cause desensitisation, this segment o f  the 
peptide being unnecessary for the strong binding o f  the endothelin-receptor complex 
(Miasiro et al., 1993). Hence the internalisation o f  tightly bound receptor complexes as a 
route for desensitisation is supported by their study. The method used in the current study, 
a maximal sarafotoxin 6c bolus repeated at 10 minute intervals, may be causing the
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maximum degree o f receptor binding and internalisation, and hence loss o f vasodilator 
effect.
The complete loss o f the coronary dilatation after desensitisation is accompanied in the 
current study by a comparable degree o f vasoconstrictor enhancement. That the difference 
between vasodilator loss and vasoconstrictor enhancement is so small (a mean o f  25mmHg 
vasodilator loss, compared with 28mmHg mean vasoconstrictor enhancement) would 
suggest that the enhancement could be a direct consequence o f  a loss o f  functional 
antagonism. This is an indication that vasodilator loss alone could be enough to result in an 
increase in vasoconstrictor effect similar to that seen after ischaemia and reperfusion.
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8.0 Conclusions from experiments performed in the isolated perfused rat heart 
preparation
The responses to all three endothelins in the isolated rat heart consisted o f a dilator and a 
constrictor phase in keeping with reports o f previous authors (Baydoun et al, 1989). 
Responses to  the ETB-selective agonist sarafotoxin 6c in the same preparation were almost 
completely vasodilator in character. The effect o f ischaemia / reperfusion included a general 
rise in basal perfusion pressure which hindered interpretation o f the cumulative 
measurement o f  vasoconstrictor responses in the reperfused hearts after a 30 minute period 
o f  ischaemia. The apparent increase in endothelin vasoconstrictor effect is therefore 
unhelpful and a better model is required. What can be stated with confidence, however, is 
that the coronary dilator component o f  the responses to endothelins -1 ,-2  and -3 as well as 
sarafotoxin 6c is markedly attenuated after the ischaemia / reperfusion protocol described in 
these experiments and this effect is common to all vasodilators tested except verapamil, 
where vasodilator loss was not significant.
Loss o f  the vasodilator component o f the endothelin responses is in itself enough to  result in 
an increase in vasoconstrictor effect as demonstrated where the coronary dilator component 
o f a response to endothelin-l was desensitised using a repeated dose o f  sarafotoxin 6c. The 
degree o f  enhancement o f vasoconstriction was almost exactly equivalent to the level o f 
vasodilatation lost, suggesting that a functional antagonism is important in the modulation 
o f the action o f the peptides. This could be o f  pathological importance where local 
endothelial disruption (such as in atheroma or after percutaneous transluminal coronary 
angioplasty) results in a loss o f  an endothelium-dependent vasodilatation to endothelin 
which has been shown in some preparations (Folta et al, 1989). This could result in local 
vasospasm mediated by the endothelin peptides.
The mechanism o f the coronaiy dilator component o f  the endothelin-3 response in the rat 
heart is not clear. From use o f the agents L-NMMA and indomethacin it appears that NO 
synthase and cyclooxygenase products are not o f  primary importance in endothelin-induced 
vasodilatation. The inhibitory effects o f the IKATP antagonist glibenclamide, suggest a
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possible role for the closure o f this ion channel in the constrictor phase o f the response (in 
agreement with the results o f Miyoshi et al, 1992). However, the current data provide no 
evidence o f any coronary dilator involvement. The possibility remains that the dilatation is 
as a result o f  the release o f an endothelially derived mediator as previous evidence suggests 
that the endothelium is involved in the coronary dilatation in rat heart (Baydoun et al., 
1989). The possibility is still open that a hyperpolarising factor could be the agent released, 
although this was not confirmed in the current study. It would be o f  interest to repeat the 
glibenclamide perfusion experiments using a second set o f  controls in which the basal 
perfusion pressure had been raised (for example by manipulation o f the flow rate o f 
perfusate) in order to separate the effect o f  the increased basal perfusion pressure from the 
effect o f  glibenclamide on the ion channel.
The current data using the ETA receptor-selective antagonist BQ-123, and the ETB 
receptor-selective agonist sarafotoxin 6c, are consistent with the coronary constrictor 
response being mediated by ETA receptors and the dilator response being mediated by ETB1 
receptors. There was no indication from the present study o f  an ETB2 receptor-mediated 
vasoconstrictor effect (data from sarafotoxin 6c).
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9.0 Calcium  responses in smooth m uscle ceils in culture
The rise in intracellular calcium concentration ([Ca2+]j) is important for a number o f 
functions including the contraction o f  smooth muscle and cell growth properties (see 
introduction, section 1.5). Extracellular and intracellular sources o f  calcium are both 
important in the regulation o f [Ca2+]b and both sources have been implicated in the 
responses to endothelins (van Renterghem et al, 1988). Cells in culture are a frequently 
used and convenient model for the determination o f calcium changes in response to 
extracellular stimuli, and this study examines responses to endothelins in smooth muscle 
cells derived and subcultured from fresh porcine coronary artery. The calcium responses 
were assessed by means o f fluorescent calcium indicators, in preparations o f  cells in small 
groups o f  -2 0  cells growing as a monolayer, in single adherent cells, and in populations o f 
cells in suspension in a concentration o f  1x106 cells per ml.
Culture conditions (i.e. culture method, serum starvation and passage number) were kept to 
a similar protocol for experiments using all three types o f measurement, as several 
phenotypic changes have been demonstrated according to  culture conditions. For example, 
freshly isolated cells are differentiated and contractile (Chamley-Campbell et al, 1979) and 
have a population o f  voltage operated calcium channels o f  mainly L-type (Neveu et al,
1994). After exposure to serum, the cells become "modulated", cease to be contractile, and 
exhibit many features o f proliferation. T-type calcium channels are the major type 
expressed in the modulated cell type (Neveu et al., 1994). A return to  the differentiated 
state can be achieved following an adequate period o f  serum starvation. Specifically for 
endothelin experiments, a change in the prominent receptor subtype has been demonstrated 
following the repeated passaging o f cells (Eguchi et al, 1994). Hence the standardisation 
o f  culture conditions was important for the comparison o f  the techniques used. In all types 
o f  experiment also, the agonist remained in contact throughout the measurement period in 
order to  standardise the procedure, as this was unavoidable when using cells in suspension.
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9.1 Monolayers of porcine coronary smooth muscle cells
The changes in [Ca2+]j in a monolayer of cells were measured in situ without the need to 
remove the cells from the culture plate, and without loss o f contact with neighbouring cells 
in a confluent monolayer. Basal [Ca2+]j under these experimental conditions was 73±6nM 
(n=4), a level comparable to the results of others using monolayers o f  confluent smooth 
muscle cells in culture from a variety o f different sources; examples o f  basal [Ca2+]j levels, 
measured using fiira-2 as an indicator, range from 73 to 115nM and smooth muscle cell 
sources include canine trachea (Yang et al, 1994), rat aorta (Iijima et al., 1991 ; Okada et 
al., 1991 ) and human umbilical artery (Gardner et al, 1992 ).
9.1.1 Calcium responses to endothelin-l
In cells grown in monolayers the addition o f endothelin (lOnM to lOpM) resulted in a rise 
in [Ca2+]j followed by a plateau phase. This is consistent with the findings o f  several 
authors using monolayer preparations of smooth muscle cells (e.g. Iijima et al., 1991; 
Okada et al, 1991; Gardner et al, 1992; Okishio et al., 1992; Yang et al, 1994), in 
which agonist remained in contact with the cells.
In the current study, the initial increase in [Ca2+]j in response to endothelin-l was 
concentration-related in most preparations, but the size o f the maximal responses was very 
variable (see figure R-23). The reasons for this are not clear, but the inter-preparation 
differences in maxima could reflect a different responsiveness in the hearts o f different pigs 
from which the cells were cultured. If this is the case, then an increase in experimental 
number would be necessary in order to gain a clearer indication o f the concentration 
relationship and the effect o f inhibitors.
9.1.2 Effect of BQ-123 on responses to endothelin-l
In porcine and human coronary smooth muscle, the increase in vascular tone to  endothelin 
has been attributed to both ETA and ETB2 receptor activation (e.g. in man, Seo et al., 1994; 
in pig, Fukuroda et al, 1992, Schoeffter & Randriantsoa, 1993). Harrison et al, (1992)
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note vasoconstrictor effects in porcine coronary artery preparations which are attributable 
to neither subtype o f receptor. Whether changes in [Ca2+]j in porcine coronary artery 
smooth muscle cells are due to activation o f  ETA or ETB2 receptors has not been 
approached. The competitive ETA antagonist BQ-123 was used here in an attempt to 
clarify the receptor subtype through which the rise in [Ca2+]i is mediated in this preparation. 
A 3 minute incubation o f cells with BQ-123 at concentrations o f lOnM and above 
successfully inhibited the [Ca2+]j rise to  endothelin-l (see figure R-21 & R-22). When 
lower concentrations were used, however, no inhibition was apparent. This could be a 
reflection o f the high degree o f variability o f the responses between preparations except that 
the individual cell preparations do not clearly show a concentration-related effect o f BQ- 
123 at lower concentrations either. The effectiveness o f  the pentapeptide at higher 
concentrations is not simply a result o f  loss o f  cell viability, as the response to bradykinin 
was not altered at BQ-123 concentrations o f  1-lOOnM. This also demonstrates the 
selectivity o f the antagonism at the higher BQ-123 concentrations. The apparent "all or 
nothing" effect o f  the antagonist has not been previously reported, but BQ-123 has other 
properties which are not consistent with the action o f  a competitive antagonist.
The marked inhibition o f the endothelin response at the lOnM BQ-123 concentration is 
clear and, within the limits o f the concentration-response curve (Emax is not clearly 
attained), appeared to  result in a reduction o f  maximal effect (figure R-22). The effects o f 
BQ-123 and a closely related compound, BQ-153, as competitive antagonists have been 
well established in dose-contraction relationships in porcine coronary arterial strips, with a 
slope not significantly different from unity on Schild plotting (Ihara et al, 1992). However, 
in experiments using monolayers of a neuroblastoma cell line, a non-competitive action o f 
BQ-123 has been demonstrated (Hiley et al., 1992). These authors suggest an uncoupling 
o f the relevant G-protein from the receptor as a result o f  BQ-123 action, resulting in loss o f 
[Ca2+]i response. In rat brain capillary endothelial cells in culture, a similar non-competitive 
antagonism was seen with BQ-123, and this has been shown to be dependent on the time o f 
interaction o f  the antagonist with the cells; simultaneous addition o f  BQ-123 and 
endothelin-l resulted in a parallel shift o f the concentration-response curve to the right
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without affecting Emax, whereas preincubation o f the cells with the antagonist resulted in a 
lower Emax (Vigne et al, 1993). In the present study, monolayers were incubated with 
BQ-123 for a 3 minute period, which would allow time for a more stable antagonist- 
receptor complex to be formed as described by Vigne el al, (1993). This phenomenon is 
reported only with BQ-123, the competitive effect o f other antagonists being independent o f 
the duration o f incubation.
It is not possible to conclude that the inhibition seen with BQ-123 is a result o f  ETA 
receptor antagonism or that the receptor is the only one involved in the increase in [Ca2+]i in 
this preparation. If  these experiments were repeated it would be advisable to employ a 
selective ETA receptor antagonist which has been shown to act competitively in similar 
preparations such as F R 13 9317 (McMurdo et a l , 1994).
9.1.3 Role of extracellular calcium in the peak and plateau phases of the endothelin 
response
The role o f extracellular calcium entering via calcium channels was investigated using the 
divalent cation Ni2+ which is known to block calcium entry via voltage operated channels 
(Tsien et al, 1988) as well as other, receptor-operated, calcium channels (Highsmith et al., 
1992). In the presence o f 5mM NiCl2 no significant change in the [Ca2+]j increase to 
endothelin-l was seen at either peak or plateau phase o f the response, although there was 
an overall trend toward depression o f both phases (figure R-25). It has been shown that 
extracellular calcium is needed for the prolonged response which is characteristic o f 
endothelin-induced vasoconstriction (Hickey et al, 1985; Yanagisawa et al, 1988). 
Vasoconstriction to endothelins is attenuated in the presence o f  low extracellular calcium 
and in the presence o f L-type calcium channel antagonists or Ni2+, although this calcium 
entry is not confined to  activation o f L-type channels (van Renterghem et al, 1988; 
Highsmith et al, 1992). The effect o f endothelin-l on [Ca2+]j in human vascular smooth 
muscle has been previously documented, and a partial dependence o f  both initial and late 
phases o f the calcium response has been shown in a monolayer o f cells (Gardner et al, 
1992). Hence an attenuation o f both phases o f the [Ca2+]j increase would have been
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expected in the presence of Ni2 '. The lack o f significance shown here may, however, be a 
reflection o f the variability between preparations, although it is likely that neither phase is 
totally dependent on the influx o f extracellular calcium.
9.1.4 Sarafotoxin 6c effect on [Ca2+]j in monolayers
The response to sarafotoxin 6c was subject to  great variability, more so than the response to 
endothelins in monolayers o f smooth muscle cells. In two preparations, no response was 
elicited from concentrations up to lOgM. In a further preparation a response at 5pM 
sarafotoxin 6c was gained, suggestive o f a role for ETB2 receptors in the calcium rise in 
these cells, as this peptide is highly selective for ETB receptors (K/ETA /Kjetb -300,000; 
Williams et al, 1991). In the responding preparation, an additional response could be 
elicited from endothelin-l (1pm) after the response to sarafotoxin 6c had returned to basal 
level, but with sarafotoxin 6c remaining in contact with the cells. The reason for this has 
not been further examined here; the secondary increase may indicate that a separate 
receptor (probably ET^) is involved in this response or that an increased number o f  the 
same receptor subtype are stimulated as a result o f addition o f a second agonist. I f  the 
initial response was a result o f  ETB2 stimulation, this would be consistent with previous 
findings (Fukuroda et al, 1992; Schoeffter & Randriantsoa, 1993) in porcine coronary 
artery where both ETA and ETB2 have been implicated in constriction. However, the 
number o f preparations responding here to sarafotoxin 6c was low (1 o f  3), which may 
indicate that the ETB2 receptor subtype is not present on all cells or in all hearts.
9.2 Calcium responses in single cells
The [Ca2+]j increases in cells on coverslips were measured in single cells as part o f a 
monolayer, by use o f a narrow diaphragm to select the cell under microscopy. The [Ca24]j 
was calibrated using a similar technique to that for monolayers and this resulted in a similar 
reading for basal [Ca2+]; levels, despite the warming o f  the cells to 37°C, which was not
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done for the monolayers. Again, this level o f calcium in unstimulated cells is consistent with 
results previously published (see section 9.1 above).
9.2.1 Responses to endothelin -l in single smooth muscle cells
Endothelin-l elicited a response in approximately 58% of cells (14 o f 24). Where this 
response occurred, the peak increase in [Ca2+]j was very variable, as may be seen in figure 
R-28. Some cells were unresponsive to endothelin-l (10 o f 24) although o f these, 4 
responded to another agonist, bradykinin. Thus, in a population o f similar cells from a 
primary culture (with >99% identified as smooth muscle on staining), sub-populations may 
exist which are not able to produce a calcium response to  a particular agonist. Whether this 
is due to a lack o f the relevant receptor or to a failure o f the coupling mechanism o f  that 
receptor to a calcium pathway is not clear. Vascular smooth muscle cells in culture have 
been shown to change in phenotype in many respects (Neveu et al, 1994), the expression o f  
receptors for endothelin being one o f  the factors affected (Eguchi et al, 1994),. However, 
this particular change has been demonstrated at "late" passage (defined as passage 30-35), 
hence substantial change in subtype expressed is not expected in cells below 10 passages as 
used in the current study. It is possible, however, that individual cells in culture (in the 
"modulated" state - Chamley-Campbell et al, 1979) may change in their receptor 
expression at different stages, and that these changes are not reversed after 24 hours o f 
serum deprivation. These changes would only become apparent where single cells are 
examined. It is likely also, that a heterogeneous population o f  cells in vivo exhibit a variety 
o f different characteristics which are not seen unless cells are examined individually. 
Different sensitivities o f individual cells to  a concentration o f agonist have been 
demonstrated in bovine tracheal smooth muscle cells (not serum deprived - personal 
communication from K.Marsh) where, in the absence o f  extracellular calcium, the response 
to bradykinin was shown to be an "all or none" phenomenon (Marsh & Hill, 1993). 
However, the number o f cells giving a uniform level o f  response was concentration 
dependent. These authors suggest a different sensitivity o f individual cells to a particular 
agonist concentration. In the current situation, a further series o f experiments using a
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greater experimental number would be necessary to determine the number o f cells 
responding to a single concentration o f agonist. However, the responses to endothelin-1 do 
not conform to the "all or none" profile as the level o f  response was also variable.
9.2.1.1 Calcium oscillations in response to endothelin-l
There are few reports analysing the actions o f endothelin in single cells, probably due to the 
high variability o f latency, peak and subsequent phases o f responses in these cells. Where 
individual cells have been used, however, there is no mention o f oscillatory effects (e.g. 
W agner Mann et al., 1992; Wagner Mann & Sturek, 1992) although their measurement 
technique may not have allowed the time resolution required for their identification. The 
response o f  vascular smooth muscle cells to a single concentration o f  endothelin-l was 
highly variable (see figure R-28) differing in both magnitude and in the oscillatory behaviour 
elicited. This is consistent with the findings o f  Linderman et al. (1990), in smooth muscle 
cells in response to ATP, where the oscillatory response is seen in 70-80% o f  cells and the 
type o f  oscillatory behaviour in individual cells varies greatly. The continued presence o f 
the agonist was required for the oscillations to  occur. In the study o f  Linderman et al., 
(ibid), where the mean o f  the oscillatory calcium responses to ATP in 5 cells was calculated, 
the result was a peak and subsequent (noisy) plateau phase. The peak increase in [Ca2+]j 
taken from larger cell numbers in a monolayer or in suspension, is thus likely to be 
dependent on the number o f individual cells which respond, and will be the mean initial 
increase. The plateau phase is probably the summation o f the oscillations in individual cells 
which are asynchronous.
9.2.1.2 Calcium oscillations in response to sarafotoxin 6c
The responses o f individual cells to sarafotoxin 6c in different preparations were very 
variable, in a manner comparable with the endothelin variability. However, when a large 
increase in [Ca2+]j in response to sarafotoxin 6c did occur, an oscillatory effect was 
produced. The selectivity o f the toxin for ETB receptors suggests that at least some o f the 
cells responding were expressing the ETB2 receptor. This would be consistent with the
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findings previously described using porcine coronary artery (e.g. Schoeffter & 
Randriantsoa, 1993; see section 9.1.4 above) where contractile responses were attributed 
to ETB2 activation. The response o f a cell to endothelin-l which did not respond to 
sarafotoxin 6c is suggestive that the ETB2 receptor is not present on all cells (see figure R- 
29).
9.3 Calcium responses in cell suspensions
The disadvantage o f using cells in suspension is that some degree o f disruption from normal 
function cannot be eliminated as loss of the extracellular matrix and potentially some 
disturbance o f normal calcium equilibrium may have followed the dispersal procedure. The 
"normal" elongated cell conformation was also lost and the cells appeared rounded. 
However, use o f  such large numbers o f  cells should produce results which overcome the 
variability associated with heterogeneous sub-populations o f  cells; problems associated 
with different sensitivities and latencies between cells will be averaged thus producing a 
more distinct concentration-response relationship from which more information can be 
gained. A plateau response, if present, is likely to be a mean o f the asynchronous 
oscillations produced in individual cells (see above, section 9.2.1.1).
The basal calcium levels produced in these populations o f cells were significantly higher 
than the basal [Ca2+]; in individual cells and monolayers. The basal [Ca2+]i levels quoted in 
populations o f cells in suspension are generally similar to those reported in monolayers and 
single cells (~100nM). However, in the current study, the basal measured [Ca2+]j in cells in 
suspension was markedly higher than that in either monolayers or in single cells. Some 
allowance must be made for potential differences arising from the difference in calibration 
method (from the equation o f  Grynkiewicz et al., 1985) rather than from a series of 
standard solutions. It is possible that some increase in apparent [Ca2+]; may be due to an 
increase in membrane leakage following cell dispersal. It is likely that the dispersal
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procedure would cause some degree of cellular activation and this would account for the 
elevated basal [Ca2+]s levels. However, the cells used in suspension were all calibrated 
similarly and thus comparison may be made between controls and treated preparations from 
these experiments, if not in the absolute [Ca2+]i between these and experiments using single 
cells and those used in monolayers.
9.3.1 Responses to endothelin-l in cells in suspension
In suspension, porcine coronary smooth muscle cells gave a peak initial response to 
endothelin-l, which showed a concentration-related rise in [Ca2+]i. There was still a degree 
o f variability in the peak responses between cells from different hearts, but this was not so 
marked as in the monolayers. A subsequent plateau component o f the response was 
uniform at 200 seconds after the endothelin-l administration, and unrelated to the 
concentration o f  endothelin-l used. The lack o f  concentration-relationship in the plateau 
phase is interesting if this component o f the response is seen as the combined effect o f  the 
highly variable oscillations in individual cells (Linderman et a l , 1990).
9.3.2 Effect o f BQ-123 on calcium responses in cell suspensions
The lower (3nM) concentration o f BQ-123 was ineffective in producing a significant 
inhibitory effect on the endothelin-l-induced calcium response. However, neither was the 
effect o f the lOnM concentration as marked as that seen with the same concentration used 
in monolayers o f cells following a 3 minute incubation. Simultaneous addition o f  the higher 
concentration o f antagonist was performed to determine whether the apparent non­
competitive effect o f the pentapeptide seen in monolayer experiments was related to its 
duration o f contact with the receptor as suggested by Vigne et al, (1993). However, when 
used in suspensions o f  cells, there was no indication that the antagonist was acting in a non­
competitive manner, which could indicate that the non-competitive appearance o f the agent 
in the monolayer experiments was a spurious result and that the antagonism would have 
been overcome by use o f  higher concentrations o f  endothelin-l.
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There has been a report (Sakam oto  et al., 1994) of a non-competitive BQ-123 antagonism 
in cells in suspension (in a mouse fibroblast cell line) after a 20 minute incubation with BQ- 
123, precluding the suggestion that the mode o f culture was responsible for the type o f 
antagonism seen. Further experiments would have been o f use, using cells in monolayers 
with both simultaneous addition o f antagonist and preincubation with BQ-123 to  determine 
the effect o f duration o f contact.
9.4 Effect of herbimvcin-A
Tyrosine kinase activity has been demonstrated in response to  endothelin-l, in several cell 
preparations (Force et al., 1991; Schvartz et al., 1992) including vascular smooth muscle 
cells (Koide et al, 1992a and b). The intention o f  these experiments using the tyrosine 
kinase inhibitor herbimycin-A, was to determine whether part o f the endothelin-l-induced 
[Ca2+]j rise could have been mediated via a tyrosine kinase-dependent pathway.
There is some evidence that tyrosine kinase activation (in response to a variety o f agonists) 
may lead to an increase in [Ca2+]i in smooth muscle and other preparations DiSalvo et al, 
(1993) showed that contractile responses in taenia coli were reduced by inhibitors of 
tyrosine kinase. Inhibition o f this enzyme using genistein has been associated with inhibition 
o f  voltage operated calcium currents in vascular smooth muscle (Wijetunge et al., 1992) 
although direct action o f the antagonist on the calcium channels was not ruled out. 
However, inhibition o f  calcium entry has also been shown in a rat basophilic leukaemia cell 
line using herbimycin-A (Teshima et al, 1994 ); this inhibitor had a significant effect on the 
plateau phase o f  the [Ca2+]j increase as well as on stimulated IP3 increase in these cells, an 
effect separate from any action on the ion channel itself. Herbimicin-A inhibited tyrosine 
phosphorylation in the basophilic cell line as shown by Western blotting (ibid), at the 
concentrations eliciting the effects on IP3 and [Ca2+]j.
A concentration o f herbimicin-A (875nM) was used in the current study, which significantly 
inhibited both IP3 and [Ca2+]j increases in the experiments o f  Teshima et al, (1994). This
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agent was used in preference to genistein as the latter antagonist would interfere with the 
measurement o f fiira-2 fluorescence.
In herbimycin-A-treated suspensions o f porcine coronary smooth muscle cells in culture, 
there was some reduction in the initial peak in [Ca2+]; in response to endothelin-l, but this 
did not achieve significance (figure R-33). The plateau phase o f the response to endothelin- 
1 was unaffected. It should be noted that the concentration o f  herbimicin-A employed here 
has not been shown to inhibit tyrosine phosphorylation in the smooth muscle cell 
preparations used. It is therefore possible that 875nM herbimicin-A was insufficient to 
cause inhibition o f the enzyme in this smooth muscle cell preparation.
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10 Sum m ary o f observations from calcium  signalling experim ents
Cell calcium measurements performed using fura-2 fluorimetry have been shown to be 
inconsistent between primary cultures of porcine coronary smooth muscle cells, when 
prepared in monolayers, suspensions or when investigated individually. This limits the 
number o f  absolute conclusions which can be drawn from the results here, but observations 
regarding the nature o f the differences between the preparations used are summarised 
below.
Basal [Ca2+]j appeared consistent in cells under microfluorimetry, at a level below lOOnM, 
and corresponded to measurements described in the literature. However, in cell suspensions 
the basal [Ca2+]j was significantly higher and the reasons for this could include leakage o f 
the indicator into the extracellular space where the calcium concentration is ImM. Little 
leakage o f fura-2 would be necessary to be seen as a calcium increase above the nanomolar 
levels present within cells. Any cell damage could be the result o f the dispersion procedure, 
which included stirring o f  cells to prevent aggregation (see methods section), and repeated 
centrifugation. Both o f  these procedures are a potential source o f shear stress to the cell 
membranes.
Responses to endothelin-l measured in the three types o f cell preparation also displayed 
inconsistencies, both in the kinetics and in the amplitude o f the responses. In all cases, the 
agonist remained in contact with the cells thus removing one variable cited by Wagner 
Mann & Sturek (1992). Within the monolayer experiments there was a large degree o f 
variation in the amplitude o f the responses between cells from different original coronary 
preparations. This could reflect a wide natural variability in the responsiveness to 
endothelins within a species. The suspensions o f  (larger numbers of) cells did not, however, 
show variability to the same extent, although this does not discount natural variation as an 
explanation for the differences between the monolayer preparations.
It is not possible to compare with confidence, the change in [Ca2+]j in response to the 
agonist between suspensions and monolayers, as the basal [Ca2+]j difference may indicate
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also a difference in the calibration. However, the form o f the responses may be compared 
between all three preparations.
Peak and subsequent plateau phases o f the increase in [Ca24]; in response to endothelin-l, 
evident in cells in suspension, were also present in most responses in monolayers. 
However, in single cells no examples o f a plateau phase were seen and instead, an 
oscillatory form o f response was produced. The oscillations lacked consistency between 
cells, in amplitude and frequency.
Another problem regarding the consistency of measurements in single cells, was the number 
o f  individual cells unresponsive to an agonist. The agonist to which a cell would respond 
and the amplitude o f  response were not predictable. This could suggest that subpopulations 
o f  cells were present which possessed different capabilities o f response, either through 
different expression o f  receptors or through variations in the signal transduction capacities 
following receptor stimulation. These could include expression o f  different ion channel 
populations or intracellular enzymes in "modulated'* as opposed to  differentiated cells 
(Chamley-Campbell et al, 1979; Neveu et al, 1994). Use o f  a considerably higher 
experimental number o f cells would be necessary before conclusions about the 
concentration-response relationship could be drawn.
Investigation into the subtype o f receptor involved in the calcium increase in these smooth 
muscle cells produced no conclusive evidence o f  either ETA or ETB2. The inhibitory effect 
o f the ETa receptor antagonist BQ-123, was o f different appearance in the suspensions 
when compared with cell monolayers. Inhibition o f the endothelin-l-induced rise in [Ca2"]; 
was significant in monolayers at a lOnM concentration, whereas at a similar concentration 
in cell suspensions, there was no significant effect. The results in monolayers were 
somewhat unusual, also. The appearance o f the inhibition was that o f  a non-competitive 
antagonist, and a similar effect has been reported previously although in different cell types 
(Hiley et al, 1992; Vigne et al, 1993). The apparent "all or none" effect o f  the inhibitor 
has not been reported previously and would require further investigation. Higher 
concentrations o f  BQ-123 would be required to investigate whether a similar unusual effect 
occurred in cell suspensions.
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Other experiments using the ETn receptor agonist sarafotoxin 6c were inconclusive, with 
some preparations responsive and others unresponsive. This was also apparent in the 
responses o f single cells. The subtype o f receptor expressed could be a result o f  cell culture 
conditions which were similar for each type o f preparation, regarding the passage number 
and duration o f serum deprivation. These conditions could have favoured a predominance 
o f  one receptor subtype over another and may not reflect the ratio o f receptors existing in 
vivo or in preparations where contraction has been shown to be mediated by both receptor 
subtypes in porcine coronary artery (e.g. Schoeffter & Randriantsoa, 1993).
Finally, attempts to discover any role for a tyrosine kinase dependent increase in [Ca2+]j 




11.1 Ischaemia reperfusion experiments
A further line o f enquiry arising from the original publications o f the group reporting the 
increased binding o f endothelin-l to cardiac membranes, would be the investigation o f  the 
effect o f  amlodipine pretreatment. Comparison o f the current results with the effects o f 
ischaemia / reperfusion in hearts from amlodipine-treated rats would be o f interest as a 
similar protocol was shown to prevent the increase in binding site density which otherwise 
followed ischaemia / reperfusion (Nayler et al., 1992).
Another point which could be addressed arising from the same source, is the origin o f  the 
cardiac membranes on which binding density was increased. This increased binding could 
equally well be on cardiomyocytes as on coronary smooth muscle. A different model in 
which it is possible to compare the effects o f  the ischaemia / reperfiision protocol used by 
Liu et al, (1991) would be required. One such model would be isolated papillary muscle 
and atrial preparations from ischaemic / reperfused hearts, where increased myocardial 
reactivity might be apparent. A separate model would be an isolated myocyte preparation in 
which fluorimetric measurement o f calcium increases could be compared from control and 
from ischaemic / reperfUsed hearts It would be technically difficult to ensure that the 
ischaemia / reperfusion conditions resembled those in the original paper, so parallel binding 
studies would be needed to confirm that the increase in binding site density was a feature of 
the protocol used.
The investigation o f the mechanism underlying the vasodilator component o f the endothelin 
and sarafotoxin 6c responses in the isolated perfused rat heart was not completed, as the 
purpose o f the experiments was to diminish vasodilatation with reliability. However, the 
full mechanisms could be examined initially by use o f separate inhibitors o f cyclooxygenase 
and nitric oxide synthase in the perfusate in a range o f  concentrations, including higher ones 
than those employed to date.
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1 1 . 2  C e l l  s i g n a l l i n g  e x p e r i m e n t s
The reasons for the differences in responsiveness between individual cells from the same 
preparation are o f concern. If the cell culture conditions are responsible for the production 
o f subpopulations o f cells o f variable degrees o f differentiation, then it would be o f value to 
optimise the conditions producing a more homogeneous cell population. The study by 
Neveu et al, (1994) showed that, although serum deprivation significantly reduced the rate 
o f  appearance o f new cells after 24 hours, a longer period could be necessary to maximise 
the numbers o f cells displaying a differentiated phenotype. This could affect many 
parameters including receptor and ion channel expression. Comparison between cells 
deprived o f serum for longer periods such as 48 and 72 hours would be o f  value. 
Measurement o f [3H]-thymidine incorporation rate could be used to  determine the rate of 
cell division and thus indicate the degree o f quiescence o f a population. Many experiments 
are performed using transformed smooth muscle cell lines which do not become 
differentiated, and these could be compared with quiescent cells using a similar protocol. It 
would also be necessary to compare non-cultured, freshly prepared cells with those in 
culture. These would be more physiologically representative although the enzymatic 
dispersion process has its own drawbacks.
Ideally, a population o f  cultured cells in a monolayer could be compared with cells in situ, 
by use o f  the front surface fluorimetry technique (see introduction). These cells in situ are 
little disturbed from their physiological state and may more closely reflect the effect o f an 
agonist in vivo.
Once cell culture conditions were optimised, further experiments could be performed with 
greater confidence. The different manifestation o f  the inhibitory effect o f  the antagonist 
BQ-123 on monolayers when compared with cells in suspension is worthy o f  further study. 
The comparison o f cell calcium responses in monolayers preincubated with BQ-123, with 
responses where the antagonist was added simultaneously with endothelin-1 would indicate 
whether competition was related to duration o f  contact as suggested by Vigne et al. (1993).
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The difference in the manifestation of inhibition could be further studied using a greater 
range o f  BQ-123 concentrations in both preparations with the aim o f showing competition 
by Schild plots. For analysis o f the receptor subtype involved, a better method o f study 
would be the use o f selective ETA and ETB receptor antagonists which are not known to 
display different kinetics after longer contact with the cells. These could include the ETA 
selective agonist FR 139317 and the novel ETB antagonist BQ-788.
In the investigation o f a role for tyrosine kinase in the rise in [Ca2+],, a series o f experiments 
using a range o f  herbimycin-A concentrations would be o f greater value. These could be 
performed in parallel with Western blotting experiments using anti-phosphotyrosine 
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